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Abstract 
 
One important field of Systems Biology encompasses the search for methodologies that allow 
using mathematical models in the treatment of clinical pathologies. Specifically, the use of gene 
expression data and its association to patient characteristics is of much interest. 
This investigation developed a general workflow that explains the basic steps needed for gene 
expression data analysis with the objective of finding significant associations between gene 
expression and clinical traits, as well as a specific novel workflow that uses bimodality to relate 
gene expression in breast cancer samples to clinical traits.  The project aims to answer two 
specific needs: to compile a set of tools and steps required to understand the available data, and to 
successfully select, in a not supervised manner, a set of genes relevant for the correlation and 
prediction of clinical parameters, specifically for relapse in breast cancer patients. 
Considering statistics and mathematical models, a survey of available methods was developed, 
they were compared on different data sets, and were summarized into a resulting workflow, that 
specifies steps for the initial analysis of gene expression data, and aids in the set of goals and 
restrictions for further analysis.  A revision of dimensionality reduction techniques, regression 
analysis, gene ontologies, clustering, correlations and distribution analysis is included. 
The results show the advantages and disadvantages of different methods applied in different 
datasets, explaining why the proposed workflow accomplishes a wide examination of the data, 
and can be used as foundation for posterior analysis. This tools and methods compilation is a 
summary of the state of the art of bioinformatics in terms of gene expression analysis for finding 
connections to clinical data. 
After following this workflow, another algorithm was proposed, so that the intrinsic bimodality of 
the data is exploited into normalization and selection steps, resulting in a final set of genes. These 
genes showed high correlation to clinical parameters in breast cancer data, and the sets analysis 
exposed the connection of these genes to important gene ontologies; some of the selected genes 
are known biomarkers, confirming the accuracy of the unsupervised methodology. 
The gene set selection workflow is a novel proposal for feature selection, and the resulting set 
showed important correlations to the available clinical parameters in breast cancer. The results 
achieved for relapse present a breakthrough in gene expression analysis, since the correlation 
showed to be much stronger than with other methods found in literature. 
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Zusammenfassung 
Ein wichtiger  Bereich der Systembiologie umfasst die Suche nach Methoden, die die Nutzung 
mathematischer Modelle bei der Behandlung von klinischen Erkrankungen ermöglichen. Dabei ist 
insbesondere die Verwendung von Genexpressionsdaten und deren Zuordnung zu Patienten-Eigenschaften 
von großem Interesse.  
In der vorliegenden Untersuchung wurde eine allgemeine Vorgehensweise ausgearbeitet, welche die 
grundlegenden Schritte für die Genexpressions-Datenanalyse zur Entdeckung signifikanter Assoziationen 
zwischen Genexpression und klinischen Eigenschaften beinhaltet. Zusätzlich wurde eine neue spezifische 
Vorgehensweise entwickelt, die signifikante Beziehungen zwischen Genexpression und klinischen 
Merkmalen beim Brustkrebs mittels Bimodalitätsmaßen aufzeigt. Bei dem bearbeiteten Projekt standen 
zwei spezifische Aufgabenstellungen im Fokus: Zum Einen die Zusammenstellung von Methoden, die ein 
besseres Verständnis der vorhandenen Daten ermöglichen und zum Anderen die datenbasierte Selektion 
eines Gensets, das die Korrelation und Vorhersage von klinischen Parametern, insbesondere des 
Brustkrebs-Rückfalls, ermöglicht. 
Zunächst wurde eine Übersicht über die verfügbaren Methoden zur statistischen Analyse und 
mathematischen Modellierung entwickelt. Die Methoden wurden dann auf verschiedenen Datensätzen 
verglichen und in einem Arbeitsablauf zusammengefasst, der die empfohlenen Schritte für die primäre 
Analyse der Genexpressionsdaten angibt und dabei hilft, Ziele und Einschränkungen für weitere Analysen 
festzulegen. Als theoretischen Hintergrund dazu beinhaltet die vorliegende Arbeit eine zusammenfassende 
Darstellung der gängigen Dimensionsreduktionstechniken, Regressionsanalysen, Gen-Ontologien, 
Clusterverfahren, sowie Korrelations- und Verteilungsanalysen. 
Die erzielten Ergebnisse zeigen die Vorteile und Nachteile der verschiedenen Methoden in 
unterschiedlichen Datensätzen auf und erklären somit, wie die vorgeschlagene Methodik zu einer 
umfassenden Beurteilung der Daten führt und als Grundlage für weitere Analysen verwendet werden kann. 
Die herausgearbeitete Zusammenstellung von Werkzeugen und Methoden ist hinsichtlich der Ermittlung 
von Verbindungen zwischen Genexpression und klinischen Daten eine Zusammenfassung des aktuellen 
Standes der Technik in der Bioinformatik. 
Nach Durchführung des allgemeinen Abeitsablaufes wird eine neue spezifische Methodik vorgeschlagen, 
welche die intrinsische Bimodalität der Daten für Normalisierungs- und Selektionsschritte nutzt und 
schließlich zur Definition eines finalen Gensets führt. Die so ausgewählten Gene zeigen hohe Korrelationen 
zu klinischen Parametern bei Brustkrebs Daten und die Genset-Analyse zeigt die Verbindung dieser Gene 
zu wichtigen Gen-Ontologien auf; einige der ausgewählten Gene sind bekannte Biomarker, was als weitere 
Bestätigung der Nützlichkeit der unüberwachten Methodik interpretiert werden kann. 
Die entwickelte spezifische Methode stellt eine neuartige Idee zur Genselektion dar und das resultierende 
Genset zeigt wichtige Zusammenhänge zu den verfügbaren klinischen Parametern bei Brustkrebs auf. Die 
Ergebnisse für den Brustkrebs-Rückfall stellen einen Durchbruch in der Genexpressionsanalyse dar, da die 
erreichten Korrelationen deutlich stärker sind als die mit Methoden aus der bisherigen Literatur erlangten. 
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Chapter 1 
Introduction 
The advent of new technologies has improved our ability to explore gene expression and to study 
the changes that different conditions impose to our genetic signatures. Alterations in genomic 
sequences can have strong effects in the behavior of cells, and therefore in the behavior of an 
organism; meaning that through gene expression analysis, it is possible to create a link between 
genotype and phenotype. This link, as important as it is, is not easy to detect.  
 
The analysis and handling of all the valuable data produced by experimental molecular biology is 
still a bottleneck in the study of biological processes.  Microarray technologies allow observing 
gene expression from thousands of genes, and then, using a transformation from images to 
numerical matrices, a gene expression matrix can be obtained, facilitating storage and allowing 
further analysis of gene regulation, metabolic and signaling pathways, genetic mechanisms of 
disease, and the response to drug treatments [13]. The speed in the generation of data forces the 
analysis experts to find better and faster workflows, which extract the maximum amount of 
information from the matrices. The task complexity grows due to the amount of data and the noise 
generated in each step of the production process, combined with the noise inherent to the genomic 
data. These complicate the statistical analysis and force the use of methodologies that can 
generate information loss. It becomes a bargain between statistical accuracy and profit in 
information.  
Then, what can we derive from gene expression data? What sort of information is there? Can we 
read it? Can we use mathematical methods to extract it? The search for answers has led to 
numerous papers that attempt to extract specific points of information with specific methods, 
many of them successful, and yet there are a lot of unknowns that still require further analysis. 
 
We are interested in the search of the correlation between gene expression and clinical 
phenotypes, in cancer samples.  
 
All diseases are important for the field of genetic research, since better understanding of the 
disease, implies better possibilities of treatment. Institutes and laboratories all over the world 
attempt to unveil the mysteries of genetic data in order to discover solutions to health problems.   
One of the most important diseases of our times is cancer; it is the leading cause of death in 
economically developed countries and the second leading cause of death in developing countries 
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[163].  About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have 
occurred in 2008 worldwide [75], according to the American Cancer Society [3] 1 in 3 woman 
develop cancer, 1 in 2 men develop cancer, 1 in 5 women die from cancer and 1 in 4 men die from 
cancer. It is also an expensive disease, in the U.S. annually it costs approximately 228.1 billion 
dollars, including direct medical costs and indirect morbidity costs [3].   
Nowadays several methods of treatment exist: chemotherapy, radiation therapy, surgery, 
immunotherapy, and some others. The application and success of these methods depend on the 
stage of the cancer, the location and grade of the tumor, and some environmental issues like the 
general health condition of the patient [3]. Nevertheless, no treatment can assure the complete 
recovery, or the absence of cancer relapse.  
 
Cancer research considers the study of the processes involved in cancer development, and by 
understanding them, it aims to develop better treatment strategies.   
After many years of study and discussion, it is currently accepted to define cancer as a multigenic, 
multistep disease originated from an abnormal cell with an altered gene function, evident in 
altered patterns of gene expression. Recent studies show that the causes of this anomaly involve 
not only genetic alterations but also acquired epigenetic abnormalities [18,59,68,76,153]. 
Uncontrolled proliferation of the abnormal cell and further mutations give origin to tumors, and 
can lead to tissue invasion and metastasis. There are multiple objectives in modern cancer 
research [15], as to understand the steps in cancer development, the oncogenes, biomarkers, 
evolutionary dynamics, and many more. 
 
In this thesis, our aim is to study gene expression data from cancer tumor samples in order to find 
patterns that lead to conclusive correlation with clinical data, with the objective of using them in 
future cancer development models. This introduction will describe the project, the overview of the 
problem and the specific objectives of this research study. 
 
1.1 MedSys: Project Description 
This investigation is part of a larger project, called “Medical systems biology: From multi-scale 
models to tangible predictors of clinical outcome in oncology therapies” [130]. 
This project is divided in 5 parts: 
•WP 1 Data delivery, definition of benchmarks and validation 
•WP 2 Data analysis, tumor stratification and biomarker identification 
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•WP 3 Modeling of rapid dynamic drug response 
•WP 4 Modeling long-term response to drugs on the gene expression and population dynamic 
levels 
•WP 5 Integration, implementation and validation of the models 
 
This investigation contributes to the fourth part, which involves the analysis of gene expression 
data in the search of correlation parameters with clinical data, in order to allow the future 
development of a stochastic population dynamics model.  
The task requires a deep study of the available data, in order to understand the range of 
possibilities available to extract information from it. This analysis requires the use of different 
statistical and computational tools to determine how to achieve the most profitable information 
extraction. Furthermore, the study of the gene expression and the correlation of individual genes 
and gene groups to clinical data must be assessed. 
The results of this project encompass the basis for a subsequent modeling of cancer tumors. 
 
1.2 Overview of the problem 
In order to treat a disease such as cancer, information on how to proceed is needed. Different 
medicaments have been designed to address different targets, but as stated before, they are still 
not completely effective, nor are they available for all types of cancer.   
Ideally, the information available in gene expression should give an idea as to the clinical 
characteristics of the patient, and with this information, laboratories and physicians could 
determine a treatment strategy. With this idea in mind, we address mainly two problems: 
 How to analyze gene expression data, in order to understand the available information 
in a dataset. There are many objectives when analyzing gene expression, and many 
more ways to search for them.  The problem is how to select an experiment scheme 
that fulfills the objectives, and we believe that this scheme has to be devised according 
to the possibilities that the data has to offer. We considered the definition of a general 
initial workflow, which encompasses the steps needed to evaluate the data, and to 
appreciate the complexity of the problem. This workflow is a novel compilation of 
steps and tools that can be used for gene expression analysis aiming to discover 
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associations between clinical data and genotype, and would be useful to standardize 
the initial process, so that results can be easily reproducible.  
 How to find gene sets that are correlated to clinical parameters. Despite the 
availability of some cancer biomarkers, there is still an important gap of information 
that cannot be retrieved through any of them [104].  We observed the presence of 
bimodality in gene expression, using these patterns to generate gene sets that show 
high correlation to clinical parameters. This new procedure generates, in a non-
supervised manner, possible biomarker sets. 
 
1.3 Gene expression analysis 
Gene expression microarray analysis involves studying thousands of genes in several samples 
and their inter-relations.  This type of investigation requires a strategy that is not prone to errors, 
does not over fit the models, can isolate noisy data, and yet is accurate enough to be reliable. The 
problem is interesting due to the nature of the data, and it is complex due to size and noise; 
experts in diverse areas have approached different steps in the analysis, working on specific 
problems that must be faced when analyzing gene expression, in this section we summarize some 
of them, so that the reader can have an impression of the obstacles that were considered.  
There are several tools available for analyzing gene expression data and the visible changes in 
it that can be associated to cancer. Many of these tools have offered already interesting findings, 
most of them are still in a development phase, and therefore the detection and evaluation of 
genetic events is still an unsolved problem [34]. 
In a typical statistical workflow, the strategy of the experiment should be clear from the 
beginning, and it should be consistent with the available data. The amount of data in the analysis 
is always a problem. When there are not enough comparable samples, most of the methodologies 
will be susceptible to false results.  And when comparing large amounts of data, significant 
differences may be found, but the probability of these differences appearing just by chance is 
exceptionally high when the assumptions underlying the statistical tests are not fulfilled, as is 
common in gene expression analysis. There are tools to help the researcher compensate for these 
problems, but this is clearly a point to consider. 
In a first step, the data should be tested to see if the samples are comparable, if there are any 
outliers, if there is any clearly overexpressed information, and where to look for more. In this 
way, many statistical tools must be used, starting with the common ones, and deciding at each 
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step where and how to look deeper into the data. Some techniques are available for this 
exploratory analysis (box plots, histograms, scatter plots, etc.), but it is important to explore 
reduced coordinate systems to facilitate the understanding and the possibilities of graphical 
analysis. Any reduction implies information loss, but can lead to clear understanding of the 
remaining information.  
The difference compared to other data mining problems is in the nature of the genetic data. The 
collection of data undergoes a series of human processes, which are prone to error and to minor 
influence that leads to noisy data. The noise in the data comes not only from the acquisition 
process, batch effects and miss-matching are some of the other possible problems. Even our 
knowledge of gene expression data still points to the fact that much of the acquired data is just 
biological noise [120]. Recent studies [127,106] have shown the need to look deeper in this 
residual information, since what may be considered as noisy data can be a different form of 
unknown pattern.  Then an important question arises as to deciding what should be considered as 
noise and what is important for the analysis; how to decide can be difficult, and lead to 
information loss or false information. A good answer is, of course, to decide on basis of a priori 
knowledge, requiring much more interaction between the biology experts and the bioinformatics 
researchers, and therefore, requiring more time and resources, and forcing the analysis to be data-
dependent. This is an important request for bioinformatics: how to make decisions without a 
priori knowledge, or how to reduce the need of specific additional expertise, without losing 
accuracy in the analysis. 
From this point, the procedure will depend on the goal of the analysis. Each goal has its own 
problems, and clearly its own possibilities. Not only statistics are involved in the analysis, 
mathematical models, artificial intelligence and even imaging techniques can be used to process 
and analyze gene expression data. Every possible methodology brings to the table its inherent 
problems, and has to be calibrated to be used with this type of data.  
In our case, even after the initial problems are settled, the link between gene expression data 
and clinical phenotypes is not necessarily clear. Many tools can be used in the process, and again 
many decisions must be made on how to treat the data, and how to decide when a result can be 
considered as final. Then how to select what can be considered as a clear link, or what should be 
analyzed further is a new challenge of the process; tests on soundness should be considered, but 
with so many decisions on the path, any step can be the key to find, or not to find the expected 
results.  
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1.4 Objectives 
We are interested in analyzing gene expression data in the search of possible links between 
genotype and clinical phenotype.   
In order to do so, we have established the following objectives. 
Definition of a workflow. There are many studies that analyze gene expression data, and there 
are probably just as many different ways of doing it. Usually the initial process is driven by the 
researchers knowledge about the data and of course, by the a priori knowledge on the expected 
results.  Even though we are aware that every experiment is different, since the goal and data 
usually are, and we are not claiming that using previous knowledge has any disadvantage for the 
specific experiment, we consider that a wider and standardized workflow can be of help at the 
beginning of any experiment, and can support expert considerations in defining the route of the 
entire experiment. Besides, it can offer an unbiased source of information over the data.  
Therefore, we defined and followed a novel workflow that includes the basic tests that we 
consider should be the base for further analyses.  
 
Search for a connection between gene expression and clinical data in cancer samples. The 
problem of connecting genotype to phenotype is considered one of the most complex in the field 
[36]. The accomplishment of this task would provide efficient prediction methods for many 
genetic processes, including diseases like cancer. Previous studies have shown strong correlation 
between selected genes and, for example, tumor classification [27].  Since there are too many 
genes to reasonably study them all, a selection must be made to study this type of correlation; the 
decision about which genes to study usually comes from previous laboratory analysis. In contrast, 
we used statistical analysis to find correlations between genotype and phenotype, without 
involving biological knowledge in the decision process, lowering the temporal and economic 
costs of the analysis. As a result, we expected to find the known relationships, which would 
validate our approach, along with new ones, which would represent an important finding for 
further analysis. 
 
Study the relationship between genes in gene expression data. We studied the relationship 
between specific genes and the effect of this relationship in the search for links between gene 
expression and clinical data.  Gene co-regulation has been studied, since it is believed that gene 
aberrations co-regulate on human diseases [20]. When genes are tested individually, some of them 
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can be considered as not important, but when tested in a group, these same genes can be 
associated and could have an impact on the phenotype [84]; in this way, we considered the co-
regulation of the genes in our data set, and we calculated the impact of this correlation in the 
clinical outcome. 
 
Consider possible genes that could be biomarkers in breast cancer data. Looking for 
biomarkers is another important task of bioinformatics.  The huge amount of data available from 
laboratory experiments broadens the possibilities of finding biomarkers, but at the same time 
makes the identification harder, due to the differences in preparation, collection and storage of 
samples. Even the proper validation of most cancer biomarkers is still not completed [104].  
Considering the idea of co-regulation, we studied the effects of specific gene clusters in the 
patient phenotype for breast cancer samples. Using different statistical tools, we defined a novel 
procedure to determine gene sets, which highlight the genes that show correlations between them, 
and with the phenotype. We analyzed these gene clusters to find common biological traces and we 
defined a list of genes that could be considered to further evaluation as biomarkers.  
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1.5 How to Read this Document 
This document is planned so it can be read in different levels, according the reader’s interest. 
There are three main reading levels. The first one considers the introduction and conclusion, 
which offers the reader a global view of the document, exposing objectives, results and 
possibilities for future work in the area.  A second level involves the introduction and summary of 
each chapter, where the main contents are comprised.   
A third level of detail is in the reading of the full chapters.  In the second chapter we do a review 
on the methodologies involved in this study, and of course on the basic concepts required to 
understand them.  This document is intended for a broad audience, without necessarily having 
deep knowledge on neither statistical analysis nor gene expression data analysis. The aim of this 
chapter is to review the concepts behind bioinformatics. Being such an ample field, we focus on 
concepts that were applied in the investigation and some concepts that explain the goal of the 
research and the intended future work. 
The third chapter describes the data sets that were used in this investigation. Besides the account 
of the available clinical data, the basic analysis of the data sets is portrayed, showing histograms 
and variance analysis results for each set. 
In the fourth chapter the proposed workflow is explained, first the basic workflow for gene 
expression data analysis, and then the specific track description for each of the studies that were 
developed. This chapter aims to give the reader an overview and a map to understand the results 
and to understand how each phase was planned, developed and validated.  
The fifth chapter describes the results achieved. In this chapter each of the methods used is 
revisited and the accomplished results are portrayed. The analysis of the results is of course the 
main focus of this chapter.  
Finally, the conclusions illustrate the major achievements of the investigation, along with the 
possibilities for future work. 
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Chapter 2 
Theoretical Background 
Abstract. This chapter aims to describe concepts and methods required to understand the development of this 
investigation. An introduction to cancer research and bioinformatics is provided, considering a description, brief 
historical review, current status and important challenges for the future. The chapter also considers techniques 
in statistics and data analysis that provide the basis for the search of relations between genomic and clinical 
data; this includes data dimensionality reduction techniques, clustering and regression, gene ontology, pathway 
and co-regulation analysis and the analysis of gene expression distribution. For each subject, a definition is 
provided, along with a short explanation on how to implement it. 
 
Since the beginning of the study of systems biology as an interdisciplinary subject, many concepts 
have been applied and redeveloped to provide innovative views to old biology problems. With the 
explosion of data collection, the analysis has become more important, and is still one step behind, 
since all the collected data remains a partial mystery.  The methodologies and possibilities of data 
analysis are too numerous to be explained in total; however this chapter comprises many of the 
basic techniques in bioinformatics, and explains the ones that we have used in this investigation. 
2.1 Cancer Research 
To understand why cancer is such a complicated disease, it is necessary to consider that the 
word 'cancer' defines a group of more than 100 different diseases. These diseases share some 
common traits [55]: 
 Self-sufficiency in growth signals 
 Insensitivity to anti-growth signals 
 Evading apoptosis (Figure 1) 
 Limitless replicative potential 
 Sustained angiogenesis 
 Tissue invasion and metastasis (Figure 2) 
 
The specific feature that distinguishes cancer from benign tumors (and in general from any 
abnormal cellular growth) is the ability of metastasis. Cancer cells are unresponsive to normal 
constraints and invade adjacent tissues replacing normal cells.  By invading adjacent tissues, it is 
possible that cancer cells reach circulatory vessels, and through them, they may be carried to 
remote tissues, where they can adhere and colonize, creating a metastatic tumor. 
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Figure 1. Cancer development. The figure shows a comparison between normal cell division and 
cancer cell division. When cell mutations appear, the cell mechanisms lead to apoptosis, when these 
mechanisms fail, the cells can accumulate mutations and evolve to uncontrolled growth.  
 
At the present time, cancer is known to be a genetic disease [152]. Cancer develops as a result 
of mutations in specific genes, which are thought to be cancer-susceptible, and are shared in both 
inherited and sporadic (non-inherited) forms of the same tumor type. Scientists have divided these 
genes in three categories, namely gatekeepers, caretakers and landscapers [152,103].   
Gatekeeper genes are those genes that take care of the control growth and differentiation 
pathways of the cell. These genes are either oncogenes or tumor suppressor genes. Oncogenes 
control cell proliferation, therefore a mutation on this gene can cause uncontrolled proliferation, 
even when external signals from the cell environment are indicating a need to stop. Tumor 
suppressor genes, on the other hand, regulate apoptosis, cell senescence and other signaling 
pathways; when mutated in both alleles (each normal cell has two alleles of a TSG), the cell 
presents increased net reproductive rate. 
Caretaker genes control the rate of mutation. In case of a defect in these genes, all other genes in 
the cell are more prone to acquire mutations, including of course, gatekeeper genes. In this way, 
defects in caretaker genes accelerate tumorigenesis, creating a cancer susceptible environment. 
Landscaper genes encode products that regulate the cell microenvironment and the interactions 
that take place within. Disruptions in the cell to extracellular matrix interactions lead to errors in 
external signals, which in turn lead to abnormal proliferation and apoptosis rates. 
Damage in one gene is not enough to trigger cancer. As explained before, an accumulation of 
mutations is necessary, so that the initiated tumorigenesis can develop into tumor progression. 
[103].  There are cases where a single genetic defect can lead to cancer: in chronic myeloid 
leukemia (CML), in chronic-phase, it is thought that only one oncogenic translocation is needed 
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to trigger its development.  This can be an advantage when observed from the therapy point of 
view, since a targeted agent could be successfully developed [83]. 
 
 
Figure 2. Metastasis [110]1 Cancer metastasis is the spread of the disease from a primary tumor 
site to another non-adjacent organ via lymphatic and/or blood vessels. 
 
But this is considered an exceptional case, since most cancers have presented two or more 
mutations when studied.  The study of this phenomenon came from the idea of exploring the 
dynamics of cancer and the incidence of age in the development of different cancers.  Many of the 
studied cancers showed a clear correlation between age and probability of development, since 
with age, there is more time to accumulate mutations.  
The analysis of cancer evolution in respect to patient’s age, leads to think that complete cancer 
development involves 3 to 7 mutations. A greater number of mutations seem to be needed in solid 
tumors (tumors in solid organs such as the colon, bladder, brain, and breast) than liquid tumors 
(leukemia and lymphomas) [152]. 
Other cancer types, that do not fit this model, show high probability when cells are dividing more 
active (like osteosarcoma during the adolescence) or lower probability when cell division is 
decreasing (like breast cancer after menopause), and of course, age curves can be affected by 
environmental changes, as is the case of lung cancer (in smoker patients). A clear example of the 
need of two hits is in the tumor suppressor genes, which as explained, need to have mutations in 
both alleles to present an effect; or hereditary cancers, where a previous mutation predisposes the 
patient to develop cancer, as is the case of retinoblastoma [83]. 
Therapy development for these tumors has proved to be much more puzzling, since more than one 
agent needs to be targeted.  
                                                     
1 This illustration is used under authorization of the Biochemical Journal according to the permissions for non-commercial use. http://www.biochemj.org/bj/rights.htm  
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The causes of cancer are not completely clear. Today is known that some genetic 
malformations can predispose the body to develop cancer, but many studies have shown the link 
between cancers and environmental factors like chemical carcinogenesis, hormonal misbalances, 
ionizing and ultraviolet radiation, inflammation, viruses like RNA tumor, herpes, papilloma or 
hepatitis and parasites [68].  
DNA mutations arise at a frequency of 1 in 20 million per gene per cell division, and humans 
form in average during a lifetime 1016 cells [59]. These averages would mean that every 
individual has the same chance to develop cancer, yet cancer incidence rates are different between 
countries [163].  This is explained by the susceptibility caused by genetic and environmental 
factors. 
 In the western world, patients with a hereditary mutation develop cancer with an estimated 
probability of 0.1 to 10 percent, depending on the cancer type [152], which leaves 90% or more of 
the cancer probability to sporadic mutations. As stated before, age has been shown to be related to 
cancer incidence and acceleration, and specific changes to those relational models can be 
explained as related to specific environmental events [47].  
Five different types of genetic alterations can be described in tumor cells: subtle alterations 
(like deletions, insertions, and single base-pair substitutions), chromosome number changes, 
chromosome translocations, amplifications and exogenous sequences [152]. 
 
These genetic alterations, as a result of cancer progression, generate changes that are 
observable in gene expression samples, by comparing them to normal samples.   Different 
methods are currently applied to find gene expression levels that are differentially expressed 
between cell populations, and the evolution of these techniques offers the possibility of large scale 
gene expression profiling, and therefore makes a global view of the genome possible [123]. Gene 
expression profiling reveals the pattern of genes used by the sampled cell, and the differentially 
expressed genes inside those patterns, aiding the study of clinical correlation. 
Understanding the progression of cancer could give means to stop the development of the 
disease at any stage (whenever is found) doing as little collateral damage as possible. 
In fact, scientists have looked for deeper understanding of tumor development and it’s 
association to clinical symptoms since Hippocrates (460-370 BC) proposed that cancer was 
caused by an excess of black bile. It was until 1862 when the modern era of cancer research 
begun, once Rudolph Virchow made the first connection between inflammation and cancer, by 
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identifying leucocytes.  Since 1953, after James Watson and Francis Crick discovered the 
molecular structure of DNA, studies on nucleic acids and DNA associations to cancer have been a 
major area of cancer research.  Gene studies lead Robert Huebner and George Todaro in 1969, to 
insinuate oncogenes (genes that have the potential to turn normal cells into cancerous) as cause of 
cancer; later in 1979 the gene p53 was discovered, being a gene whose protein products help 
control cell growth, and is the most frequently mutated in human cancer. Genomic databases 
allowed from 1980 the study of pathways of signal transduction, and the explosion of new 
technologies allowed in the past decade further studies on gene expression, genomics and systems 
biology, and better development and control studies for new cancer treatments [109,159].  
This short review of cancer research illustrates how many different aspects should be 
considered when studying cancer development, and it is clear that many external factors interact 
with cancer tumors. Indeed, the effect of drugs over cancer advance is very important when 
studying the disease, knowledge about different reactions to different drugs can lead the treatment 
to success. But not only drug effects are important, the body itself attempts to fight back the 
disease, and the immune system takes an important part in cancer development, and in the general 
health of the patient, since it can help the process of treatment, or it can initiate yet another 
disease, by generating an autoimmune response.   
The influence of the immune system over cancer response was first hypothesized by Paul 
Ehrlich (1854-1915), when proposing that the incidence of cancer would be higher if the immune 
system did not had the ability to identify and eliminate tumor cells.  An association between 
immune system and cancers related to oncogenic viruses is suggested by the fact that certain 
tumors have shown greater incidence in immunosuppressed individuals (some skin cancers, 
Kaposi sarcoma, and lymphomas), whilst  the frequency of non-cutaneous, non-virally-induced 
cancers was generally not increased [68].  
Drugs used to treat patients with cancer are highly effective in a limited number of patients and 
less effective in most [68]. But even when they are not effective against cancer cells, they have an 
effect on other cells, and they can produce important side effects.  The effect of drugs can be 
tested in laboratory experiments, the effect of each agent in particular can be tested, and even 
some combinations of agents, but it is not possible to reproduce a more realistic stage: all the 
agents through a long period of time. Then it is important to study patients and find similarities 
and differences from their genetic codes to the treatment and environment in which they are 
studied.  
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Cancer research has still many open questions, it advances in many fronts, so it is difficult to 
clearly expose the current state and predict future results:  Advances in nanotechnology have 
improved imaging tests and have provided an better way of transporting a drug to a specific cell; 
robotic surgery has upgraded the removal of tumors, so that future systems are expected to 
remove tumors completely and with less surgical trauma [3].  Many scientists consider that 
targeted therapies are the best way to treat cancer, and therefore they consider that more targets 
are necessary for new drug developments, leading to research on pathway inhibitors and the 
development of new classes of molecules [3].  Experts consider that cancer drug development 
should be focused on biomarker-driven and hypothesis-testing trials, leading to individualized 
medicine, based on laboratory studies combined with a model of molecular biomarker-based 
patient selection. DNA-sequencing capabilities should offer much more opportunities, since 
decreasing costs should enable personalized genome and expression data, allowing understanding 
the progression of individual tumors and state-specific markers for diagnosis and monitoring of 
the disease. They believe that the integration of all the new gathered information will probably be 
the biggest problem, since more than ever multidisciplinary research groups would have to coexist 
in order to create the bigger picture that relates genomics with metabolism and its alterations [15]. 
 
In our consideration, mechanisms that allow the understanding of that bigger picture are the main 
need in bioinformatics research. We consider that there is still much to know on the alteration of 
genomics and its connection to clinical phenotypes. In this way, a deep investigation of the gene 
expression and models of cancer progression can lead to further understanding of the development 
of cancer tumors. Deeper understanding of the behavior of genes and the search for new 
biomarkers are the way to find parameters to model cancer evolution, and therefore is in the gene 
expression data analysis where the answers must be sought. 
 
2.1.1 Gene Expression Data 
"Gene expression" is the term used to describe the transcription of the information contained 
within the DNA, the repository of genetic information, into messenger RNA (mRNA) molecules 
that are then translated into the proteins that perform most of the critical functions of cells [107]. 
Using microarrays, it is possible to study changes in gene expression levels, genomic gains and 
losses, as well as mutations in DNA. Figure 3 shows the process of gene expression profiling. 
Using hybridization probing, a colored microarray is produced. These colors represent the 
expression of a specific gene in a specific probe, with the differentiation for sample and control. 
This microarray is then translated into a matrix of numbers, representing this gene expression.  
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This type of process results in a two color microarray, our data comes from a one color 
microarray, indicating the level of hybridization with the target, which describe a relative value 
for the gene when compared to other samples in the same experiment. 
Expression profiling allows finding genetic patterns, gene-expression changes that can be 
related to known interesting genes (like oncogenes), known pathways or environmental factors. 
These applications enable scientist to study clinical classifications, even when considering genes 
with unidentified function, since the overall patterns are the main purpose of microarray analysis. 
Molecular pathways can be unveiled, and with them, further knowledge on the clinical traits, 
drugs or environmental factors that have an effect on gene expression.  
There are two main techniques for the analysis of whole genome genes expression: DNA 
microarray technology and sequenced-based techniques.  These techniques have been used with 
positive results; for example, SAGE (serial analysis of gene expression [147]) was used in the 
identification of genes related to p-53 induced apoptosis, many of those genes where unknown, 
and opened the door for new investigations on the mechanism of p53-mediated apoptosis; 
complementary DNA (cDNA) arrays pointed a relevant target for estrogen derivatives, superoxide 
dismutase, for the attack against leukemia cells.  These examples are part of a long list of 
interesting findings using expression profiling [123]. 
 
Figure 3. Gene profiling2 Microarray analysis extracts RNA from a control and a test strain, through 
reverse transcription a cyanine dye is added, and the strains are combined into a DNA chip. Through 
a scanning process, an image with different intensities is revealed, and can be transformed into a gene 
expression matrix.  
                                                     
2 Microarray image taken from Pedagogy in Action [155], reuse and dissemination of their material is granted for non-commercial purposes 
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2.2 Bioinformatics and Systems biology 
Bioinformatics is the field that studies the application of information technologies in biology and 
medicine.  The first use of the term came in the 1970s, when Ben Hesper coined the word 
“bioinformatics” as “the study of informatics processes in biotic systems”, it was later popularized 
in publications by Paulien Hogeweg [67].  The idea of bioinformatics as a science comes from the 
requirement of accessing, organizing and analyzing biomedical data. Since the explosion of new 
data gathering technologies, the problem scaled to the point of needing experts on different fields 
to design precise algorithms that could be used with the current computational resources to 
manipulate all the collected data. Then mathematicians would help decipher the models that lay 
behind the data patterns, biologist would interpret the data and physicians would connect it to 
clinical data. Today the domain has broadened so much, that there is a new bio* field for each of 
the experts involved in the area. 
The goals of bioinformatics can be summarized in three areas: data organization, data analysis, 
and interpretation of results [95].  
The first one aims to offer access to available information, and the possibility for researchers to 
propose new records. It deals with data management problems and with the synchronization of 
different platforms, which present, for instance, different names for a same gene.  
Available data need to be analyzed. There are many biological analysis tools available for 
different objectives, and there are as many objectives in requirement of better (or any) tool. Here 
is where the joint collaboration of several research fields meets its higher point, since every 
development requires deep knowledge and expertise in informatics, mathematics, biology and 
medicine. 
Interpretation of the analysis results is the final goal of the whole study. The purpose is that 
researchers are able to use these results to determine the next research step, to postulate new 
theories or even better to uncover features that can be used in clinical research. 
The major research areas in bioinformatics are [117]: 
 Sequence analysis 
 Genome annotation 
 Computational evolutionary biology 
 Analysis of gene expression (pathways, regulatory networks, cell modeling) 
 Analysis of protein expression and structure 
 Comparative genomics 
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 Systems Biology (modeling of biological systems) 
 Image analysis 
 
The history of bioinformatics is closely linked to the information technologies evolution. Data 
gathering has offered extensive catalogues of DNA and protein sequences, and complete genomes 
of diverse organisms. With these discoveries, sequence comparison was possible and with it, the 
finding of genetic links between species and better classifications of organisms. 
Clearly, the need of analysis has pushed the development of new algorithms and the use of 
faster and reliable software, so not only the evolutionary process can be assessed now, but also 
disease and interaction processes. 
Attwood et al [7] present a figure that hold the summary of the most important landmarks of the 
development of bioinformatics. In Figure 4, the most important institutes are shown in light blue, 
databases in orange, technology relevant points in dark blue, some achievements in black and the 
number of nucleotide sequences in purple. 
Bioinformatics has had an impact in all biology related fields. A visible and interesting field is 
healthcare, where information on clinical traits as well as genomics and proteomics are expected 
to combine and result in better detection of diseases, as well as treatment and even prediction on 
the patient evolution. This field has received the name of Biomedical Informatics (BMI), aiming 
to discover novel methods of diagnosis and therapy for the improvement of the quality of life and 
the productivity and profitability of healthcare systems [117]. Along these lines, all health-related 
information is analyzed, meaning a broad spectrum, which includes molecular information, 
cellular signaling as well as proteomic profiles, tissue classification, organism genotypes and 
population epidemiology, synthesizing data to create a bigger and more complete picture of the 
mechanisms, across the different biological systems, which produce health alterations. 
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When discussing a field as broad as bioinformatics, one could claim that everything is still an 
open question. The evolution of technology pushes new possibilities, and reshapes the processes 
every time, giving space to new or to better answers. As so, every technology, every process, 
every analysis is subjected to the evolution of the different knowledge areas that congregate   in 
bioinformatics, and every question is still open for improvement. But new knowledge also opens 
new questions, and shows us that many solutions are still far away from being definitive. This is 
the case of databases. Although they have evolved incredibly in the past 50 years, the accelerated 
collection of information leaves behind the old search algorithms, and brings up new informatics 
problems, like the creation of frameworks of bioinformatics research [142], where not only 
modeling data, but also models, applications and discoveries can be classified, stored and 
retrieved easily to facilitate the advance of investigation by using as a base accumulated 
knowledge from all over the world. In order to do so, scientists must be trained in standardized 
Figure 4. Bioinformatics development   
The figure summarizes some of the milestones in bioinformatics development. The most important
institutes are shown in light blue, databases in orange, technology relevant points in dark blue, some
achievements in black and the number of nucleotide sequences in purple.
1950  1960  1970  1980 1990 2000 
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data analysis and storage, and informatics must deal with knowledge representations, that can be 
stored, processed, retrieved and complex systems for information extraction from natural 
language (papers). Even more, simulation tools should be created for complex systems, so that 
uncertainty, statistical analysis and decision theory can be combined in prediction processes. Each 
of these challenges is being addressed by research institutes all over the globe, and many 
successful tools have been developed [142]. Chris Burge and his colleagues [11] summarized in 
2002 a list of 11 challenges in bioinformatics, which consider the modeling of transcription, RNA 
splicing and signal transduction, structure prediction, understanding of protein evolution and 
speciation, among others.  
Despite the large advances in the field, many of these challenges still require more precise 
answers, and new challenges in terms of prediction and analysis of the developed models are now 
open.   
Systems biology comes as an answer to the need of interdisciplinary solutions to biomedical 
problems, looking for universal perspectives that allow a broad view on complex interactions 
within organisms [82]. This approach intends to go beyond the idea of identifying single 
components, and uses the outcomes of all bioinformatics solutions to create integrative models for 
system-level understanding of biological systems, considering the system structures and dynamics 
and its control and design methods [82]. Systems biology has had a great impact in prognosis and 
diagnostics prediction, by relating clinical data with genomic and proteomic information into 
predictive models for medical and pharmaceutical research [125,148].  
 
2.3 Information technologies 
The field of information technologies considers the use of mathematical and computational aids to 
retrieve and manipulate information. This is a broad field that includes statistical processes, 
evolutionary computation as well as data mining and database design and support. 
This subchapter will consider three basic multivariate analysis techniques: dimensionality 
reduction, clustering and regression.  
 
2.3.1 Data Dimensionality Reduction 
Data analysis instances where the number of explanatory variables exceeds the number of samples 
present analysts with problems in the manipulation and display of findings and also in time and 
space computational complexity. These kinds of problems are common in fields like image or 
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microarray data analysis, and in general, all over bioinformatics subjects.  Dimension reduction is 
often used as a pre-processing step, and the advantages of applying it are associated with the 
identification of important features, the reduction of training complexity for many learning 
algorithms, the elimination (or at least reduction) of noise and its effect on accuracy, and the 
improvement of true classification performance by having less variables [25].  
The dimensionality can be reduced by applying feature transformation or feature selection 
techniques [45].  
In feature selection the objective is to find a subset of variables that optimize the analysis of the 
specific problem, for example variables that will formulate a precise classifier or that are 
correlated with a specific trait. The fact that the reduced coordinates are a subset of the original 
variables can be helpful in the interpretation of results and further analysis of the variables that are 
selected. The clear problem in this technique is how to select a subset. Supervised and 
unsupervised learning techniques, with diverse filters and wrappers are used, depending on the 
problem definition, size and objective. 
In feature transformation the variables are processed so a new set of variables is generated, 
retaining as much information as possible. The information can be either extracted from the 
original data (feature extraction) or generated by discovering hidden information in the original 
dataset (feature generation). Feature extraction has been more widely used than feature 
generation. Algorithms for feature extraction consider the similarity of the samples using a 
specific measure, for example variance or trait classification, and with the layout of this similarity 
new coordinates are generated. 
Two of the most common techniques for coordinate reduction are principal components analysis 
(PCA) and non-negative matrix factorization (NMF), which will be further explained in this 
section. 
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Figure 5. PCA Example of principal components decomposition. On top, a 3 dimensional image shows points of different 
groups (colors) scattered in the space, and the calculation of the principal components is shown with orange arrows. On the bottom, the 
same points are shown in the reduced space, of two principal components, differentiating clearly the different groups. 
2.3.1.1 Principal components analysis (PCA) 
When samples are correlated and data variability is considered to be produced by the investigated 
process, the data can be restricted to a lower dimensionality. Principal components analysis (PCA) 
aims to find the structure in the data that hold the most variance.  
PCA is an orthogonal linear transformation, converting the data to a new coordinate system. The 
highest variance by any projection of the data lies on the first coordinate (principal component), 
and so on [114]. Figure 5 shows how the data classification can become clearer by changing the 
coordinate system; the top of the figure shows the data on the original data space, and the 
principal components are represented by arrows; the bottom shows the plane created by the first 2 
principal components. The transformation of the data into this new coordinate system is given by:  
  ܻ௧ ൌ ܺ௧ܹ  (2.1)
 
Where X is the data matrix and W is the transformation (rotation) matrix, which can be obtained 
by singular value decomposition (SVD), multidimensional scaling (MDS) or an adaptive PCA 
method [128].  
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Singular value decomposition. The factorization of X can be achieved efficiently with the use of 
SVD. This is the method used in this investigation.  
SVD modern algorithms come from Golub and Kahan [52], whose use of Householder reflections 
to perform the linear transformation is still employed today.  The SVD of Xmxn is defined by [154] 
  ܺ ൌ ܹΣܸ௧   (2.2) 
Where W is an m x m matrix, Σ is an m x n diagonal matrix, and Vt is an n x n matrix. The 
columns of W are the left singular vectors, the rows of Vt contain the right singular vectors, the 
elements of Σ are the singular values (only different from zero on the diagonal). If the rows of X 
are centered, the matrix W can be fitted in the PCA equation, this explanation is further developed 
in Wall et.al. [154]. 
 
PCA is restricted to orthogonal basis functions, but the implementation is simple and can be done 
with linear algebra methods. The major disadvantage of PCA is in its definition: if the variability 
in the data is explained not only by the underlying studied process but also by undesirable 
technical or environmental disturbances, the dimensionality reduction will be strongly influenced 
by unwanted noise. The effect of that noise can be reduced by the use of normalization, but often 
supervised approaches are needed to eliminate outliers and determine interesting contributors. 
 
2.3.1.2 NMF 
Non-negative matrix factorization (NMF) is a group of algorithms in multivariate analysis and 
linear algebra where a matrix X, is factorized into two matrices W and H: 
  ܺ ൎ ܹܪ  (2.3) 
Where W holds the factors (is also called basis matrix or metagenes), and H represents the 
mixture coefficient matrix (metagene expression profiles).  A graphical exemplification of the 
factorization is shown in Figure 6, where m x n are the dimensions of X and r denotes the 
factorization rank. This rank is defined by the user before starting the factorization process. 
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Figure 6. NMF definition Factorization of the non-negative matrix X into two matrices W and H, using a rank r. 
 
For NMF, data must be non-negative, but basis functions are not restricted (basis functions are not 
orthogonal, unless they are not overlapping) and different objective functions can be used. Figure 
7 shows a graphical representation of samples grouped using NMF. 
The history of modern NMF can be traced to Paatero and Taper [111], who defined in 1994 a 
variant of factor analysis that they called Positive Matrix Factorization (PMF). Their approach 
considered the idea that in many physical and chemical models 
values below zero do not make sense (for instance mass), and 
therefore methods like PCA that require normalization of the data 
generate loss of information. Their method was popularized in 1999 
by Lee and Seung [91], who coined the term Non-Negative Matrix 
Factorization (NMF) and defined an iterative algorithm [90] that 
proved to be simple and effective. The implementation involves 
nonlinear iterative optimization, which can be computationally 
expensive.  
Many other algorithms have been designed since, most of them are variations of three 
fundamental algorithms [9,112]: 
 Multiplicative Update Algorithms. These algorithms have been proven to converge to 
fixed point, but this fixed point may be local. (The pseudo-code for the basic version of 
this algorithm is provided in Figure 8). Some implementations: 
o Lee and Seung, 1999 [91].  Original multiplicative updates algorithms. O(n3) 
computational cost, and six component-wise operations with O(n2). 
o Hoyer, 2002 [71].  
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Figure 7. NMF 
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o Gonzalez and Zhang, 2005 [53]. 
o Lin, 2005 [94]. 
o Dhillon and Sra, 2005 [30]. 
 Alternating least squares (ALS). These algorithms consider that one of the matrices W or 
H is fixed, deriving in a convex optimization problem. Consequently, given one matrix, 
the other matrix can be found with a least squares computation. (The pseudo-code for the 
basic version of this algorithm is provided in Figure 8) 
o Paatero and Tapper, 1994 [111]. This is the original ALS algorithm. 
Modifications to this have been done in order to add sparsity and non-negativity 
constraints (Alternating nonnegative least squares (ANLS)) 
 
 Gradient Descent. These algorithms step towards the negative gradient, and then project 
onto the constraint space, under the consideration that the objective function is reduced at 
every step by choosing a small enough step. The projection operator enforces the desired 
degree of sparseness. Some implementations: 
o Hoyer, 2004 [70].  
o Pauca et al, 2004 [113] 
 
 
Figure 8. Pseudo code for two NMF algorithms 
W = rand(n,r); //initialize W as a non-negative dense matrix
for iter = 1 : maxiter 
(Least Squares) Solve for H  
WTW H =WTA 
Set all negative elements in H to 0. 
(Least Squares) Solve for W  
HHT WT = HAT 
Set all negative elements in W to 0. 
end 
∀ሺ݅ ∈ ሾ1: ݊ሿ, ߙ ∈ ሾ1: ݎሿ, ߤ ∈ ሾ1: ݌ሿሿ 
ܪఈ,ఓ ← ܪఈ,ఓ෍ ௜ܹ,ఈ ௜ܺ,ఓሺܹܪሻ௜,ఓ௜
 
௜ܹ,ఈ ← ௜ܹ,ఈ෍ ௜ܺ,ఓሺܹܪሻ௜,ఓ ܪఈ,ఓఓ
 
௜ܹ,ఈ ← ௜ܹ,ఈ∑ ௝ܹ,ఈ௝  
W = rand(n,r); //initialize W as a non-negative dense matrix
H = rand(r,p); // initialize H as a non-negative dense matrix 
for iter = 1 : maxiter 
end 
  
ALS Algorithm MU Algorithm
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2.3.2 Clustering methodologies 
Clustering refers to the division of observations into subsets (clusters), in such a way that data 
in each cluster have similar characteristics. The final objective is to maximize homogeneity inside 
the clusters and maximize the dissimilarity between groups. In most problems, the definition of 
cluster is per se a difficulty, since the observations must be compared with a ‘good’ metric, so that 
the clusters are well formed, and even then, there may be observations that seem to belong to 
more than one cluster, bringing up the question on what does ‘good’ metric mean. The number of 
clusters also plays a role in the goodness of the classification, and can lead to different 
interpretations in the results. Computationally speaking, large data sets require multiple 
comparisons and therefore the required time grows exponentially with the dimension.  In this 
way, clustering techniques are pondered according to the input data and to the investigative 
objective of the classification, giving as result several types of clustering algorithms. 
Clusters can be exclusive, when each element belongs to a specific cluster, overlapping, when 
an element can simultaneously belong to more than one group, or fuzzy, when every element 
belong to every cluster, and the membership is qualified between 0 (absolutely does not belong to 
the cluster) and 1 (absolutely belongs to a cluster).  Clusters can also be complete when all 
elements are classified in clusters or partial when some elements are considered outliers and are 
removed from the classification [141]. 
According to the way the clusters are formed, there are 6 main types [57,141]: 
Hierarchical algorithms. This category consist in algorithms that create a hierarchical 
representation of the data such that the lower level has one cluster per element, and in each 
posterior level, clusters are combined, to the highest level, where all elements belong to the same 
cluster. A clear advantage is that the number of clusters does not have to be defined before 
starting. The implementation can be agglomerative (bottom-up) or divisive (top-down). The 
results of hierical clustering are usually visualized in a dendrogram. 
Partitional algorithms. Objects are divided in non-overlapping clusters. The number of 
clusters must be given as an input parameter. K-means, fuzzy clustering and K-nearest neighbors 
(KNN) clustering belong to this group. 
Density-based clustering algorithms. In this approach, a cluster is regarded as a region in 
which the density of data objects exceeds a threshold. DBSCAN [43] and OPTICS [6] are two 
typical algorithms of this kind. 
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Grid based. The value space that surrounds the data points is the center of consideration for 
these algorithms. A grid structure is constructed and then the density of each cell is calculated, 
and the cells are grouped. Examples of these algorithms are STING [158] and OptiGrid [64]. 
Model based. In this approach, the data is considered as derived from a combination of 
probability distributions, and each cluster represents a distribution. The EM (expectation 
maximization) [28] algorithms belong to this category. 
Subspace clustering methods look for clusters that can only be seen in a particular projection 
(subspace, manifold) of the data. 
 
In this investigation we have considered hierarchical clustering, k-means, KNN and fuzzy 
algorithms. 
2.3.2.1 Hierarchical clustering and dendrograms 
A dendrogram is a nested tree, where the leaves represent the samples to be clustered. At each 
level, elements of the level below are grouped, so every internal node has an associated height 
such that in any branch h(A) ≤ h(B)  A  B (See Figure 9) 
 
Figure 9. Dendrogram example 
In hierarchical clustering, different measures of dissimilarity can be used to cluster the samples, 
for example Euclidean, Manhattan or Cosine distance.  Clusters are linked using specific criteria, 
which consider the chosen measure of dissimilarity and applies it between elements of the 
clusters; an example of this is the single-linkage clustering [141], where the distance between two 
clusters Γ, Θ is calculated as the minimum distance between elements ߛ, ߟ belonging to the 
clusters ݀ሺΓ, Θሻ ൌ min	ሼ݀ሺߛ, ߟሻ: ߛ ∈ Γ, ߟ ∈ Θሽ, or the complete linkage clustering [141], where 
݀ሺΓ, Θሻ ൌ max	ሼ݀ሺߛ, ߟሻ: ߛ ∈ Γ, ߟ ∈ Θሽ.  
Figure 10 shows the pseudo code for a bottom-up clustering. xi represents the i-th sample and Ci 
the i-th cluster. 
A
B
a  b   c   d   e   f   g   h   i   j   k   l   m  n   o  p  
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Figure 10. Algorithm for bottom-up approach of hierarchical clustering 
2.3.2.2 K-Means 
The k-Means algorithm attempts to divide the samples into k clusters, such that the within cluster 
sum of squares is minimized:  
  ݉݅݊෍ ෍ ݀൫ݔ௝, ߣ௜൯ଶ
௫ೕ∈஼೔
௞
௜ୀଵ
  (2.4)
Where Ci represents the i-th cluster and i is the centroid of the i-th cluster. xj is the j-th 
sample. 
 
Figure 11. Algorithm for k-means 
Figure 11 shows the pseudo-code for the k-means algorithm. The initialization is the first 
problem here, since the choosing of the first centroid will have an impact on the convergence of 
//create one cluster for each sample
(i|i[1:n]: Ci={xi}) 
level=n 
while level>0  
 find i,j where d(Ci,Cj)= mina,b d(Ca,Cb) 
 merge Ci and Cj 
 level=level-1 
end 
Hierarchical clustering              . 
//define initial centroids for every cluster
(i|i[1:k]: i=centroid) 
do  
    assign each point to the closest centroid 
    re-compute centroids 
until clusters don’t change 
K-Means Clustering                    . 
  42 
the algorithm. Typically, random initial centroids produce different errors for different runs of the 
algorithm [141], which shows the sensitivity of the procedure to initialization. There are some 
strategies to choose the initial points, and in general it is convenient to include a priori 
information about the data in the selection. 
To create the clusters, points are assigned to the closest centroid. The definition of closest is 
given by a distance measure, and again, the distance measure can be defined through different 
metrics.  
To calculate the centroid of a cluster, a measure should be defined. In many cases it has been 
shown [141] that the mean of the cluster is the best measure for a centroid, but that depends on the 
data and on the defined distance metric. 
The time requirements are linear in the order of the number of data points: O(I*c*n*m) where 
n*m is the dimension of the data, c is the number of clusters and I the number of iterations. Due to 
the fact that the algorithm depends on the initial clusters, there is no guarantee that it will 
converge to the global optimum.  
 
2.3.2.3 K- Nearest Neighbor (KNN) 
The k-nearest neighbor algorithm classifies the samples in clusters such that a sample is assigned 
to the most common cluster between its k nearest neighbors. This means that an initial set of 
clusters must be defined already, and the algorithm aims to classify test samples. Therefore, to 
perform clustering using the KNN algorithm, an initialization step must be considered, where 
cluster centers are defined. 
The choosing of k depends on the data, since in general a smaller k implies higher variance 
(less stable) and a larger k implies	higher bias (less precise) [144].  
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Figure 12. Pseudo-code for KNN algorithm 
     Figure 12 shows the pseudo-code for the KNN algorithm. One of the inputs, along with k, is 
the number of clusters. The initialization phase can be prepared by assigning randomly one 
sample to each cluster, and then running the k nearest neighbor algorithm. This would mean that 
at the end the error should be measured and the initial conditions re-adjusted, with very high costs 
in time and space. In reality, the previous knowledge about the data should be enough to define 
the initial set of clusters, and then classify the rest of the samples.   
The distance metric can be defined according to the data type; the Euclidean distance is the 
most commonly used in this algorithm. Many complex distance metrics have been implemented 
to aid in specific problems, for instance by adding weights to the neighbors, and therefore using a 
different way to choose the cluster instead of just the most common, or by calculating 
probabilities along with the distances to the neighbors, so that the elected cluster would depend on 
the probabilities of the k nearest neighbors [26]. After the k nearest neighbors are found (the ones 
with the smaller distance), the clusters of these k elements can be retrieved, and then the studied 
sample will be classified in the most common cluster. 
 
2.3.2.4 Fuzzy clustering 
Fuzzy clustering algorithms allow the samples to belong to several clusters simultaneously, with 
different degrees of membership. Most analytical fuzzy clustering algorithms are based on 
optimization of the basic c-means objective function [8]. 
//define initial clusters (Training Set)
for i in Samples 
    for j in Training Set 
           calculate Di,j=d(xi,xj) 
    end 
   KNi=find the k minimum elements in Di 
   CKNi=clusters(KNi) 
   Ci=mode(CKNi) 
    Assign xi to cluster Ci 
end 
KNN Clustering                     . 
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Figure 13. Pseudo-code for Fuzzy clustering algorithm 
 
The c-means algorithm is very similar to the k-Means in section 2.3.2.2, the difference is that 
each sample holds c values, one for each cluster, with the membership coefficients. The 
initialization can be done randomly (but as with k-means, the sensitivity of the algorithm is high), 
by assigning random values between zero and one to each sample in each cluster. They also share 
the fact that the convergence hits a local minimum, instead of the global one. 
Then, iteratively, the centroids are recomputed and the membership is recalculated until 
convergence is reached. 
The computation of the centroids in the c-means algorithm is the weighted mean of all the 
samples [115]: 
  ߪ௜ ൌ
∑ ݉௜௝ଶ ݔ௝௖௝ୀଵ
∑ ݉௜௝ଶ௖௝ୀଵ  
(2.5) 
Where mij is the membership coefficient of sample xj to the cluster i. 
To recalculate the membership coefficients, a distance metric is needed d().  Again this metric 
can be defined according to the data type. The new membership values can be calculated as [115]: 
  ݉௜௝ ൌ
1
∑ ൬݀ሺݔ௝, ߪ௜ሻ݀ሺݔ௝, ߪ௞ሻ൰
ଶ
௖௞ୀଵ
 
(2.6) 
//define initial clusters  
for i in Samples 
    for j in Clusters 
           mi,j= rand(0:1) 
    end 
end 
do  
    re-compute centroids 
    re-calculate membership coefficients 
until coefficients don’t change 
c-Means Fuzzy Clustering         . 
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The termination condition is defined with a specific threshold value, such that when 2 iterations 
differ in less than the defined value, the algorithm ends. A metric to compare two iterations must 
be specified.  Convergence is guaranteed for some implementations of the algorithm [69]. 
A Fuzziness Parameter f is usually added to this type of algorithm, influencing the fuzziness of 
the resulting partition. As f approaches one from above, the partition becomes hard and I result in 
the ordinary means of the clusters. This parameter is added as an exponential to m (instead of the 
squared), when calculating the centroids; and modifying the exponent of the denominator when 
calculating membership values, so that it becomes ଶ௙ିଵ [8].  
 
2.3.3 Regression methodologies 
Regression analysis describes the behavior of a dependent variable when any of the 
independent variables is varied, while the other independent variables are held fixed. The 
objective is to quantify the effects of a specific factor in the observed model, which is known as 
simple regression, when multiple factors are analyzed simultaneously, the regression is known as 
multiple regression.  The study of variables and its effects can be used to explain or/and predict 
the outcome of an experiment, by learning from previous trials; in this way, a descriptive model 
should be designed, so that it explains the outcome of the dependent variable minimizing the 
error, but also avoiding over-fitting, so that new inputs can be successfully predicted. 
There are several techniques that have been studied for regression. As usual, the selection of the 
techniques depends on the nature of the data and on the assumptions that must be made for the 
technique to be used. Some common regression algorithms are [37]: distribution fitting, 
regression trees, cascade correlation, group method data handling, multivariate adaptive 
regression splines (MARS) [49], multilinear interpolation, radial basis functions, robust 
regression, and neural networks. In this subchapter some techniques are going to be further 
explained: linear, logistic regression, splines regression and neural networks, selected because we 
have used them at some point of the investigation. 
2.3.3.1 Linear Regression 
The simplest regression analysis is linear regression, which defines the dependent variable as a 
linear combination of parameters.  Let us start with simple regression: y would be the dependent 
variable and x would be the explanatory variable. If we assume a linear relation, we could 
represent y as a function of x, and for any observation i: 
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  ݕ௜ ൌ ߚ଴ ൅ ߚଵݔ௜ ൅ ߝ௜   (2.7) 
Usually this sort of relation is affected by disturbances, or errors, that should be added to the 
equation ( ߝ௜)  
In this way, regression analysis is concerned with finding the y-intercept and the slope of the 
relationship (parameters 0 and 1).   
This type of regression assumes that the error has a zero mean and equal variance through all 
the observations. It also assumes that there is no correlation between observations. 
To find the parameters, data is gathered, and an estimated model is calculated from the data. 
  ݕො௜ ൌ ߚመ଴ ൅ ߚመଵݔ௜   (2.8) 
The estimated error consists in the difference between the actual value of y and the one 
predicted from the data. (Figure 14)  
  ߝ௜̂ ൌ ݕ௜ െ ݕො௜ ൌ ݕ௜ െ ߚመ଴ ൅ ߚመଵݔ௜   (2.9) 
There are several possible techniques to estimate 0 and 1, such as least squares, maximum 
likelihood, quantile regression, principal component regression, mixed models or Bayesian 
regression [37]. The most commonly used is ordinary least squares (OLS) [24]. 
 
Figure 14. Linear regression Example of linear regression fitting, where the original data, in purple, is fitted into a model 
represented by the orange line. The error is calculated using the difference between the original points and the calculated ones. 
 
 
 
ݕො௜ 
ݕ௜
ߝ௜̂
ݔ௜ 
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Ordinary least squares (OLS). In this method, parameters for a linear regression are predicted 
using a minimization of the sum of squared residuals (SSR). 
  ܴܵܵ ൌ ෍ߝ̂ଶ ൌ෍ݕ௜ െ ݕො௜ ൌ ෍ݕ௜ െ ߚመ଴ ൅ ߚመଵݔ௜   (2.10)
With simple calculations, one can see that the minimum would be achieved when: 
  ߚመ଴ ൌ ݕത െ ߚመଵ̅ݔ  (2.11)
  ߚመଵ ൌ
∑ݔ௜ݕ௜ െ ݕത ∑ ݔ௜
∑ ݔ௜ଶ െ ̅ݔ ∑ ݔ௜   (2.12)
2.3.3.2 Logistic Regression 
Logistic regression is an approach to predict dichotomous outcome. In this case, the residuals are 
not normally distributed, and their variance is not equal through all the observations (differing 
from the linear regression case).  
In this way, the variable y is predicted considering its probability: ݌̂ is the probability that y is 1 
and 1 െ ݌̂ is the probability that y is 0. The logistic equation is: 
  ݈݊ ݌̂௜1 െ ݌̂௜ ൌ ߚ଴ ൅ ߚଵݔ௜ ൅ ߝ௜   (2.13)
And then: 
  ݌̂௜ ൌ ݁
ఉబାఉభ௫೔ାఌ೔
1 ൅ ݁ఉబାఉభ௫೔ାఌ೔   (2.14)
Contrary to linear regression, there is no analytical solution for this case. Maximum Likelihood 
is used to find the smallest possible deviance between the observed and predicted values [122]. 
This is an iterative process, which begins with a possible answer and reviews it to find 
improvement possibilities, until the improvement is minimum, at which point the algorithm is 
considered to have converged. The deviance (quality of fit statistic) is defined by: 
  ܦ ൌ െ2݈݊ ࣦ௙௜௧௧௘ௗࣦ௦௔௧௨௥௔௧௘ௗ   (2.15)
Where ࣦ is the likelihood of the fitted or the saturated model (the latter being a theoretical 
model that fits the data perfectly). The likelihood is the probability of the observed data as a 
function of the parameter values [4]. 
  48 
 
Figure 15. Logistic regression example A data set with 20 points was generated for this example, the independent 
variable was plotted in the x axis, while the dependent variable lies in the y axis. The initial data is plotted in black, a logistic 
regression algorithm was run over the data, resulting in a fitting plotted in blue.  
2.3.3.3 MARS 
Multivariate adaptive regression splines [49] is a non-parametric regression technique and can 
be seen as an extension of linear models that automatically models non-linearities and 
interactions. The model is formed by a set of basis functions: 
  መ݂ሺݔሻ ൌ ෍ ܽ௠ܤ௠ሺݔሻ
ெ
௠ୀଵ
  (2.16)
Where Bm(x) represents a basis function, which can be a constant, a hinge function or a product 
of two or more hinge functions.  The hinge functions can be max(0,x − c) or max(0,c − x), where 
c is a constant, a knot.  
A forward algorithm generates a first approximation of the regression model, and a backward 
algorithm removes terms to avoid overfitting, deleting the least effective term at each step, and 
using the ‘Generalized cross validation criterion’ to decide when to stop. 
The forward algorithm starts with only the intercept and adds in each step a pair of basis 
functions that minimizes the squared sum of errors as much as possible, making of this a greedy 
algorithm. The named pair of basis functions are mirrored hinge functions, created using a term 
that already belongs to the model multiplied by a new basis function.  All possible new functions 
must be evaluated to choose the best one, but there are techniques that allow to improve the 
required time [48]. The termination criteria for this algorithm depend on the implementation, but 
it usually considers a maximum number of terms and a minimum change in the error. 
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In the backward step, all functions are tested, and one (not a pair, but a single function) is 
deleted. The choice is made considering which function improves the fit of the model when 
removed, or degrades it the least [49]. 
 
Figure 16. MARS example An example dataset was created and plotted so that the independent variable lies in the x axis, 
and the dependent variable lies in the y axis. The pink points represent the initial data, while the blue line is the resulting fitting after 
applying the MARS algorithm. 
 
2.3.3.4 Neural Networks 
This mathematical model looks to emulate biological neurons, by using interconnection 
patterns (layers), a learning process for updating the weights (of the interconnections) and 
activation functions.  
In order to generate a regression formula, inputs are given to the network, according to the 
number of variables on the equation, and the output is the predicted variable. In Figure 17 a 
simple network is trained with specific activation functions, and the resulting regression is an 
equation that involves all the given parameters [74]. 
 
Figure 17. Example of a neural network A neural network with 3 layers is depicted, with only one input and one 
output. The hidden layer, in purple, considers a hyperbolic tangent, applying this function to the initial weights, and the output layer is 
a linear layer, generating a linear combination of the results of the hidden layer.  The final equation is showed in the square on the 
right.  
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Different types of networks can be built to deal with different types of inputs. Many activation 
functions can be implemented, being linear, sigmoid and Gaussian the most common.  
In terms of topologies, a neural network can be classified according to its connections and the 
way the data propagates. Between the common connectivity models one can find: 
 Direct synapse.  Elements in one layer are connected 1 to 1 with elements in the next 
layer. Of course, both layers require the same number of nodes. 
 Full synapse. Every element in one layer is connected to every element in the next 
layer. It is the most common type of synapse, since it allows a large range of 
possibilities during the learning process [12]. 
 Sanger synapse.  Applies a PCA algorithm over the elements in the input layer. 
 SOM synapse. Defines a self-organizing map of the inputs. 
According to the data propagation a network can be [86]: 
 Feed forward. The data flow extends over multiple units always from input to output, 
so there are no connections between output units and input units of the same layer or 
previous layers (feedback-connections). 
 Recurrent. In this type of network feedback connections are allowed. In order to reach 
a stable state, the dynamics of the network must be considered during the learning 
phase, so that the activation functions are delayed or changed to include the feedback 
inputs. 
 
The training process of a neural network is the core of this methodology. It has proved to 
be complicated, and require a lot of time and computational power [29]. With a priori 
knowledge, one could set the weights for the connections between nodes, but since this 
type of knowledge is often unfamiliar, the normal way of setting the weights is through 
algorithms that allow the network to change itself iteratively until the inputs match the 
expected outputs, or until specific criteria is reached. Learning processes are categorized as 
supervised and unsupervised [86]: 
 Supervised learning. Also called associative learning, requires a set of input-
output combinations, and the networks will adjust the weights of the connections 
  51 
to minimize the difference between the calculated and expected output for all 
inputs. 
 Unsupervised learning. In this type of training the network learns to respond to 
specific patterns in the input, developing a new representation of the given values. 
 
The learning process starts usually with random initial weights, in each iteration all the weights 
are modified, so the input-output combination is reached.  When multiple layers are being used 
(instead of only an input and an output layer), the errors of the middle layers are dependent on the 
errors of the output layer, and therefore, the errors of the output layer should propagate to the 
hidden layers so the errors in this layers can be calculated. This method is called back-
propagation [86].  
In this way, in each iteration the network is evaluated, and then according to the error in the 
output, all the weights in the network are adjusted by an amount  proportional to the calculated 
error. So a connection between the output y of node j and the input of node k would be 
  ∆ݓ௝௞ ൌ ߛߜ௞ݕ௝   (2.17)
When dealing with an output node, the error is calculated using the derivative of the output 
function ࣠ and the desired output d.    
  ߜ௢ ൌ ሺ݀௢ െ ݕ௢ሻ࣠′ሺݏ௢ሻ  (2.18)
In a hidden unit, the error of the output layer must be considered. 
  ߜ௛ ൌ ࣠′ሺݏ௛ሻ෍ߜ௢ݓ௛௢
ே೚
௢ୀଵ
  (2.19)
Here  represents the learning rate, which should be high so the network can test different 
possibilities, but that creates unwanted oscillations in the process. Therefore, a momentum rate is 
usually added so that the oscillations are reduced. 
  ∆ݓ௝௞ሺݐ ൅ 1ሻ ൌ ߛߜ௞ݕ௝ ൅ ߙ∆ݓ௝௞ሺݐሻ  (2.20)
In this project we have used feed-forward supervised networks. 
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2.3.3.5 Model evaluation 
Several measures can be used to evaluate the goodness of a model. The most common are the 
mean squared error and the coefficient of determination.  
The mean squared error, MSE, measures the expected value of the squared error. The error is 
difference between the estimated value and the real value.  
  ܯܵܧ൫ߠ෠൯ ൌ ܧ ቂ൫ߠ෠ െ ߠ൯ଶቃ  (2.21)
The coefficient of determination, R2, is the fraction of variability explained by the model. It can 
be considered as a measure of prediction accuracy. 
  ܴଶ ൌ 1 െ ∑ ൫ߠ௜ െ ߠ෠௜൯
ଶ
௜
∑ ሺߠ௜ െ ̅ߠሻଶ௜  
(2.22)
The numerator calculates the deviation about the regression, meaning a measure of the noise 
(the extent to which the regression fails to explain the dependent variable); the denominator 
calculates the total variation. Therefore, R2 measures the amount of total variation explained by 
the regression [140]. 
 
 
2.3.4 Microarray Analysis 
Many tools are used in the analysis of biological processes from genetic data sets. In this 
section we describe briefly a couple of them that are used in our procedures. 
2.3.4.1 Half maximal inhibitory concentration (IC50) 
The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a 
compound in inhibiting biological or biochemical function.  
This quantitative measure indicates how much of a particular drug or other substance (inhibitor) 
is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, 
cell receptor or microorganism) by half [73]. The analysis of variances and similarities in the 
values can be used to predict new values and to find outliers that represent cell lines with more or 
less resistance to a medicament. 
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2.3.4.2 Information ratio 
The information ratio (IR) [127] is a measure that compares gene‐wise measurements to large‐
scale patterns, and allows classification of genome‐wide differential expression patterns with 
respect to biomarker development into classes of different stability and predictability.  The 
information ratio is calculated using a dimensionality reduction method, and correlating the 
resulting principal components and the residuals to an information pattern, such that:  
  ܫܴ ൌ ∑ ݓ௜log൫݌௥,௜൯/log൫݌௥,௜൯ ൅ logሺ݌௣,௜ሻ௜ ∑ ݓ௜௜  
(2.23)
Where pr,i is the p-value of the residual for gene i, and pp,i is the p-value of principle component 
projections for gene i.  wi represents weights, calculated for each gene i so that genes with high 
sensitivity contribute more to the calculation. 
This method has shown that predictive power depends on the clinical phenotype as much as on 
the size of the studies, since after applying dimensionality reduction techniques, some of the 
information lies in the residuum and therefore it cannot be characterized by this sort of 
methodology. The information ratio calculates how much information on a specific characteristic 
is associated to the residuals, and in this way it allows to consider different strategies to obtain the 
intended predictive results. A dataset can be classified into three types according to its 
information ratio (see Figure 18), type I refers to datasets where the information of interest lie in 
the principal components, while in type III the information is scattered through all components. 
 
Figure 18. Information ratio classification [151] The information ratio classifies datasets in relation to a variable 
in three types. Type 1 means that the information on the variable can be found in the first principal components, while in type 3 the 
information is scattered through all the components. The figure shows the frequency of different p-values when comparing two sides 
of a variable over the data. 
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2.3.4.3 Gene ontology analysis 
The Gene Ontology project is a major bioinformatics initiative with the aim of standardizing 
the representation of gene and gene product attributes across species and databases [51]. 
Specific terminology is used to identify different gene products and their characteristics. 
The use of statistics over a sample enables finding significant gene characteristics and 
therefore, allows analyzing and establishing a profile for it. The use of enrichment analysis can 
give information about the behavior of a group of genes, and the patterns of interaction. The 
simplest way of calculating enrichment scores consist of measuring differential expression by 
combining t-statistics. The idea is to use a two sample t-statistic over each gene, being the two 
samples the two different phenotypes to compare. The genes are then ranked according to this 
measure, generating a list where the top and bottom elements show the largest difference. The list 
is then compared to known ontologies and/or gene lists, creating an enrichment score according to 
the association of the gene to the known data and its position on the list. This approach requires 
the use of a correction for multiple hypothesis testing. 
Several methodologies have been developed to calculate the enrichment, in order to improve 
the meaning of the list and to improve the predictive capability; some examples are Onto-Express, 
MAPPFinder, GoMiner, DAVID or EASE [72]. 
As a methodology for this analysis, we have worked with GSEA [138]. Gene Set Enrichment 
Analysis (GSEA) is a computational method that determines whether an a priori defined set of 
genes shows statistically significant, concordant differences between two biological states. The 
results of this analysis allow finding common pathways and important differences between data 
clusters, thus linking the clinical data to gene expression. This method was developed to avoid 
common disadvantages of other methods [132]: (i) Single gene methods tend to ignore effects on 
pathways, and work better when individual genes have a very large and consistent effects on a 
specific phenotype. Subtle effects are commonly ignored and after correcting for multiple tests, 
very few genes may be still significant. (ii) When testing different samples of the same system, 
the gene overlap tend to be very small, then the real effect of a single gene is unclear if it 
significant in a sample and it is not in another. 
As with other methods, GSEA starts by ranking the genes in a list L, according to the 
correlation between their expression and the class distinction [138]. Then an a priori set of genes 
S, that share a particular characteristic of interest (like belonging to the same GO category), is 
studied to analyze if their members are concentrated in a specific zone of the list L (top or bottom) 
or perhaps they are randomly distributed through all the list. An enrichment score ES is calculated 
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for the set S, that represents the overrepresentation of the elements in S in the top or bottom of the 
list L. The significance level of ES is calculated and the values are corrected for multiple testing. 
Many methods have been developed to improve the performance of GSEA [132], including the 
search for more accurate inferences [39], and methods that attempt to avoid restrictions of the 
method, like the predefined list of genes S, by exploring random set methods [108]. 
GSEA seems to be a very consistent method in finding enriched gene sets [1]. 
2.3.4.4 Mixture models 
A linear mixed model is a statistical model that considers a mixture of random effects and fixed 
effects. Fixed effects are specified by observing a finite set of levels of an interesting factor, 
whilst random effects come from an infinite set of levels of a factor, of which only a random 
sample is deemed to occur in the data [131].  
A mixed model explains a vector of observations ݕ with the following components: 
  ݕ ൌ ܣߤ ൅ ܤߙ ൅ ߝ  (2.24)
Where ߤ is a vector of fixed effects, ߙ is a vector of IID random effects and ߝ is a vector of 
random IID error terms. Many methods can be used to calculate the matrices ܣ and ܤ, like 
expectation maximization or maximum likelihood. 
Several studies have used this type of model in assessing profiles in gene expression data [65], 
either gene specific [166], or global [79]. 
A mixture model in probability is a model that represents the presence of subpopulations. This 
procedure is related to clustering, having as advantage the fact that dominant patterns in the data 
are captured by component distributions [102]. 
Mixture models have proved to be useful in clustering and profiling of gene expression data, 
some examples can be found in [21,35,80,92].   
A mixture of linear mixed models for clustering of gene expression profiles was proposed by 
Celeux et al. [16], where the effects of repeated samples are considered and reduced. 
2.3.4.5 Bimodality 
Figure 19 shows a bimodal distribution. This type of continuous distribution is characterized by 
having two different peaks (modes) usually obtained as a mixture of two unimodal distributions. 
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Figure 19. Bimodal distribution A bimodal distribution is characterized by having two different peaks.  
Gene expression distribution of cancer tumors has shown not to be normal, but bimodal, as 
shown by Bessarabova et al. in breast cancer [10], by Willey in lung cancer [165], by Wang et al. 
in prostate cancer [157] and some more. This result is accompanied by the found association of 
physiological states to each of the bimodal peaks, and the clustering of bimodal genes into groups 
of correlated expression [10]. The use of bimodality in cancer biomarker discovery has been 
discussed as a clear and biologically interpretable strategy [41]. A difficulty of the method 
consists in determining when the bimodality comes from an intrinsic state or when it comes from 
the heterogeneity of the samples [133]. 
Diverse tests have been defined to determine if a set follows a bimodal distribution. Based on 
the paper by Hellwig et al. [60], we have chosen the following: 
VRS (and WVRS).The Variance Reduction Score is the ratio between the within clusters sum 
of squares and the total sum of squares, while the Weighted VRS is a measure that does not 
depend on the cluster size. They are calculated as: 
  ܸܴܵ ൌ ∑ ∑ ൫ݔ െ ̅ݔ௝൯
ଶ
௫∈஼ೕ
௞௝ୀଵ
∑ ሺݔ െ ̅ݔ௜ሻଶ௡௜ୀଵ  
(2.25)
  ܹܸܴܵ ൌ
1
2 ቂ
1
݊ଵ ∑ ሺݔ െ ̅ݔଵሻ
ଶ௫∈஼భ ൅ 1݊ଶ ∑ ሺݔ െ ̅ݔଶሻ
ଶ௫∈஼మ ቃ
1
݊ ൣ∑ ሺݔ െ ̅ݔ௜ሻଶ௡௜ୀଵ ൧
  (2.26)
Where Ci represents the i-th cluster and x are the elements belonging to the clusters. n is the 
number of elements (ni would be the number of elements in cluster i), and k is the number of 
clusters –should be 2 for bimodal testing. 
Dip Test. The Dip test of unimodality [56] measures multimodality by calculating, for all 
sample points, the maximum difference between the empirical distribution function and the 
unimodal distribution function that minimizes that maximum difference. Hartigan and Hartigan 
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[56] defined a dip statistic where ܨ, ܩ are bounded functions, ࣛ is a class of functions, ࣯ is the 
class of unimodal distribution functions and ܦሺܨሻ is the dip of the function ܨ. 
  ߩሺܨ, ܩሻ ൌ ݏݑ݌௫|ܨሺݔሻ െ ܩሺݔሻ|  (2.27)
  ߩሺܨ,ࣛሻ ൌ ݂݅݊ீ ∈ࣛ ߩሺܨ, ܩሻ  (2.28)
  ܦሺܨሻ ൌ ߩሺܨ,࣯ሻ  (2.29)
They have shown that the uniform distribution is the asymptotically least favorable unimodal 
distribution, making its dip larger than any other. Then a dip test can be carried out, where the null 
hypothesis is a unimodal distribution. 
The R package diptest [98] was used for this calculations. 
Kurtosis. Kurtosis is a measure that describes the shape of a probability distribution, in terms 
of how sharp its peak is. This measure was used by Teschendorff et al. [143] to classify genes and 
find outliers, creating a successful feature selection algorithm. The idea is to calculate an 
estimator of the kurtosis value for each gene, and use this estimator to determine whether or not 
the gene is relevant. 
Snedecor and Cochran [135] determined that an unbiased estimate for the kurtosis can be 
calculated as 
  ܭሺݔሻ ൌෝ ݊ሺ݊ ൅ 1ሻ∑ ሺݔ௜ െ ̅ݔሻ
ସ௡௜ୀଵ
ሺ݊ െ 1ሻሺ݊ െ 2ሻሺ݊ െ 3ሻߪସ െ
3ሺ݊ െ 1ሻଶ
ሺ݊ െ 2ሻሺ݊ െ 3ሻ  (2.30)
Where ݔ ൌ ሺݔଵ, … , ݔ௡ሻ is a gene’s expression profile, and ̅ݔ and ߪ are the mean and standard 
deviation estimates. 
This estimator will be 0 in case of a Gaussian distribution (for most non-gaussian distributions 
will be different than 0). In case of bimodality, when a mixture of two normal distributions with 
nearly equal mass is given, the kurtosis will have negative value; in case of highly unequal mass, 
the kurtosis will be positive [135].  A drawback from this method is the fact that when the 
samples are split in to 80-20 % groups, the kurtosis is close to 0, making the method prone to 
false negatives, and consequently ignoring possible interesting genes [157]. 
Likelihood ratio. This statistical test allows to compare the fit of two models, by determining 
how many times is the data more likely under one model than the other.  
Its use in gene expression data analysis was proposed by Ertel and Tozeren [42], whose work in 
the mouse genoma showed that bimodal genes comprise a candidate set of biomarkers for a large 
number of disease states because their expressions are tightly regulated at the transcription level. 
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The ratio is calculated as 
  ܮܴ ൌ ܮ௠௢ௗ௘௟ ଵܮ௠௢ௗ௘௟ ଶ  (2.31)
Where ݉݋݈݀݁ 1 and 2 are the models to be tested. Then the numerator is the likelihood of the 
model of the mixture (bimodal distribution), while the denominator is the likelihood of the normal 
model. In this way, small ratios indicate that the distribution is unimodal and large ratios suggest 
that the expression values are bimodally distributed [60]. 
The fitting of the data to the unimodal and bimodal models was performed using the mclust 
package for R [46]. 
Bimodality index. The bimodality index criterion was proposed by Wang et al. [157] as a 
reliable alternative for the search and ranking of bimodal patterns. The index is calculated under 
the assumption that, for a gene with bimodal expression, the distribution can be expressed as a 
mixture of two normal distributions with means ߤଵ and ߤଶ, and equal standard deviation ߪ. Then 
the standardized distance ߜ between the two populations is defined as 
  ߜ ൌ |ߤଵ െ ߤଶ|ߪ   (2.32)
For identifying genes with bimodal expression, the null hypothesis is ߜ = 0 and the alternative 
hypothesis is ߜ > 0 [157]. 
The bimodality index is defined as ܤܫ ൌ ሾߨሺ1 െ ߨሻሿଵ ଶ⁄ ߜ where ߨ is the proportion of samples 
in the first group. Larger values of BI correspond to bimodal distributions. 
Outlier Sum. This method was proposed by Tibshirani and Hastie [145] for detecting genes 
that, in a disease group, exhibit unusually high gene expression in some but not all samples. The 
definition of the outlier sum statistic requires an initial standardization of the genes, using the 
median ݉݁݀௜ and the median absolute deviation ݉ܽ݀௜ of the values for gene ݅, so that 
  ݔ௜௝ᇱ ൌ ൫ݔ௜௝ െ ݉݁݀௜൯ ݉ܽ݀௜൘   (2.33)
 
 
Then the interquartile range is defined as ܫܴܳሺ݅ሻ ൌ ݍ଻ହሺ݅ሻ െ ݍଶହሺ݅ሻ, where ݍ௥ሺ݅ሻ is the ݎth 
percentile of the ݔ௜௝ᇱ  values.  Finally the outlier sum statistic is calculated as the sum of values that 
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are beyond a limit, either positive ܹሺ݅ሻ or negative ܹ′ሺ݅ሻ, and the result is the larger of those two 
in absolute value.  
  ௜ܹ ൌ ෍ ݔ௜௝ᇱ ∙ ܫሾ
௝∈஼మ
ݔ௜௝ᇱ ൐ ݍ଻ହሺ݅ሻ ൅ ܫܴܳሺ݅ሻሿ  (2.34)
  ௜ܹᇱ ൌ ෍ ݔ௜௝ᇱ ∙ ܫሾ
௝∈஼మ
ݔ௜௝ᇱ ൏ ݍଶହሺ݅ሻ െ ܫܴܳሺ݅ሻሿ  (2.35)
Normalization. Once bimodal genes are selected, a normalization step is considered, so that 
the peaks of the expression correspond to -1 and 1 [10].  The normalization transforms the 
expression xi,j as follows: 
  ݔ෤௜,௝ ൌ 2
ݔ௜,௝ െ ݈௜
ݑ௜ െ ݈௜ െ 1  (2.36)
Where ui and li are the means of the two peaks. The normalization step allows comparing genes 
through different studies. 
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Chapter 3 
Data description 
Abstract. We have worked with 4 data sets. The first one, supplied by our project partners (BSP, VTT), shows 
expression data for 22 cell lines, from different cancerous tumors; information about IC50 is given. A breast 
cancer data set (BC) was also used, where 1601 patients are profiled, and clinical information is provided. A 
chronic myeloid leukemia (CML) study is considered, with 119 samples, and clinical data on imatinib response. 
Finally a breast cancer set (Sørlie) with 295 patients is used to test the results obtained with the BC data set. 
 
Data set selection and availability are very important for the research possibilities. In fact, many 
times the available data is responsible for the design of the investigation path and the possibilities 
of the results. Despite of the increase in gene expression data availability, many investigations are 
restricted to use smaller datasets due to costs, poor annotation or simply because integrating data 
from different platforms can generate biased results. Description of the used data sets gives the 
lector a deeper understanding of the decisions during the workflow, and explains the objectives. 
In this section, each of the data sets that we work with holds a subsection. For each data set, a 
description of the data and their basic statistical analysis are described. 
3.1 VTT-BSP Data 
This data was provided by our project partners. The objective with this data is to understand what 
sort of information it is possible to retrieve from gene expression in relation to cancer origin and 
medication response data.  
This data set contains two studies, VTT and BSP, each of which has gene expression data for 
54675 probes, for different samples of 23 cell lines, in total 69 and 60 samples, respectively. 
These cell lines are described in the following table, the last two columns correspond to the 
number of replicates of each cell line in each of the studies. 
  
Name	 Species	 Origin	 BSP	 VTT	
786‐O	 human	 Renal	cell	carcinoma	 3	 3	
A549	 human	 Lung	carcinoma	 3	 3	
CaCo‐2	 human	 Colorectal	adenocarcinoma	 3	 3	
COLO320	HSR	 human	 Adenocarcinoma	 3	 ‐	
DU‐145	 human	 Prostate		epithelial	carcinoma	 3	 3	
HaCaT	 human	 Spontaneously	immortilized	keratinocytes	 3	 3	
HCT‐116	 human	 Colorectal	carcinoma	 3	 3	
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HeLa	 human	 Cervix	epithelial	adenocarcinoma	 3	 3	
HeLa‐MaTu	 human	 Cervix	epithelial	carcinoma	 ‐	 3	
HS68	 human	 Fibroblasts	from	foreskin	 3	 3	
HT‐29	 human	 Colorectal	adenocarcinoma	 3	 3	
KPL‐4	 human	 Breast	cancer	cell	line	 ‐	 3	
MCF‐10A	 human	 Epithelial	breast	cell	line	 3	 3	
MCF‐7	 human	 Breast	adenocarcinoma/	epithelial‐like	 3	 3	
MDA‐MB‐231	 human	 Breast	epithelial	cancer	 6	 3	
MIA‐Paca‐2	 human	 Pancreatic	carcinoma	 3	 3	
NCI‐H460	 human	 Large	cell	lung	carcinoma	 ‐	 3	
PC‐3	 human	 Prostate	adenocarcinoma	 3	 3	
SK‐MEL‐28	 human	 Malignant	skin	melanoma	 3	 3	
SK‐OV‐3	 human	 Ovarian	adenocarcinoma	 3	 3	
SW‐480	 human	 Colorectal	adenocarcinoma	 3	 3	
T47D	 human	 Breast	ductal	carcinoma	 ‐	 3	
U2‐OS	 human	 Osteosarcroma	 3	 3	
 
Additionally, information on IC50 results is given for some medicaments. The following 
preparations are observed in this project (descriptions from Cancer Quest [40]): 
CARBOPLATIN: Doctors use carboplatin for lung cancer, ovarian cancer, testicular cancer, head 
cancer, brain tumors, bladder cancer, and retinoblastom. The pharmacologic category is 
"antineoplastic agent" or "alkylating agent". 
CISPLATIN: Cisplatin is a chemotherapy drug that is given to treat testicular, bladder, lung, 
gullet esophagus, stomach and ovarian cancers.  
DOCETAXEL: Malignancies for which docetaxel is used include: breast cancer (advanced or 
metastatic) and non-small cell lung cancer.  
ERLOTINIB: The FDA has approved erlotinib to treat: Locally advanced or metastatic non-small 
cell lung cancer (after failure of at least one prior therapy), locally advanced, unresectable or 
metastatic pancreatic cancer (in combination with gemcitabine). 
GEMCITABINE: Malignancies for which gemcitabine is used include non-small cell lung cancer 
(in combination with cisplatin), pancreatic cancer (advanced or metastatic), advanced ovarian 
cancer (in combination with carboplatin). Gemcitabine is administered as an intravenous infusion.  
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PACLITAXEL:  The FDA approved paclitaxel for the treatment of ovarian cancer. Today the 
drug is used for several types of cancer, including ovarian, breast, small cell and large cell lung 
cancers, and Kaposi's sarcoma. 
PEMETREXED: Pemetrexed was approved for use in combination with cisplatin as an injected 
chemotherapy agent. Pemetrexed as a single-agent is indicated for the treatment of patients with 
locally advanced or metastatic non-small cell lung cancer after prior chemotherapy. 
VINOREBLINE: Cancers for which vinorelbine is used include breast cancers, testicular cancers, 
epithelial ovarian cancers, non-small cell lung cancers. 
 
In Figure 20 the availability of IC50 data is given, for each cell line and each medicament.  Pink 
represents unavailable values. As the graphic shows, there is almost complete information for 
Docetaxel and Paclitaxel from BSP studies, but other medicaments have much less available data. 
 
 
Figure 20. Clinical data availability IC50 Available information is presented in purple. 
 
 
From Figure 21 and Figure 22, one can observe how samples from the same cell line are highly 
correlated, as expected. The heat maps show the covariance between the cell lines; each name on 
the Y axis corresponds to the three samples of the same cell line (or 6 samples), and they repeat in 
  64 
the same order in the X axis. Cell lines with the same origin show correlation: for instance HT.29 
and CaCo.2, both from colorectal adenocarcinoma, seem related in the BSP and in the VTT 
studies. 
 
Figure 21. Cell line covariance, BSP data 
The labels on the right and bottom of the figure 
represent the 3 samples of each cell line (or 6 in specific 
cases). The heat map shows lighter colors when there is 
a correlation. 
 
 
Figure 22. Cell line covariance, VTT data 
The labels on the right and bottom of the figure represent 
the 3 samples of each cell line (or 6 in specific cases). The 
heat map shows lighter colors when there is a correlation. 
 
 
 
 
3.2 Breast cancer data 
We used 9 data sets from NCBI [107]: GSE 6532, GSE 7390, GSE 11121, GSE 158, GSE 4922, 
GSE 2990, GSE 5847, and GSE 2034. For each study we know the gene expression (6384 genes), 
and we have patient information (for the 1601 patients): 
•Relapse, zero when the patient is relapse free, one when not. 
•Nodal Status, one when cancer has spread to lymph nodes, zero otherwise. 
•Tumor size, measured in millimeters. 
•Age 
•Grade, which measures the abnormality of the tumor cells, is 1 when the tumor sample is well-
differentiated (Low grade), 2 when moderately differentiated (Intermediate grade) and 3 when 
poorly differentiated (High grade) 
•Estrogen receptor Status, or ER status, is 1 when the sample is ER+, 0 otherwise. 
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We also have information about the treatment in the studies, which give us the possibility of 
dividing them in 4 groups: 
Group 1 Studies 3 and 9. Without systemic treatment 
Group 2 Studies 1 and 7. Treated with Tamoxyfen (in study 1 only half of the patients were 
treated) 
Group 3 Study 5. Treated with Chemotherapy. 
Group 4 Studies 2, 6 and 8. No information on treatment. 
 
Study 4 is left out of this group classification because it presents too many outliers when 
combined with other studies. It will be analysed alone.  
 
In Figure 23 the availability of clinical data in the breast cancer study is shown. Pink represent 
unavailable data, accordingly study 8 has information only for ER status, and studies 1,2,4,5 and 7 
have information for all aspects.  
Figure 24 shows the distribution of values for the different clinical parameters through all the 
patients. Grade 2, negative nodal status, positive estrogen receptor status and negative relapse are 
the most common characteristics. 
 
Figure 23. Clinical data availability breast cancer Available data is shown in purple. 
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Figure 24. Histograms for clinical data in breast cancer study 
 
In Figure 25 the covariance between samples is studied. The heat map shows no specific 
correlations. 
 
Figure 25. Covariance of breast cancer samples 
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3.3 CML data 
119 samples from chronic myelogenous (or myeloid) leukemia were considered. Each sample 
contains 24481 probes. The data is accessible through the NCBI data base, series GSE4170. 
These samples correspond to different stages of the leukemia development (chronic phase, 
accelerated phase, blast crisis) and the samples are tagged to provide information on this CML 
type. Besides this, there is information on the blast count, the center code and imatinib treatment. 
This disease is classified in three possible phases, according to the number of blast cells in the 
blood and bone marrow and by the magnitude of the symptoms. Blast cells are immature cells, 
which in a healthy patient would mature and perform important immune system functions. The 
disease develops when too many blast cells do not mature, and therefore the ratio of blast cells is 
higher than normal. These mutated blast cells continue to be immature and being often formed in 
a rapid pace, they take the space of normal cells. 
CML is most commonly diagnosed in the chronic phase. Symptoms of a low ratio of white blood 
cells, red blood cells and platelets are for example infections, anemia, easy bleeding and bone 
pain.  
Chronic phase. In this phase, fewer than 10% of the cells in the blood and bone marrow are blast 
cells [109]. CML develops slowly in this phase, so it is often stable for long periods of time. 
There exist successful treatments that allow control of the symptoms and of the disease but not all 
the patients are responsive to this treatment [97]. For these patients, the transition to accelerated 
phase occurs within 5 years of diagnosis. 
Accelerated phase. In this phase, 10% to 19% of the cells in the blood and bone marrow are blast 
cells [109]. When a patient reaches this phase, the treatment becomes much more intensive, since 
this transition indicates the progress of the disease and the possibility of advancing to blast crisis 
is very high. The transition to blast phase requires less than 12 months. 
Blast phase.  In this phase, 20% or more of the cells in the blood or bone marrow are blast cells 
[109]. This phase is also known as blast crisis. Drug treatments are often not successful in this 
phase. 
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Figure 26. Distribution of samples in the different CML types 
118 of the samples have information on CML classification. The distribution of the samples in the 
different types is shown in Figure 26. cd34 are samples of normal immature CD34+ cells, chronic- 
are chronic samples, not treated with imatinib, chronic+ are chronic samples treated 
unsuccessfully with imatinib, ap are samples from accelerated phase by blast count criteria and 
ap-cyto by the occurrence of additional clonal cytogenetic changes, blast c are blast crisis samples 
and bc rem are blast crisis samples of patients in remission after chemotherapy [119]. 
Figure 27 shows the sample covariance, where is clear that the chronic samples are highly 
separated by their type, in the heat map, this region shows a lighter color. 
 
 
Figure 27. Correlation of the CML 
samples 
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3.4 Sorlie dataset 
This data set was introduced in 2002 in a study for predicting breast cancer survival [149], and it 
has been widely used in studies on breast cancer classification and pattern search [10,5,78,96,17]. 
The set consist of 295 tumor samples, 151 patients who had lymph node-negative disease and 144 
who had lymph node-positive disease, 10 from the first group and 120 from the second had 
received adjuvant systemic therapy consisting of chemotherapy (90 patients), hormonal therapy 
(20), or both (20) [17]. Additionally there is available information on clinical data as tumor size, 
ER status, tumor grade, age, nodal status, and information on events such as new metastasis, 
surgery and death.  No data is missing. Figure 28 shows the histograms for the distribution of the 
clinical data in the set.  
 
 
Figure 28. Histograms for clinical data in Sorlie data set 
 
Figure 29 is a heatmap of the covariance, None of the correlations seem significant as to have 
an impact in future analysis. 
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Figure 29. Correlation of the Sorlie 
samples 
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Chapter 4 
Workflow 
Abstract. One of the most valuable results of this investigation is the definition of a clear workflow that not only 
reflects the course of the research, but also states some basic steps that should be run over any data set before 
further analysis is considered. This chapter explains the steps that were considered to accomplish the results of 
this investigation and clearly exposes the algorithms and parameters that were implemented and used. The 
chapter is divided in sections that can also be found in Chapter 5, establishing a one to one relation of workflow 
and results. 
4.1 Overview of the workflow 
We have defined a workflow that addresses the first steps (after preprocessing and normalization) 
in gene expression analysis for relating genomic and clinical data, and should be the base for any 
further analysis, since it encompasses simple and effective tasks that provide information over 
gene expression data sets.  
Any analysis should provide information on the pattern finding possibilities, and also on the 
soundness of the applied analysis. Clearly, gene expression exploration is highly dependent on the 
final objective of the study, but in general some steps can help clarify the search for information. 
The steps correspond to basic analyses performed by many investigators at the beginning of their 
research. As important as it is, most studies do not follow all steps, and until now, is not clear 
which preprocessing steps are important and which aren’t.   
Under this idea, we propose a standardization of the initial processing, so that datasets can be 
explored and compared accurately. The workflow represents a novel compilation of processes and 
tools that, unlike any other in literature [136], addresses general gene expression analysis, and 
compares different methods, whose advantages and disadvantages can aid in the search for 
information.  This helpful suite is a valuable tool for the researcher, by exploring different fronts, 
and avoiding gaps in the investigation process. Its benefits include the possibility of comparing 
different datasets under the same considerations; extraction of information under different 
methodologies, minimizing the possibilities of missing concealed information; evaluation of the 
results, so that outcomes are assessed by comparison to other processes, as by valuation 
processes; and easy reproduction and publication of the results, by following the same detailed 
workflow. 
Figure 30 shows the suggested steps to understand any data set and the intrinsic relation of the 
clinical data and the genetic data. Blue boxes represent mandatory steps, green boxes represent 
  72 
advised steps, and purple boxes are steps that, depending on the objective of the study, can be 
valuable for the research.  
Once a goal for the investigation is established, the workflow can be followed so that the 
further steps can be clearly planned. The figure shows how the first step should be data selection, 
where the available datasets are analyzed (what data is available, how is it distributed, etc.) and 
cleaned (outliers are removed, normalization, etc.).   After the data is ready, a common step is 
dimensionality reduction, since it facilitates the statistical and graphical analysis. We propose to 
consider at least two possibilities for feature extraction: PCA (or SVD) and NMF (see section 
2.3.1).  These methodologies have restrictions that result in reduced data with different embedded 
information, which can be more or less valuable to final goal of the investigation; therefore, we 
consider that at least two methodologies should be applied, so that the results achieved with each 
of the methodologies should be compared, in order to accurately retrieve the maximum amount of 
information. The following steps in this branch would be clustering, which includes cluster 
assessment analysis, and once stable clusters are defined, tools in pathway analysis (as gene 
ontology methods) would offer important information on the clusters and their validity. The 
information ratio (IR, section 2.3.4.2) is suggested as an important decision helper, since its result 
can lead to further analysis inside the reduced data, or to go back to the beginning and try a 
different possibility.  We consider also cell line correlations, as a good method to find interesting 
relation between samples, and IC50 analysis (section 2.3.4.1), when the data is available, so that 
the clusters can be evaluated under medication measures. 
A second branch considers regression. Different regression methodologies can show the 
correlation between gene expression and clinical parameters, so we propose to consider simple 
linear and logistic regression, and tools such as spline regression or neural network regression to 
discover the patterns in the data. This step should also be considered after dimensionality 
reduction, since the methods perform better in a reduced data set. Again, the proposed method 
comparison aids in the search for information, that can show different behavioral patterns for 
different variables, and therefore can be retrieved with only a set of methods; by using more than 
the basic ones, we increase the possibility of finding these patterns. 
Mixture models represent another possibility for data analysis, which does not require feature 
extraction as a preprocessing step, avoiding eventual information loss. Although mixture models 
in themselves can be very important for information search, we propose to consider specific 
bimodal distributions in the data, since they have been found to be common in gene expression 
data, as explained in section 2.3.4.5.  
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It is our view that this proposed workflow analysis should be followed as preprocessing, since it 
allows the researcher to decipher the data and to understand where the information is lying and 
which methods can be helpful in retrieving it. 
The steps are specified in this chapter, along with a description of our specific approach, and 
more detailed workflows, meant for the specific goal of relating clinical to genetic data. The 
methods used in this section are described in Chapter 2, so that here we give additional 
information on the specific software and parameters used. 
We have applied this workflow to the BC, BSP, VTT and CML data sets (see Chapter 3). 
 
Figure 30. Workflow 
4.2 Dimensionality reduction 
PCA and NMF were selected as methods for dimensionality reduction.  The results obtained from 
the dimensionality reduction techniques allow understanding the correlation between samples and 
the relation between clusters and clinical parameters, from where prediction methodologies, such 
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as regression, can be applied, and the methodologies can be focused on specific interesting 
clusters. 
The data was normalized so that every sample has mean zero and standard deviation 1. 
PCA. Singular value decomposition and principal component techniques were applied to the 
data sets. The results were analyzed considering the relation of each of the principal components 
to the clinical traits. In the specific case of the BC data set, information on clinical characteristics 
was included in the extraction of the components, creating a reduced data set, with 3 components, 
or Malignancy Axes, as they will be referred from now on [129]. The resulting components are 
related to proliferation, stress response and metabolic processes. These malignancy axes show 
higher accuracy in dividing the data according to clinical traits. 
Matlab  functions svd and princomp were used.  
 
 NMF. For the non-negative matrix factorization method, the 
data was transformed to avoid negative points. Different 
algorithms and different platforms were tested (see Table 1), 
due to the dimensions of the problem, the C++ algorithm was 
chosen to take advantage of its speed and accuracy, and it was 
run on a Linux cluster.  As for the parameter k, that defines the 
number of factors, several possibilities were tested, ranging from 2 to 15. Heatmaps are produced 
with the function consensusmap, which generates plots of the consensus matrix (the average 
connectivity matrix calculated over multiple runs of the NMF factorization).  
 
4.3 Clustering 
By dividing the genetic data into clusters, and then analyzing them, we expected to obtain 
information about those clusters, and then associate information about the cluster characteristics 
to the genes that belong to them. For instance, knowledge on the IC50 indexes over certain 
samples that belong to a cluster may indicate that some other samples in the cluster (for which we 
don't have information) behave similarly. In this way it is important to find stable clusters and to 
retrieve as much information from them as possible. In this step we focus on the clustering of the 
samples (patients), and we used the available information to add clinical relevance to the clusters. 
Therefore, in the BC dataset we divided the studies in the 4 treatment groups and performed the 
clustering inside these groups.  The clustering methodologies were described in section 2.3.2. 
Platform Package 
R NMF [50] 
Matlab NMF [93] 
C++ Lawrence [89] 
Table 1. Software for NMF 
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 After applying PCA, we considered as clustering methodology k-means and k-nearest 
neighbors, whose results were very similar. A fuzzy clustering algorithm was also used 
to determine the amount of important outliers and the possible need of removing them. 
The clustering is considered over the matrix Yt (See section 2.3.1.1). 
 When NMF was applied, the resultant matrices (nmf(X) = WH) were used to define the 
clusters. Ding et al. [33] have shown that, when a least square NMF is applied, the W 
matrix holds cluster centroids and the H matrix can be used to define membership. 
4.3.1 Clustering algorithms 
We considered three Matlab functions for clustering. In Table 2 a short description on the 
functions and parameters is given. 
Table 2. Software for clustering 
Algorithm Function Replicates Clusters Description 
k-means kmeans 500 N/35 The number of clusters was decided according to the number of 
samples in the group divided by 35, so that the clusters would have 
more than 20 elements, and less than a 100 
KNN knnsearch 100 Defined by 
algorithm 
 
Fuzzy 
clustering 
FCMclust from 
Clustering 
Toolbox [2] 
 5 The weighting exponent (which determines the fuzziness of the 
clusters) was fixed as 2, the termination tolerance was set to 1e-6, 
and all other parameters were left to defaults. 
 
4.3.2 Cluster Analysis 
Clustering the samples offers a possibility to analyze the behavior of gene expression under 
specific related samples. With this approach, specific genes are not directly considered, 
transferring the focus to samples and patient related data. Given the information available for the 
datasets, different analysis methodologies where implemented: 
 
Clusters and traits. The clusters were graphically depicted using colors and signs to highlight 
positive and negative values for the clinical traits. This analysis relays on the clustering ability to 
congregate samples with similar traits, and allows comparing the different treatment groups in the 
light of the clinical information. The plots were implemented in Matlab.  Specifically, in the 
case of the BSP and VTT data sets, the clusters were evaluated under the light of the available 
IC50 data, obtaining plots that showed the behavior of specific drugs in specific sample groups. 
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Gene Ontologies. A gene ontology analysis (described in section 2.3.4.3) was conducted using 
the GSEABase [105] package in R. Since the clusters contain samples instead of genes, the 
package NMF [50] in R was used to extract the features that are the most specific to each basis 
vector according to [81]. This extracted gene set was used as an input for the GSEA algorithm, 
performing a hypergeometric test where interesting genes (according to the feature extraction 
method) are tested to see their relation to GO categories [44]. The cut-off parameter was defined 
as 0.05, we looked for overrepresented GO terms in the BP (Biological Processes) GO annotation 
lists.  
 
4.3.3 Comparison of dimensionality reduction techniques 
The results obtained with NMF and with PCA were compared to understand the advantages and 
disadvantages of both methods, in order to provide reliable results, and to prove that unsupervised 
analysis can reveal interesting findings, not only by highlighting biological findings, but also by 
pointing to new markers that may be interesting for research. 
The comparison of the NMF and PCA results was done for each k in the NMF analysis. Inside 
each group of clusters (each k), for each cluster, a t-test was performed over gene expression data, 
defining as null hypothesis the fact that the elements in the cluster and the rest of the elements are 
independent random samples from normal distributions with equal means and equal but unknown 
variances, against the alternative that the means are not equal, resulting in one p-value per gene. 
These p-values are plotted against each component of the reduced coordinate system achieved 
through PCA, there is a point for each gene. These plots can show correlation between a specific 
NMF cluster and a specific PCA component. 
 
4.4 Regression Analysis 
A regression analysis step was performed both before and after applying dimensionality reduction 
techniques. The different types of regression considered were explained in Subchapter 2.3.3, and 
the software functions used are summarized in Table 3, along with a short description on the 
parameters. 
Table 3. Software for regression analysis 
 Software Function Description 
Linear 
regression Matlab polyfit 
Finds coefficients for a polynomial of a given grade n, that will fit the given 
data
 Matlab regress Multiple linear regression 
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Logistic 
regression R rms [77] 
The method was used by treatment groups (in the BC dataset) over the 3 
malignancy axes obtained after PCA. Applied also in the BC data over the 
mean of the reduced data (PCA) in each cluster. 
Neural 
network 
regression 
Matlab GMDH [74] For polynomial neural networks. Used on reduced data (PCA) in the BC dataset, with 3 inputs and default values on the other parameters. 
MARS 
regression Matlab AresLab [49] 
Applied to the BC dataset, with 200 as maximal number of basis functions, 
3 as the Generalized Cross-Validation (GCV) penalty per knot, allowing 
piecewise-cubic modeling with 3 maximum variable interactions. Other 
parameters where set to their default values. 
RBF 
regression Matlab 
Radial Basis 
Function 
Network [164] 
The package was modified to apply radial basis functions for data 
regression. The centers were picked as points with the smallest sum of 
squared Euclidean distance to all other points.  
 
4.5 Correlations 
In the VTT and BSP data sets the samples come from different tissues, as exposed in Chapter 3. 
Using results from different runs of NMF, with different k, we sought to find the relation between 
different cell lines, based on the number of times they were classified in the same cluster, and 
considering whether or not they are classified together in large k since it is more probable that 
unrelated samples are clustered together when the number of modules is low than when it’s high. 
In this way, each pair of cell lines has an associated grading, that adds (1+ 0.2*k) when the cell 
lines appear clustered together after applying NMF with factor k. 
 
4.6 Gene expression distribution 
IR. We applied the information ratio criteria to the BC data set. We used R to fit the original 
dataset, the projected dataset and the residuals to a specific clinical trait, through the lmFit 
function. We calculate an empirical Bayes (eBayes function) on all fittings, and we use the 
logarithm of the p-values to plot comparisons between projected data and residual information. 
Genome graphic comparison. By modifying the Bioconductor package GenomeGraphs [38], 
we developed a graphic comparison of the CML data for the different types, by plotting the gene 
expression data under a genome coordinate system. In this way, it is possible to compare the 
expression levels of different chromosomes in different CML types, and to add information on 
chromosomal alterations (such as copy number variations) to create a full scheme of the dataset. 
Since we didn’t have additional genomic information for any of our datasets, we used an 
additional set of pluripotent data to develop and test the graphics, and we applied it to the CML 
dataset, ignoring the additional graphic possibilities. Even when not all information on genome 
alterations is available, it has been shown that it is possible to infer it from the gene expression 
values [106], and this method allows to compare known chromosome alterations and their 
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differences in the pathology groups. We consider that this comparison is an important part of our 
workflow and can have major influence in cases where more genomic information is available. 
In the specific case of CML data, there is evidence on the mutations on chromosome 22, and in 
worst cases, also chromosome 8 or chromosome 9 [124]. 
Mixture models. With the aid of a mixture model we searched for correlations in gene sets, so 
that this sets characteristics could be proposed as explanatory for specific clinical traits. We used 
the BC data set and the clinical information on tumor grade to divide the data into 3 categories 
(we tried also 6 categories, by adding ER status to the division, having then 6 possible states). The 
mixture model used assumes that the data is a combination of low grade and high grade. 
For each group the mean of the clinical parameters was evaluated and an estimator for the median 
(mx) and standard deviation was calculated using bootstrap (Matlab function bootstrap 
with 10000 repetitions). The population was checked through a t-test to evaluate whether or not 
the mean expression of genes in samples with low grade is the same as it is in high grade. The 
genes where this condition shows a difference where selected, by choosing those whose p-value is 
in the lower 0.5 quantile.  
We calculated then a model such that the expression of those selected genes  (xw) could be 
factorized in the estimated medians and a matrix rlg that would contain additional information. 
ݔݓ ൌ ݉ݔ ∗ ݎ݈݃ 
This new matrix was used to calculate windows of genes with similar values. Several window 
sizes were tested, such that the correlation (calculated using the function corrcoef) inside those 
windows was as high as possible. We used t -tests to show that these gene windows can be 
considered as clustered apart from the rest of the data.  In this way, sets of correlated genes, which 
showed a bimodal property, were selected, and their correlation to other genes with similar 
properties was shown. This workflow lead us to believe that the bimodality property shown by 
these genes can be further exploited into more precise predictive models, which would be 
explained in the next sub-chapter. 
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Figure 31. Workflow for finding bimodal genes (Sections 4.7.1 and 4.7.2) 
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Figure 32. Workflow for finding trait-gene relationships in bimodal genes (Section 4.7.3) 
and second gene selection (Section 4.8) 
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4.7 Bimodality 
We searched for bimodal genes over the breast cancer data set. Given the nature of this data set, 
divided in 9 different studies, the analysis was performed by study to find the bimodal genes and 
then as a whole to cluster them and finding trait relationships. Figure 31 and Figure 32 expose the 
specific workflow, starting from the raw data and ending in a set of interesting genes. The 
objective is to take advantage of the bimodal distribution seen in gene expression, to select genes 
that are highly correlated to the clinical parameters, and can perhaps be used to predict them. As a 
major benefit, the process performs automatically, in the sense that it does not require interaction 
with expert knowledge to take decisions. 
The process considers two gene selections: a first one by study, where bimodal scores are 
calculated and used to decide (as seen in Figure 31); the second one occurs after clustering the 
genes (inside each study), a correlation with clinical traits is calculated (Figure 32), and the genes 
are assigned a score, which is used to perform the assortment. 
This novel set of procedures assembles a methodology for feature selection, which does not 
require previous knowledge on the genes, and uses the available data to grade and classify genes.  
Each of the steps in this workflow is described in this section, along with the software used. 
 
4.7.1 Bimodality scores 
The data was analyzed separately by study and bimodal genes were selected in each of the 
studies. A first normalization step was considered, where samples were taken to mean zero and 
standard deviation 1. Then seven different bimodality scores were calculated using R (see Table 
4), the description of the methods was given in section 2.3.4.5.  
Table 4. Software for bimodality scores 
Score Function Description 
VRS and 
WVRS kmeans 
The centers were initialized using the minimum and maximum value of the 
expression for each gene. Low scores reflect bimodality. 
DIP diptest [98] The function dip computes Hartigans’ dip test statistic for testing unimodality. A low score is considered a sign of bimodality. 
Kurtosis e1071 [32] The genes with the lower kurtosis are considered as bimodal 
LR 
loglik from the package stats 
 
mclust from MClust [46] 
This model based approach applies maximum likelihood estimation and 
Bayes criteria to identify the optimal model, and it is initialized by 
hierarchical clustering for parameterized Gaussian mixture models. Large 
ratios suggest that the expression is bimodally distributed. 
BI bimodalIndex, package ClassDiscovery [23].  
OS median and mad quantile 
 
The 25 and 75 quartiles were considered. 
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4.7.2 Bimodal genes selection 
Using the seven different bimodal scores, genes where selected considering the amount of 
times they were classified as bimodal. In this way, for each study, each gene has a score 
from 0 to 7; 7 representing that a gene is considered bimodal by all the methods, and 0 that 
it is not recognized as bimodal by any method. We chose as a cutting point 3, so that all 
genes considered bimodal by more than 3 methods were selected. 
Bimodal genes normalization. Once selected, the bimodal genes are normalized so they 
can be compared and correlated (see section 2.3.4.5). This normalization is done by study 
using the returned values of the bimodality index method as the two bimodal means. 
Further data cleaning. Patients with unavailable gene expression data are removed. 
 
4.7.3 Clustering 
Once a list of interesting genes is defined, the objectives become the study of this list, the 
correlation between this interesting genes and their relation with clinical traits. 
In order to do this analysis, the genes were clustered using k-means and NMF (Table 5). 
The two methods where compared in terms of clustering results, by analyzing the in-cluster 
correlation and the prediction ability of the clusters when looking for different clinical 
traits. All the cluster sets were tested for robustness and reliability using the R package 
Clusterv [146]. 
Table 5. Software for bimodal clustering 
 Package Number of clusters Parameters 
k-means kmeans 7-13 Random inicial centers, 100 replicates and cosine distance. 
NMF NMFCluster 7-20  
 
For k-means cosine distance was used, based on the paper by Bessarova et.al [10], where they 
select groups of synchronously expressed genes using this type of distance measure.  
4.7.3.1 Cluster relation to clinical traits 
The clusters were tested to see the relation with clinical traits. For each of the traits (ER 
status, nodal status, grade and relapse) two different approaches were considered: 
Distance. Consider one specific trait and one specific cluster. We divided the 
patients that hold a negative value of a trait (in the case of grade, the lowest 
  83 
grading: 1), and with positive value, to be referred as p- and p+ patients. We 
calculated for each gene the mean value of the patients with this negative trait 
(for future reference: m(p-) ). Then the distance from every patient data point to 
this mean is calculated.  In this way, under the assumption that low and high 
values for clinical traits can be seen in gene expression data, low distances should 
correspond to negative values of a trait, while high distances correspond to 
positive values.  Then, a new matrix of distances is now considered, so that we 
can also divide these values according to corresponding patient, d- would be the 
distances of the patients with a negative trait and d+ the distances of those with 
positive trait. For each gene, the mean of d- and d+ was calculated, and a rank 
test for the cluster was performed, where the null hypothesis is that both sets have 
the same median. 
This process was repeated for all traits in all clusters, so that each cluster has an 
associated p value for each trait, defining whether or not the specific gene cluster 
can be used to differentiate between positive and negative values of a trait. 
LOG(p). Again, consider a specific cluster and a specific trait, where the patients 
are divided according to the latest in p- and p+. A rank test is performed for each 
gene, where the null hypothesis is that gene expression of p- and p+ patients have 
the same median.  In this way, each gene has an associated p-value. We tested 
these values to see the fit to a uniform distribution, expecting to prove that the 
null hypothesis is indeed false. In this way, each cluster has an associated p-value 
that states whether or not the cluster is relevant to differentiate the clinical trait 
values.  
For plotting, the logarithmic transformations of the p-values of the genes are 
used, and the value is forced to be positive when the mean of the expression of 
the p+ patients in the gene is larger than the mean of the p- patients, and negative 
otherwise. 
Cluster analysis. The clusters were analyzed using enrichment analysis and network 
correlation analysis tools [138,88]. Besides, the clusters were tested to confirm the co-expression 
of the genes inside them.   
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4.8 Second gene selection (GTK) 
A further selection of genes was performed using the results of the cluster analysis. We used 
the results of the different clusters to find those where the p-values were significant. Since we 
used different numbers of clusters, and followed an analysis on all these different clusters, we 
could compare the robustness of the cluster analysis results and the p-values trough the different 
cluster sets, and different studies. Each gene was assigned points whenever it belonged to a cluster 
with significant p-value for a trait in a study, and extra points when the cluster analysis gave 
additional information.  10% of the top ranked genes were selected at each time (for each factor or 
each k), and those who belonged to at least 80% of the lists where considered. 
Using this system, a new reduced set of genes (GTK) was generated, that is not dependent on 
the study and holds genes with bimodal distribution and high relation to traits. 
GTK analysis. The new set of genes was analyzed individually and then in new generated 
clusters.  A similar workflow was followed to analyze this set, as with the previous larger one. 
The gene expression data of all the studies was used together to generate clusters using the k-
means algorithm. Then, the relation of these clusters to clinical traits was assessed, followed by 
the respective cluster analysis. 
Cluster stability was tested using the function clusterboot in R, from the package fpc 
[63].  The inherent unstable grouping of gene expression data, combined with the sensitivity of k-
means to outliers can generate unsteady clusters. The stability assessment algorithm resamples the 
data using several schemes (we used bootstrap, jittering, and a combination of both) and computes 
the Jaccard similarities of the original clusters to the most similar clusters in the resampled data. 
The mean over these similarities is used as an index of the stability of a cluster [61]. We generated 
a new interface for the package, so that the method skmeans (k-means with cosine distance) 
could be tested. The interpretation of the results depends on the Jaccard similarity value, when it 
is smaller or equal to 0.5 as an indication of a "dissolved cluster" [62]. A highly stable cluster will 
have a value above 0.85, a stable cluster should be above 0.7, and between 0.6 and 0.7 the cluster 
indicates a pattern, but the stability cannot be guaranteed. Below average Jaccard values of 0.6, 
clusters should not be trusted. All of this refers to bootstrap, for the other resampling schemes it 
depends on the tuning constants, though their default values should grant similar interpretations in 
most cases [61]. 
The clusters were analyzed using GSEA [132] and WGCNA [88]. Besides using the gene 
ontology analysis, we used the WGCNA package to test the Pearson correlation between the 
genes in each cluster, in order to confirm the stability of the results. Also, the WGCNA package 
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allows the development of trait-expression relationship analysis, by using the eigengenes of a 
cluster and calculating their correlation to the clinical traits. We used this technique to further 
analyze the predictive ability of the genes in each cluster. 
We used the concept of hierarchical organization and gene network interconnectedness 
[168,121] to study the gene associations inside the clusters, by generating a Topological Overlap 
Measure (TOM) and gene networks with the aid of the WGCNA and the GeneNet [126] R 
packages. 
GTK analysis in the Sorlie data set. The same process as before was applied to Sorlie data set, 
using only the reduced set of genes defined before. The cluster-trait relations were studied for 
each cluster, and compared between the two data sets. 
4.9 Neural Network prediction 
The clusters that showed significant correlation to the clinical information were used to train a 
neural network to predict the outcome of a specific trait. A three layer neural network was used, 
where the input layer is a Linear layer and the output layer is a Sigmoid layer. The hidden layer 
was tested using an RBF layer, Linear layer and a Gaussian layer with 200 nodes.  The initial 
momentum was set to 0.8 and the learning rate to 0.4, with 10000 cycles. The Java framework 
Joone [99] was used in the implementation of the predictor. 
We considered the first 5 eigenvectors in the clusters, and we feed the network with them in order 
to produce a relapse prediction. We performed training and testing using only the BC dataset and 
also training with the BC dataset and testing in the Sorlie dataset.  The result is a predictive 
number per cluster, which we combined in another neural network using a sigmoid hidden layer, 
resulting in a single predicted value.  
BC training and testing. We choose randomly 80% of the samples in the BC data set for the 
training phase, and we used the rest of the samples for testing. We repeated the random choosing 
5 times, to confirm that the results are not dependent on the used samples. 
BC and Sorlie training and testing. We used all the BC samples to train and all the Sorlie 
samples to test. 
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Chapter 5 
Results 
The results obtained from applying the workflow of chapter four to the data sets described in chapter three are 
shown in this chapter. Many procedures were applied with different parameters, so the amount of results is too 
high to expose completely. We have chosen a set of results that shows the accomplished goals from the workflow 
and the turning points that took us to the next step.  Methods like regression and dimensionality reduction can 
offer nice results, but they are usually not good predictors unless combined with techniques like clustering.  In 
many cases, it is necessary to add expert knowledge to drive some methods to the specific goals, generating a 
draw back in the search for an autonomous prediction process. The results obtained with NMF were compared 
to those obtained with PCA, from where we conclude that, in this specific type of data, NMF offers better results. 
Linear regression was not enough for variables like relapse or grade, where MARS, NN and RBF regression 
worked much better. These results were not perfect, especially for relapse, but the improvement attained 
through complex methods, cluster analysis, and IR, led us to consider mixture models and to study in detail the 
intrinsic bimodality found in gene expression. Bimodality selection and further clustering showed accurate 
results in the correlation of gene groups and clinical traits. These predictive characteristics were summarized 
into a Neural Network that showed prognostic capabilities of up to 80%. 
 
In this chapter we attempt to summarize the results of applying the methods in chapter 2 by 
using the workflow in chapter 4 to the datasets in chapter 3. The amount of data obtained is very 
high, since many methods were considered, and different parameters were tested over some or all 
parts of some or all datasets.  The subchapter division resembles that of the fourth chapter, so the 
results are attached to the workflow that leads to them. We have selected a set of graphics and 
tables that exemplify the form of the obtained results, larger tables can be found in the appendices 
or online upon request. 
5.1 Data Dimensionality Reduction and Clustering 
This branch of the workflow attempts to find correlation between samples, and cluster and 
correlate them to clinical traits, by using feature extraction and clustering techniques. We applied 
PCA and NMF to the BSP, VTT, BC and CML datasets. In general, the results of PCA are poorer 
than those of NMF, in the sense that clusters are better differentiated for matrices resulting from 
NMF, and the clusters show biological meaning.  
The results obtained for each of the datasets will be described in this section, and will be 
employed in the development of cluster analysis, regression and cell line correlations. 
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5.1.1 BSP-VTT Data 
First we used the combined data as one big study. When the data was broken into clusters, it was 
clear that the clustering was guided by the study, showing that normalization was not enough to 
reduce the bias. We tried different k values in NMF, from 2 to 10 and the best results are in k = 
3, where the clusters showed high cohesion and less outliers, since samples were clearly related to 
those in the same study. Figure 33 presents the results for SVD and for NMF with k = 3; the SVD 
analysis, on the left, shows the samples framed under the resulting first 2 components. Samples 
with the same origin are colored alike, showing in the graphic that samples from the same cell line 
lay very close to each other, but there is not a clear division by cancer type. A similar result is 
obtained with NMF, where samples from the same cell line cluster together, and as the heatmap 
shows, samples from VTT and BSP don’t cluster together. This fact appears independently of the 
parameter k, as shown in the figure with 3 components.  
 
 
Figure 33. SVD and NMF on BSP and VTT combined data The left graphic shows the samples 
in the reduced component space (first and second component), the colors represent sample groups (according to 
the tumor type); on the right a heatmap for NMF with 3 factors, where the samples divide according to the study. 
 
Given the clear separations present in the data analysis, generated by the combination of the 
studies, we applied the same analysis to each study (VTT, BSP) separately, obtaining clusters that 
showed correlation between cell lines.  
For the BSP dataset, PCA analysis did not offer any improvement in clustering, making clear that 
NMF did a better job dividing the data, and the obtained clusters had biological relevance 
(samples of the same type were clustered together).  When applied over the VTT dataset, the 
results where clearer for PCA than in the BSP case; NMF showed good separation into clusters, 
showing high inner cluster correlation, and few outliers, sepecially for 2, 6, 7 and 8 clusters. 
VTT 
cell lines 
BSP 
cell lines 
  89 
Figure 34 shows on the left the 3 first principal components, colored by clusters obtained by 
applying k-means; these clusters do not seem related to the cancer type. On the right, a heatmap 
for NMF with 3 factors is presented, where, as in the BTT case, samples from the same cell line 
cluster together, and the clusters show good differentiation. In the graphic each label represents 
the samples of the cell line (in general 3, see section 3.1 for data description), to facilitate the 
reading.  
 
Figure 34. PCA and NMF on VTT data On the left, the VTT samples are plotted on the first 3 PCA 
components. The colors represent 5 different clusters, generated using knn. On the right an NMF heatmap with 3 factors, 
each label represents 3 samples of the same cell line.  
 
 
5.1.2 Breast Cancer data 
Through mean and standard deviation comparisons, all the treatment groups were tested for 
outliers and obvious trends. The malignancy axes should lie in similar spaces inside each group; 
since we don't want that the group division to alter the cohesion of the data. Anova analysis and 
box plots were generated for the malignancy axes in the 4 treatment groups, Figure 35 shows the 
results for the first malignancy axis. 
PCA NMF
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Figure 35. ANOVA analysis for the first malignancy axis, BC dataThe analysis was performed 
inside the treatment groups. All groups show similar values, not only for the malignancy axis, but also for the 
clinical parameters. The slight differences imply that no important outliers are found and yet they can be useful 
when differentiating the groups through methods as regression. In the left plot, the central red mark is the median, 
the edges of the box are the 25th and 75th percentiles, the black lines extend to the most extreme data points not 
considered outliers, and outliers are plotted individually in red crosses.  
 
The analysis illustrated that there are no important values outside the expected fringe. This same 
examination was carried out for all variables (patient information), and was important to 
understand the amount of information that was available and to check that all variables have a 
similar behavior inside the groups.  This simple analysis allowed classifying the different clusters, 
according to the different variables, and of course to analyze the effect of treatment over the 
variables, if there is any. In case of relapse, it is clear that study 3 has the lower value for relapse, 
which can make sense, since patients that don’t require a systemic treatment are usually the ones 
that have a less malign cancer.  This same result can be seen in tumor grade.  
After applying PCA, with the malignancy axes methodology [129], we clustered inside each 
group through the malignancy axes values using k-means and KNN, since the results were very 
similar, we consider only the results of the k-means algorithm. A total of 27 clusters were 
obtained, by diving the sample size into 35, an empirical decision so that the clusters contain more 
than 30 samples and less than a 100. When plotted in 3 dimensions, the clusters show no 
graphical differentiation, mixing in the planes independently of their treatment group or they 
mean values for clinical parameters.  
 
We explored the clustering results through box plots, which showed, as expected, a difference in 
the malignancy axes values for the different clusters, and also showed important differences in the 
values of some variables between clusters. 
For instance, for ER Status, the mean of the clusters can be easily divided in low and high (Figure 
36, in the left organized by cluster number, in the right organized by value). 
  91 
 
Figure 36. Histogram for ER status values in the different clusters On the left, the histograms are 
organized by cluster number, while on the right the same histogram is shown but sorted according to the mean ER status value. 
 
This difference was further analyzed to find similarities between these clusters. The exploration 
showed that samples with similar ER status are more likely to cluster together, and therefore, the 
differences in ER status through the clusters should be clearly different. With only two clusters, 
ER positive and ER negative samples can be separated with high accuracy. 
As a test for the malignancy axes and the k-means, a fuzzy distribution algorithm was run over the 
data, using only 2 dimensions at each time to allow graphics. This clustering show some outliers 
and some groups where the division is not so clear, but in general shows that it is possible to 
cluster the points without further complications. 
Figure 37 shows the results of fuzzy clustering over the first 2 malignancy axes, with 27 clusters, 
as a comparison to the k-means results.  From the graphics it is clear that the amount of outliers is 
low and can be interpreted as noise from the raw data.  
 
Figure 37. Fuzzy clustering in BC data The results of fuzzy clustering over the first two malignancy axes, 
with 27 clusters is shown. Most samples cluster together closely, but there are some points that seem far from the 
cluster centers, and should be further studied.  
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5.1.3 CML data 
Figure 38 shows the PCA decomposition for the data. Using the clinical information, colors where 
used to differentiate between CML types. The figure shows a clear division between chronic and 
blast crisis samples, and it shows how the accelerated phase samples are more related to chronic 
than to blast crisis samples. 
 
Figure 38. PCA for CML data The CML samples are plotted under the first 3 principal components. The 
coloring represents the type of the sample. Chronic and blast crisis samples differentiate clearly, whilst 
accelerated phase samples mix with the chronic ones. 
 
This separations show also in NMF: Figure 39 presents heatmaps for NMF with 3 (left) and 9 
(right) factors. This clustering divides the samples according to their type, and the evolution of the 
clusters through the different factors showed a profound similarity to the PCA results,  
 
Figure 39. NMF for CML data (k=3, k=9) Heatmaps for NMF, on the left with 3 factors and on the right 9 
factors. In the first plot, chronic samples separate from others, giving no more information, as the factor increases, more 
information can be taken from the clustering, in the right plot chronic samples are still clustering together, as well as blast 
crisis, and accelerated phase samples show, as with PCA, not good differentiation.   
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5.2 Cluster Analysis 
Once the clusters are defined, they should be analyzed in order to evaluate them and find 
biological meaning.  We have considered gene ontology analysis to extract the relevant ontologies 
in all the clusters, and to compare them through the different datasets.  
In the case of the BSP and VTT datasets, the ontology analysis presented ontologies relevant for 
the specific cancer types in the clusters, when the cluster division was appropriate, and offering 
only general ontologies, when the number of clusters was too low. Information on IC50 was 
analyzed inside the clusters, so that differences could be detected between clusters. No significant 
information was found; nevertheless, since the clusters seem to be robust, the results on IC50 may 
be useful to extrapolate their values to the samples with no information, acting as a predictor. 
For the CML dataset, the clustering analysis showed important differentiation of the samples by 
type, specifically extracting chronic samples with high accuracy. The other types show some 
differentiation but with noise produced apparently by accelerated phase samples. The gene 
ontology analysis validated these considerations, showing specific gene ontologies for the best 
clusters, and little to no information in the clusters with accelerated phase samples. This result 
implies that there is information available for differentiating the cell lines, and should be retrieved 
by other methods, since only clustering is not enough. 
We also compared the results obtained through PCA and NMF, showing how only for the case 
of BC data the results show similarity, and this is only because in this case the method used for 
calculating PCA considers additional information, and therefore delivers a better component 
reduction. This means that NMF has more robust results for our data sets, and performs a better 
differentiation when only the gene expression information is used in the reduction. 
In this section, a sample of the specific results is exposed for each data set. 
 
5.2.1 Gene ontology analysis and IC50 analysis 
We ran a GSEA analysis over the VTT, BSP and CML datasets, in order to explore the biological 
meaning of the clusters. The analysis uses NMF clusters, and was implemented for all the 
clustering results (k=2-10). 
BSP-VTT 
As explained before, NMF sets cluster samples of the same line together, and that is the case 
independent of the number of factors, such that when many factors are used, the only grouping 
visible corresponds to samples of the same cell line. The ontology analysis shows general 
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processes when the groups are big; when clusters involve less samples, the analysis shows clearer 
correlation to the sample type, as part of the many general ontologies that are common in the 
output of the analysis. Apoptosis, cell cycle regulation and specific organ processes are results 
that confirm the effect of important clusters over gene expression, demonstrating that the clusters 
have indeed clinical sense, since they are grouped by organs. Nevertheless, there are some 
exceptions, where cell lines of different types of cancers group together.  These particularities will 
be studied when analyzing cell line correlations (Section 5.4).  
In Figure 40 results for the VTT dataset are shown, using the results of NMF with 7 factors, gene 
ontology extract for the third factor and IC50 analysis for the fourth factor are depicted.  
The analysis is similar to the one for the BSP dataset; the ontology results also show the strength 
of the clusters and their biological meaning. In the case of the figure, the cluster is composed only 
by breast cancer samples; the ontologies show relation to cancer related processes as estrogen 
stimulus and apoptosis [31], and also to the “regulation of biological process” network, implying 
a relation to breast cancer [156]. 
The IC50 graphic shows the IC50 value for the cell lines in the cluster, subject to the available 
information. This type of figure allows comparing the IC50 values in the different clusters, and 
once the strength of the cluster is proven, these mean values can serve as estimates for the rest of 
the overrepresented genes in the cluster.   
There is clear similarity between the clusters generated in the two different data sets. Most 
clusters can be defined by their gene ontologies, but others show only general genes, which could 
be a sign of clusters with less valuable information for our purposes.  
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Figure 40. NMF, GO and IC50 analysis for VTT Data After performing NMF with 7 factors, the 
clusters were analyzed using gene ontology analysis, on top, an extract of the significant ontologies for the 
third factor is shown. The IC50 analysis considers the mean over the samples of the available values, an 
example for the fourth factor is shown in the figure. 
 
 
 
  
Cluster 3 
GOBPID  Pvalue  OddsRatio  ExpCount  Count  Size  Term 
GO:0002260  0  6.98  1.06  6  28  lymphocyte homeostasis 
GO:0033032  0  12.76  0.46  4  12  regulation of myeloid cell apoptosis 
GO:0048523  0  1.39  69.15  90  1821  negative regulation of cellular process 
GO:0009987  0.02  1.32  414.54  431  10917  cellular process 
GO:0043627  0.03  2.21  4.29  9  113  response to estrogen stimulus 
GO:0007565  0.03  2.17  4.37  9  115  female pregnancy 
GO:0010556  0.04  1.22  102.79  119  2707  regulation of macromolecule biosynthetic process 
GO:0060603  0.05  4.02  0.84  3  22  mammary gland duct morphogenesis 
IC50 value, Cluster 4 of 7 
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CML 
NMF results show good divisions for the data, but the resulting clusters are not perfectly dividing 
the different states of cancer, although they do a good job in finding chronic samples and 
clustering them apart. Figure 39 shows a heat map for NMF with 3 and 9 factors; the amount of 
noise is clear, and also the amount of information won by a higher factor. 
 
The gene ontology analysis showed specific overrepresentation of apoptosis and cell fate 
processes, as well as general processes. Interestingly, the clusters with only blast crisis samples 
showed no significant overrepresentation according to the GSEA analysis. We studied deeply the 
clustering result of NMF with 9 factors, and 4 of those clusters show no significant gene 
ontologies,  precisely the clusters that hold blast crisis samples (except cluster 1 that has only 2 
samples). 
 
The results of NMF clustering, with factors 3 to 10, were combined in a table, so that the first 
column shows the gene id, the next 8 columns represent the different clusters according to the 
factor, and the last column explains the sample type. Using this representation, it was simple to 
find that with 8 factors, most of the chronic samples can be found in the same cluster, blast crisis 
samples also cluster together but the accelerated phase samples are not clearly differentiated and  
they are found divided in the different clusters. This result leads us to think that there are 
commonalities between samples of the same type, which could be extracted with other methods, 
and we do it through mixture models (section 5.5.3). 
5.2.2 Clustering improvements for BC data 
In order to analyze the effect of the clustering and preprocessing methodology, another way of 
handling the gene expression data was used.  In this case, patients with positive ER Status were 
considered as the point of reference for normalization of the malignancy axes values. 
We used a knn approach to generate clusters; our best result was achieved when the cluster size 
was 25. The twist in the algorithm consist in using each element as cluster center, and then using 
the 25 samples with closest distance (according to the first two malignancy axes) to the element to 
generate a mean value for all the clinical data.  In this way, each element holds now a mean value 
for all clinical traits that reflects the effect of the neighbor samples.  This approach produced 
excellent results in the search for a relapse predictor. Figure 41 shows a plot of the first two 
malignancy axes colored according to relapse: the relapse values were divided in quartiles, so that 
the lowest quartile got the lightest color and the highest quartile got the strongest color. This plot 
shows a clear separation between low and high relapse values.  
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Figure 41. Relapse in knn clusters The graphic plots the samples over the first two malignancy axes (x=first 
malignancy axis, y= second malignancy axis). After performing knn, the values of relapse are recalculated for each 
sample, considering the mean value of the cluster, and included as a color pattern in the graphic. The relapse values 
are divided in quartiles, the lower values are represented in light color and the higher values in dark color.  
 
 
5.2.3 Comparison of the dimensionality reduction techniques 
The advantages and disadvantages of NMF and PCA are clear, but in a specific data set it is not 
clear which one could bring more information. Both techniques are widely used, and PCA is 
considered simpler. The question that arises is whether or not NMF can reproduce results as 
reliable as the ones achieved through PCA. 
In the specific data sets that we have, PCA showed great results in the breast cancer data, but not 
so good on the BSP and VTT datasets. 
 
5.2.3.1 Breast Cancer Data 
The comparison of the NMF and PCA results was done for each k in the NMF results. Inside each 
group of clusters, for each cluster a t-test was performed, over gene expression data, defining as 
null hypothesis the fact that the elements in the cluster and the rest of the elements are 
independent random samples from normal distributions with equal means and equal but unknown 
variances, against the alternative that the means are not equal. These p-values are plotted against 
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each component of the reduced coordinate system achieved through PCA. These plots can show 
correlation between a specific NMF cluster and a specific PCA component. The main result is the 
confirmation that most NMF clusters are highly correlated to some PCA component. Figure 42 
shows an example of this. But here the used PCA has expert knowledge enriching the result, and 
therefore, NMF has proved to discover that additional knowledge automatically, giving results 
that are at least as good as the ones for PCA (extracted as malignancy axes). 
This result exposes a clear strength of NMF, which allows clustering data sets into groups with 
biological meaning. 
 
 
Figure 42. PCA and NMF comparison (BC data) . The plot shows p values of a t-test over gene 
expression data in NMF clusters (x axis), plotted against each component of the reduced coordinate system 
achieved through PCA (y axis). In the plot, as an example of the results, study 3, cluster 3 of 9 compared to 
PC 1 is shown. 
 
5.2.3.2 BSP-VTT Data 
We considered the first 5 principal components, applying the algorithm to the separated data sets, 
Figure 43 shows the results of the PCA analysis without clusters. The data does not seem to have 
clear groups, although we know they exist and they can be found in NMF. 
  99 
 
Figure 43. PCA, 3 first principal components for BSP and VTT Data sets On the left, the 3 principal 
components for the BSP dataset are shown. On the right for the VTT dataset. The PCA analysis does not differentiate clear clusters in 
these datasets. 
 
We ran NMF with k ranging from 2 to 10, in subsets of data divided according to the defined 
studies. For each k in each study, a Gene Ontology analysis was run, and an analysis of the IC50 
data inside that cluster. 
 
 
VTT 
Figure 44 shows the different clusters obtained when running NMF. As explained before, 
different samples of the same cell line are clustered together; therefore, high values of k don’t add 
much information to the analysis.  k=5 and k=6 give a good cluster division, by putting together 
related cell lines, like for instance MCF7 and T47D, both breast cancer cell lines.  
   
 
Figure 44. Heatmaps for NMF clusters on VTT Data The result of performing NMF over the VTT dataset 
is plotted in 9 different heatmaps, according to the factor, the first map on the top-left has factor 2 and the last map 
on the down-right has factor 10. The gain of information is clear as the factor increases, but in the highest factor, the 
clustering corresponds to samples of the same cell line. The best factor should be in the middle. 
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BSP 
When running NMF over BSP data, results were not as clean as in the VTT data set. The 
comparison of the different heatmap results showed that above k=7 no interesting information is 
revealed by the clustering.  For k=9 for example, the clusters reflect only the expected cell line 
relations, when they come from the same tissue, for instance Caco2 and HCT.116 both from 
colorectal carcinomas. 
 
Comparison 
The comparison was performed in the same way as for the Breast Cancer Data set. Results were 
not as strong as before, this data set does not show the same strong correlation between PCA and 
NMF. As an example for k=5, the comparison of the first cluster with the first principal 
component, for VTT and BSP data, is shown in Figure 45.   
 
Figure 45. Comparison between PCA and NMF for BSP and VTT data The p values of ttest 
in the NMF clusters are plotted against the principal components. On the left, an example of the comparison for 
the VTT dataset, of the first cluster (NMF k=5) against the first principal component. On the right, the BSP 
dataset, again the first cluster (NMF k=5) against the first principal component. The graphics showed that there is 
no significant correlation between the NMF clusters and the principal components, except when the parameter k is 
low. 
 
The main conclusion is that NMF performs a better division of the datasets, only correlating to 
the principal components when the parameter k is low. As stated before, a low value for this 
parameter compromises the amount of information that can be extracted from the clusters, as well 
as a very high value, that would create singular cluster with no additional information. This 
indicates that the PCA analysis is returning a poor amount of information, and therefore NMF is a 
better option to explore this dataset.  
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5.3 Regression 
We considered regression analysis on the BC dataset, which has the most information available on 
clinical parameters.   
Different regression methodologies (section 2.3.3) were applied to the complete dataset and, 
considering the results of section 5.2, we applied them also to the clusters obtained through k-
means after PCA (malignancy axes); we tried to fit distributions to the behavior of the data for the 
different variables. 
This analysis allows extracting patterns in the data, and it can develop a prediction model for 
some variables, and give information on correlation difficulties for others. In our case, regression 
techniques showed accurate results for ER status, and limited results for relapse. The other 
variables showed correlations, but the accuracy was never above 90%. In this section we will 
show how the different regression methodologies behave for ER status and relapse, showing that 
they were not enough for predicting this last variable with precision, and therefore implying the 
need for other methodologies. 
 
ER Status 
This variable can be used as an indicator of the quality of the work methodology, since it is 
strongly involved with the generation of the malignancy axes, and it is known [134] to be related 
to other variables like tumor grade.  
The linear regression shows a clear relation with the first two malignancy axes, as well as a 
relation with grade. 
We applied also the MARS model, and a neural network model, and we used the median standard 
error and the average R2 to evaluate the goodness of the model.  
 
 
Figure 46. MARS for ER status 
The spline regression of the BC data is shown over 2 
malignancy axes for ER status. The error and the R2 show a 
good fit for this regression. 
 
Figure 47. Neural network for ER status 
Neural network regression was performed over the BC data 
set. The graphic shows the results over 2 malignancy axes. 
The network seems to fit the values accurately. 
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The results are depicted in Figure 46 and Figure 47. The regression was performed over the 3 
malignancy axes, and the plotting considers 2 axes and fixes the third one, so that the error is 
minimized.  The MARS model provides a clearer graphic and a lower standard error, but the R2 is 
better for the neural network. The main difference is that the MARS model performs better with 
the first two malignance axes, while the neural network works better with axes 1 and 3. The 
models present a good prediction capability. 
 
Relapse 
For relapse the results are not that clear. There is no explicit linear relation with any of the 
variables, as seen from the results of linear regression.  Again, a splines and a neural network 
model were used.  
 
 
As shown in Figure 48, the R2 value for the mars model is negative, which states that the model is 
failing to predict the variable. The neural network shows better results (Figure 49), with a very 
low standard error, and a relatively good R2, but with further testing, the networks results show to 
be over fitted, hence the resulting model cannot be used for accurate prediction.  
 
Since the results were not clear, we tried to approach the regression before clustering.  We used 
logistic regression.  Again in the case of ER Status, the results were very positive, and in the case 
of Relapse, they were not so clear. Figure 50 and Figure 51show the result for logistic regression 
against the first malignancy axis. 
Figure 48. MARS for relapse 
Spline regression over the BC dataset for relapse. The 
graphic shows the resulting fitted plane over the 3 
malignancy axes. The R2 value resulted negative, what 
reveals a very poor fitting of the regression. 
Figure 49. Neural network for relapse 
Neural network regression over BC dataset for relapse. The 
network results in a very low error, and an acceptable R2, 
nevertheless, this network is over fitted to the data, and 
therefore cannot act as an accurate predictor. 
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We considered this same logistic regression inside the groups (without clusters).  For ER status, 
the relation was clear in every group, and an Anova study reassured this relation.  In the case of 
relapse an interesting relation was found in the first group, and a not so strong relation in the 
second group, and a bad relation in the other groups.  These results showed that the accuracy of 
the regression depends on the type of data available for each group, and it shows that the groups 
with no systemic treatment have a clearer correlation for relapse. This result also shows that 
correlation can be clearer when considering the data divided by group, instead of as a whole. 
 
5.4 Cell Line Correlations 
Another step in the workflow consists of finding sample correlations using the obtained clusters. 
This process corroborates the robustness of the clusters, and gives information on relations that 
could require further analysis.  
Using the different results from different runs of NMF with different k, we tried to find the 
relation between the different cell lines, based on the number of times they were classified in the 
same cluster, and whether they are classified together more often in a high or low number of 
cluster. 
 
5.4.1 VTT  
Figure 52 shows the number of times that two cell lines where classified together in different 
NMF runs, with k ranging from 2 to 10. 
Figure 50. Logistic regression for ER 
status 
Logistic regression over the BC dataset. The first 
malignancy axis is plotted against the model for ER status. 
The calculated p-value is below 0.01 and the R2 is 0.5, the 
dashed lines show the 95% confidence intervals. 
Figure 51. Logistic regression for relapse 
Logistic regression over the BC dataset. The first 
malignancy axis is plotted against the model for relapse. The 
calculated p-value is 0.1 and the R2 is 0.27, the dashed lines 
show the 95% confidence intervals.  
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As expected, different samples of the same cell line are clustered together in most cases.  The 
interesting results come from other cell lines.  The most notable example is MCF7 and T47D, 
both breast cancer cell lines. We also see strong correlation between HT.29 and Caco2, both 
colorectal adenocarcinoma cell lines. Other strong correlation results are not so clear, like the 
relation between NCI.H460 and Hela, the first one is a lung adenocarcinoma cell line, and the last 
belong to a cervix epithelial cell line. Further investigation is required to explain these relations, 
we infer that these correlations reveal mechanisms relevant to both cancer types. 
 
 
Figure 52. Correlation between cell lines for VTT Data Using the resulting NMF clusters, with 
different values for the parameter k, we calculated a sample correlation, using the amount of times 2 samples were 
clustered together. The results show high correlation between samples of the same cancer type, and some other 
correlations that should be further studied. 
5.4.2 BSP  
When looking for relation between cell lines, the analysis exposed besides the expected self-
correlations, a very strong dependency between Hela and MCF.10A, which belong to cervix 
epithelial cells and epithelial breast cells, respectively. Other relations shown are even less 
evident, like in the case of HCT.116 (colorectal carcinoma) and MCF7 (breast adenocarcinoma). 
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5.4.3 CML 
In the case of CML data, the correlation between NMF clusters shows a good result for chronic 
phase, but a lot of noise for the other cases. It seems that the NMF algorithm requires some 
preprocessing in this case to show the same quality of results accomplished in the other data sets.  
Figure 53 shows the results in this case. 
 
Figure 53. Correlation for CML As with the VTT and BSP datasets, the NMF clusters were used to calculate 
correlations between samples. The results show noise, but the chronic samples show high correlation amongst them. 
5.5 Gene Expression distribution 
As shown in the previous results sections, the information loss caused by dimensionality 
reduction can be an impediment for finding accurate prediction models for clinical parameters. To 
test this affirmation, we used the information ratio (IR), which showed how a variable such as 
relapse loses too much information when dimensionality reduction techniques are considered.  
This result, combined with those before, exposed the importance of using other methodologies to 
find correlations, which would lead to mixture models, also considered in this section. This 
method showed strong correlations between genes, and showed how the gene expression seems to 
behave similarly inside groups of highly correlated genes. There is a clear bimodal distribution for 
many of the genes, and this lead to the analysis in section 5.6. 
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5.5.1 Information ratio 
By using information ratio calculations, we demonstrated the superiority of genome wide patterns 
associated with a favorable IR-classification. We applied this methodology to the breast cancer 
dataset, comparing the IR values obtained for the different clinical traits.  The value for ER status 
show a classification of type I, explaining the good results obtained through techniques like 
simple clustering and simple regression.  Other classification tasks in oncology, such as relapse, 
that have proven to be more complicated, show unfavorable IR characteristics, adding a challenge 
to the prediction.  
 
Figure 54. IR status on BC data: grade and relapse P-values for the fitting of the complete data matrix 
to the variable (x axis) are plotted against p-values for the fitting of the projected data matrix to the variable (y 
axis). Blue points represent the fitting to the principal components, whilst red points represent the fitting to the 
residuals. Left: samples are divided according to grade in two groups, those with grade 1 and 2 are tested 
against those with grade 3. The result shows that the information on grade can be retrieved from the reduced 
data dimensions. Right: samples are divided according to relapse. The graphic shows that the information on 
this parameter cannot be retrieved by only analyzing principal components. 
 
 
Figure 54 shows a plot of the results of the original data against the projected data. On the left is 
the result for grade, where the test was performed using samples of grade 1 and 2 against those of 
grade 3; the plot shows how most of the information can be retrieved from the 10 principal 
components and the residuals show little importance. On the right, the same type of graphic is 
shown for relapse, positive against negative; the plot shows that the information is not clearly 
separated, and projecting the data to a lower dimension will cause loss of information. 
This important result was key to the workflow, since it lead the process to a different approach, 
avoiding dimensionality reduction, and looking for gain in information. 
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5.5.2 Genome graphic comparisons 
We analyzed the CML dataset using 
chromosomal comparisons, in order to look 
for specific variation that could affect the 
gene expression, and would give more 
information on the variation.  
Figure 55 shows the residual expression 
(after applying PCA with 5 factors) on 
chromosome 22, while the red line represents 
the Loess regression [22] applied to this data. 
The graphics hold data for the CML types, 
they are (in order) chronic, accelerated phase, 
ap-cyto, and blast crisis. 
When comparing it to non-tumor samples, 
the curves show higher pronunciation in the 
tumor data, and between the different types 
one can see the variations in the regression 
and how it gets more pronounced in the latter 
stages.  
This effect is also visible in chromosome 9, 
and less clear for chromosome 8. 
 
 
5.5.3 Mixture models 
The mixture models provided information on the gene-gene correlations and showed bimodal 
patterns that had influence on the clinical traits. We run our workflow on the BC dataset, and we 
found clusters of genes that indicate similar behavior, and have a “pulling” effect over other 
genes. This effect and the generated clusters can be seen in Figure 56; each plot depicts the 
correlation of the selected genes against their differential expression, showing for the selected set 
how the related genes behave around it. The tested gene can be seen at the rightmost part of the 
graphic, and the colors show some of the clusters (the ones with higher correlations), all other 
points are shown in light blue. In the left, a graphic for ESR1 shows how this gene has an 
Figure 55. Chromosome 22 for different
CML types 
Chromosome 22 is shown for CML data, comparing, from top-
down the types chronic, accelerated phase, ap-cyto and blast
crisis. The red line shows the Loess regression to the blue points
(residuals). 
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important effect on its neighborhood, and shows a selection of closely related genes, as expected 
for a gene involved in pathological processes such as breast cancer [161].  On the right, the gene 
PDE9A shows correlation to genes in the pink cluster, but the data seems pulled by the genes in 
the green cluster (the one where ESR1 is included); this gene has no known direct association to 
breast cancer [161].  
 
Figure 56. Gene correlations in mixture models The plot shows the correlation of the selected genes 
against their expression, showing for the selected set how the related genes behave around it. The bold colored 
points are groups of strongly correlated genes. The last point on the right represents the selected gene (ERS1 on 
the left, PDE9A on the right). The left graphic shows that genes around ESR1 have strong correlation, and the 
gene expression values are associated to that correlation. On the right graphic, only a few genes are related to 
PDE9A, and the gene expression seems to be affected by other genes more than it, specifically, the gene 
expression is being ‘pulled’ by genes in the ESR1 correlation group.  
 
Using this result, we considered the next step as the search for these highly related genes and 
their association to clinical traits. 
 
5.6 Bimodality 
As stated in the previous chapters (see Figure 31 and Figure 32), the gene data shows bimodal 
distributions for most genes. Figure 57 shows the histograms of the gene expression in the BC 
dataset, after normalization, of four genes that have known bimodal expression [10].   
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Figure 57. Histograms for gene expression in genes ERBB2, GATA3, ESR1 and SerpinB3 
This part of the workflow uses this bimodality to select genes, normalize them and cluster them, 
so that a final set of 4 gene clusters is offered. These genes were tested to evaluate their 
correlation to clinical traits, showing interesting high correlations, even for relapse. The achieved 
results are shown in this section. 
Table 6. Number of genes per study after first selection 
Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 Study 7 Study 8 Study 9 
375 374 335 156 298 363 324 388 356 
5.6.1 Gene selection 
Following the workflow stated in the previous chapter, we applied different methods (section 
2.3.4.5) to assess bimodality. In Table 7 a short sample of the results is shown for 10 of the top 
ranked genes in study 2 (BC data). For each gene there are 15 columns, 2 for each method 
applied, with the method value and assigned ranking.  Using the cutting points stated in the 
workflow, each gene was assigned points, to a final total depicted in the last column of the table. 
Although the maximum possible score is 7, none of the genes achieved it, the real maximum is 6. 
All genes with score larger than 3 were selected as interesting for further study, therefore the 
number of selected genes may be different for every study (as shown in Table 6), and circa 25% 
of the selected genes are different between studies.   
Table 7. Bimodality tests on BC data 
  vrs$x  vrs  wvrs$x  wvrs  dip$x  dip  kurtN$x  kurtN  LR$x  LRP  BI$x  BI  OS$x  OS  TOTAL 
ESR1  0.16  6  0.16  5  0.004438  54  ‐1.04  166  1.18271E+26  42  2.25  6  0.00  6018  6 
SERPINA5  0.21  94  0.21  56  0.0009401  27  ‐1.05  148  6.86852E+15  334  1.83  90  0.00  6254  6 
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PGR  0.22  124  0.21  67  0.0048409  55  ‐1.23  31  6.83474E+13  575  1.79  125  0.00  6229  6 
TNNT1  0.22  138  0.21  60  0.0004395  20  ‐1.29  13  2.20009E+15  383  1.75  163  0.00  6292  6 
CHAD  0.13  1  0.15  3  1.698E‐05  5  ‐1.05  149  4.91597E+33  18  2.51  1  0.00  6111  6 
 
After choosing the genes, we performed a new normalization, now considering the means 
generated by the Bimodality Index method [157]. Figure 58 shows the comparison of the 
histograms of genes CA12 and ESR1, on the left before normalization and on the right after 
normalization. The new histograms show two peaks in -1 and 1, improving the comparison 
accuracy for the genes. 
 
Figure 58. Bimodal genes normalization The normalization of the genes CA12 (top) and ESR1(bottom) 
is shown. On the left, the histogram of the raw data is depicted, and on the right, after applying 
normalization. The process ensures that the peaks of the bimodal distribution will be situated in -1 and 1. 
 
5.6.2 Clustering: NMF 
After comparing the results of all the possible values for k, we choose 10 factors as a stable 
number that produced a good cluster division. Figure 59 shows the heatmap generated from the 
NMF algorithm for 10 clusters in study 2. 
 
Figure 59. NMF heatmap for study 2 with 10 factors 
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Following the exemplification using study 2, Figure 60 shows the results of applying the distance 
algorithm (see section 4.7.3.1) in the first cluster, for relapse and grade. In the case of relapse, the 
rank test gave as result that the null hypothesis could not be rejected, but for grade (and ER status) 
the p-value was low enough to reject the null hypothesis. The figures show the differences 
between the values for the clinical traits. We summarized the results in a table, where for each 
gene in each study a number shows to which cluster it belongs, or if it is not present (then it was 
not considered bimodal by the tests). Besides, for four clinical traits (ER status, grade, nodal 
status and relapse), a score was calculated using the rank tests information, as explained in the 
workflow (See  
Table 8). A similar table was created for every factor tested, so that a comparison of the results 
could be developed. 
 
 
Figure 60. Study2, Cluster 1, NMF clusters The genes belonging to the first NMF factor are plotted against 
the distances to the mean of grade 1 (left) and negative relapse (right) in the samples. The blue points represent 
grade one or negative relapse, and the red points, grade 3 or positive relapse. A t-test comparing the blue and red 
point populations was performed, giving a p-value of 0.23 for relapse and 3.8e-5 for grade. 
 
Table 8. Summary for NMF clustering with 10 factors 
  Study1  Study2  Study3  Study4  Study5  Study6  Study7  Study8  Study9  Grade  Relapse 
Nodal 
Status  ER 
ESR1  4  1  5  1  1  6  9  4  4  6  1  2  8 
GRIA2  7  1  3  3  6  3  9  4  3  4  1  0  5 
MUC5B  4  9  1  6  7  7  6  8  5  6  1  1  4 
GSTT1  4  7  3  1  ‐  3  8  4  4  3  2  2  5 
PSG11  8  5  3  ‐  10  2  5  4  9  3  2  1  3 
TNNT1  4  7  3  1  ‐  3  1  4  4  4  2  2  5 
CDC45L  4  10  1  6  ‐  7  6  8  5  5  1  1  3 
F2RL2  2  2  4  ‐  8  1  7  8  2  4  1  0  1 
CHAD  4  1  3  ‐  1  3  9  4  4  4  1  1  7 
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5.6.3 Clustering: k-means, distances.  
Again, several values of k (number of clusters) where tested; we selected 10 clusters to 
exemplify here, since they showed a cluster division with similar sizes and few outliers. Figure 61 
shows the distances workflow on the seventh cluster of study 2 for relapse; in this case, grade and 
ER status present a rank test value that allows rejecting the null hypothesis, whilst in the case of 
relapse it cannot be rejected. This result is consistent with previous studies for the case of ER 
status, since this cluster contains some genes that are known biomarkers for it, as ESR1, CA12 
and TNNT1. This indicates that the genes in this cluster are related to ER status and grade, and 
that they can be predictors for these clinical traits. The figures show in two colors (or three in the 
case of grade) the mean distance values calculated, so that the differentiation between low and 
high values of a trait should be easily recognized. The genes in the cluster are reorganized in the 
graphics, so that the larger differences are shown first, and then in descending order. 
 
Figure 61. Study2, Cluster 7, k-means clusters (distance) The genes belonging to the seventh cluster are 
plotted against the distances to the mean of negative relapse in the samples. The blue points represent negative 
mean, and the red points, positive. A t-test comparing the blue and red point populations was performed, giving a 
p-value of 0.86 for relapse, unable to reject the null hypothesis, and 1.17e-5 for grade, rejecting it. The results 
achieved in this same cluster on ER status presented p-values lower than 0.05. 
 
5.6.4 Clustering: k-means, Log(p)  
 
To compare, the same seventh cluster of the second study, for k=10, is shown in Figure 62, 
comparing relapse. Again, in the case of relapse, the null hypothesis cannot be rejected, but it can 
be for ER status and grade.  In this case, the graphics show for each gene the log(p) value, and to 
simplify the review of the graphics, the points are colored so that the result of the rank test that 
generated that p-value is included in the graphic. The legends explain the symbols, and they show 
whether the trait in its positive value (mean) is larger than in its negative value for a specific gene, 
and whether or not the rank test can be rejected with a confidence of 95% (h=1 means it can be 
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rejected). In the top of the graphics, a p value is shown, for the test of uniformity, as explained in 
the workflow. 
The results with both techniques are very similar, from what we deduce that the clustering is 
robust and in fact related to the clinical traits as expected. 
 
 
 
Figure 62. Study2, Cluster 7, k-means clusters (Log(p)) The genes belonging to the seventh cluster are 
plotted against the log p value of the samples with positive vs negative values. The triangles represent significant p-
values, while the circles represent p-values over 0.05. A test of uniformity was performed, giving a p-value of 0.09 for 
relapse, and 0.0003 for grade. The results achieved in this same cluster on ER status also gave p-values under 0.05. 
 
As with the NMF clustering, a table was also used to summarize the results. Table 9 shows 9 of 
the genes with high score for grade, meaning that these genes belonged to clusters were the rank 
test showed a clear differentiation between the values of low and high grade. This sort of 
summary was created for all the different k (numbers of clusters) that were tested.  There is a clear 
relationship between the genes that belong to clusters that differentiate grade and those who 
differentiate ER status. 
 
Table 9. Summary for k-means clustering with 10 clusters 
name  Study1  Study2  Study3  Study4  Study5  Study6  Study7  Study8  Study9  Grade  Relapse  Nodal Status  ER 
ESR1  7  7  6  7  6  9  8  1  1  6  2  3  8 
GATA3  ‐  7  6  7  6  9  8  ‐  1  6  2  2  6 
MUC5B  5  3  1  3  10  2  6  10  4  6  0  1  3 
PGR  2  7  6  ‐  6  9  8  1  1  5  1  1  7 
CBLC  ‐  2  6  ‐  10  9  8  4  7  5  2  1  5 
CA12  ‐  7  6  7  6  9  ‐  ‐  1  5  2  2  5 
GRIA2  2  3  1  3  1  10  6  10  4  5  0  1  4 
ZIC1  5  3  1  9  ‐  2  6  ‐  5  5  1  1  3 
BMP4  5  3  7  ‐  6  2  6  10  4  5  1  0  2 
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Table 10. GTK extract 
Name  Grade  Relapse  NodalS  ER 
ESR1  7  7  7  7 
GATA3  7  7  5  7 
CA12  7  7  5  7 
TFAP2B  7  6  0  7 
HPR  7  6  1  6 
VILL  7  5  0  7 
KCNA2  7  5  0  7 
KLF13  7  5  0  7 
GTF2A1  7  5  0  6 
F2RL2  7  4  2  7 
CDC45L  7  4  7  7 
BST1  7  4  0  5 
EDN2  7  4  0  0 
RGS11  7  3  0  7 
PTGIR  7  3  0  7 
TNFRSF4  7  3  1  5 
AKAP4  7  3  0  3 
GYPE  7  3  0  1 
ZNF287  7  2  4  7 
TNNT1  7  2  2  7 
CBLC  7  2  0  7 
 
5.6.5 Second gene selection: GTK 
From the summary tables, a score for each gene was calculated (see section 4.8). Table 10 shows 
an extract of the selected genes (the ‘genes to keep’, which will be referred as GTK from now on), 
the full list can be reviewed in Appendix A. In total, 323 genes were selected. All these genes 
show a bimodal distribution and are highly correlated to the clinical traits.  
These genes were further clustered using k-means with different numbers of clusters from 2 to 
10. We selected 4 clusters to continue the analysis, since from 4 up the clustering generated 
several empty or singleton clusters. An interesting particularity of this set of genes is that most of 
the genes cluster together, no matter how many clusters are used, and therefore with many 
clusters, half of them are created with little elements.  The cluster stability was tested with good 
results, Figure 63 shows the output of the stability assessment algorithms, where it is clear that the 
clusters are highly consistent and there is little possibility of error in the associations. The fourth 
cluster shows clear stability, whilst the second and third show a strong pattern. The first one, 
according to the clusterboot [63] algorithm, shows the lowest mean, although not too far 
from the cutting point, it could mean that this cluster needs to be reviewed. Appendix A also 
shows to which cluster each gene belongs. 
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Figure 63. Output of clusterbot Cluster assessment was considered using algorithms for bootstrap, jittering and a 
combination of both. The output produced by the software is showed in this figure. With 4 clusters and 1000 runs, 
the fourth cluster showed the highest stability, followed by cluster 3 and 2. Cluster 1 results indicate that the 
cluster is not stable, and it may need to be reviewed. 
 
5.6.5.1 BC results for the GTK set 
Each of these clusters was then tested against the clinical traits in the breast cancer data set. 
Since the Log(p) and the distances algorithms showed very similar results, we choose the 
distances algorithm to do the analysis in these clusters. Figure 64 to Figure 67 show the results for 
nodal status, relapse, grade and ER status in each of the four clusters. Each figure has on the title 
the p-value for the rank test, so that a significant p-value indicates that the gene expression data 
for low and high trait values using the genes in that cluster can be considered to have different 
means, and therefore that cluster can be used to estimate the value of the trait. 
 
 
 
* Cluster stability assessment * 
Cluster method:  skmeans  
Full clustering results are given as parameter result 
of the clusterboot object, which also provides further statistics 
of the resampling results. 
Number of resampling runs:  1000  
 
Number of clusters found in data:  4 
 
 Clusterwise Jaccard bootstrap mean: 
 [1] 0.5669964 0.6463562 0.6975695 0.7619095 
dissolved: 
 [1]  375  283   53   85 
recovered: 
 [1]  83 276 365 56 
 Clusterwise Jaccard jittering mean: 
 [1] 0.6059320 0.6810333 0.6403713 0.6880545  
dissolved: 
 [1]  198   93   53  258  
recovered: 
 [1]  48 411 139 251    
 Clusterwise Jaccard bootstrap/jittering mean: 
 [1] 0.5780976 0.6388301 0.6881771 0.7735647  
dissolved: 
 [1]  345  304   63   81  
recovered: 
 [1] 109 274 328 606    
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Figure 64. GTK-BC: cluster 1 distances analysis Comparison of clinical parameters in cluster 1. Using the 
distance algorithm (as discussed in section 4.7.3.1 ), positive and negative values of each trait were compared. The 
figure shows for graphics, for NS (nodal status) on the top left, relapse on the top right, grade on the bottom left and 
ER status on the bottom right. According to the methodology, cluster one can accurately differentiate grade and ER 
status, with a p-value under 0.05. 
 
 
Figure 65. GTK-BC: cluster 2 distances analysis  Comparison of clinical parameters in cluster 2. Using the 
distance algorithm (as discussed in section 4.7.3.1 ), positive and negative values of each trait were compared. The 
figure shows for graphics, for NS (nodal status) on the top left, relapse on the top right, grade on the bottom left and 
ER status on the bottom right. According to the methodology, cluster two cannot be used for differentiation in any of 
the traits, due to the small size of the cluster. 
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Figure 66. GTK-BC: cluster 3 distances analysis Comparison of clinical parameters in cluster 3. Using the 
distance algorithm (as discussed in section 4.7.3.1 ), positive and negative values of each trait were compared. The 
figure shows for graphics, for NS (nodal status) on the top left, relapse on the top right, grade on the bottom left and 
ER status on the bottom right. According to the methodology, cluster three can accurately differentiate nodal status, 
grade and relapse, with a p-value under 0.05. 
 
 
Figure 67. GTK-BC: cluster 4 distances analysis Comparison of clinical parameters in cluster 4. Using the 
distance algorithm (as discussed in section 4.7.3.1 ), positive and negative values of each trait were compared. The 
figure shows for graphics, for NS (nodal status) on the top left, relapse on the top right, grade on the bottom left and 
ER status on the bottom right. According to the methodology, cluster four can accurately differentiate relapse and 
grade, with a p-value under 0.05. 
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The first cluster shows significant p-values for grade and ER status, the second does not show 
any particular relation, the third shows relation with nodal status, grade and relapse, and the fourth 
cluster shows significant differentiation of grade and relapse. This last result is interesting, since 
this cluster should be highly related to ER status too, since the known biomarkers for this trait are 
included in the cluster, but due to noise, the relation cannot be clearly found, although is strongly 
related when using dimensionality reduction (as shown in previous results). In the case of the 
second cluster, the small amount of samples can explain the lack of significant p-values. 
These results lead us to review further the correlation between the genes in each cluster, and with 
this to further ensure the soundness of the clusters. We used Pearson correlation analysis, where 
the clusters show high correlation inside them, but the fourth one shows a possible division to 
consider. 
5.6.5.2 Sorlie results for the GTK set 
In order to test the obtained results, the gene clusters where applied to the Sorlie dataset. The 
same group of GTK genes was used and the same clusters were considered. Following the 
assumption about these genes being important in the differentiation of clinical parameters, the 
expected results over any data set should be similar.  
 
Figure 72 to Figure 75 (in Appendix B) show the results of applying the same distance 
algorithm to the Sorlie dataset. Again, each figure holds the p-value for the rank test that evaluates 
the null hypothesis of equal means between the high and low value of a trait in a cluster. Cluster 4 
behaves here as expected (considering the genes that belong to the cluster), and shows a highly 
related pattern to ER status and grade. Similarly, the second cluster does not show any particular 
relation to the clinical traits, except from grade where there is a relation near the cutting point.  
The results in this case are not as positive as with the BC data set, only ER status seems to be 
highly correlated in this metric. Nevertheless, some of the results are positive for grade and a 
deeper analysis showed better correlations as will be shown. 
 
5.6.6 Gene ontology analysis for the GTK set 
A gene ontology analysis was implemented over the gene clusters. Appendix C show the results 
of the analysis using WGCNA, and we also applied GSEA. 
These analyses showed similar outcomes: 
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Cluster 1. The first cluster shows association to cell development and differentiation processes. 
13 of the 20 genes in this cluster have known links to tumors and 8 are specifically related to 
breast cancer. An extract of interesting genes can be found in Table 11. 
Table 11. Some genes in cluster 1 (GTK) 
Gene Description 
APC encodes a tumor suppressor protein… [14] 
PGR …affect cellular proliferation and differentiation [14] 
GRIA2 Decreased editing at the Q/R site is also found in some human tumors [14] 
SERPINA5 Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis [161,66] 
 
Cluster 2. This cluster is related to inflammatory response and organ induction, in general with 
body morphogenesis and specifically with heart induction and morphogenesis. 6 of the 9 genes in 
this cluster have known associations to tumors [160], and some of them are connected with 
specific cancers, but there is not known association specific to breast cancer. See Table 12. 
Table 12. Some genes in cluster 2 (GTK) 
Gene Description 
DKK1 Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease [161] 
PEG3 Induces apoptosis in cooperation with SIAH1 [161] 
 
Cluster 3. Since this cluster contains significantly more genes as the others, the gene ontology 
analysis results are less specific. The genes in this cluster seem to express highly in transportation 
and behavioral processes. Cell fate and sexual reproduction are also linked to these genes. 72 of 
the 242 genes in this cluster are related to tumors. Some of these genes can be seen in Table 13. 
Table 13. Some genes in cluster 3 (GTK) 
Gene Description 
IL13, IL2 
and IL5 
On some cancers… they modulate apoptosis and tumor cell growth [66] 
LCAT The cholesterol-esterifying activity of LCAT was significantly lower in cancer patients… [137] 
OSM Inhibits the proliferation of a number of tumor cell lines [161] 
SRC Participates in … gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, … [161] 
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Cluster 4. The fourth cluster, as expected from a first inspection over the genes, show high 
expression of estrogen and, in general, hormonal gene ontologies. Form the 44 genes in this set, 
19 are known to be associated to cancer and tumors [160], and 14 are specifically related to breast 
cancer. An example of the genes in this cluster is in Table 14. 
Table 14. Some genes in cluster 4 (GTK) 
Gene Description 
ERBB2 
Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian 
tumors [161] 
ERBB4 Mutations in this gene have been associated with cancer [161] 
CA12 …has been found to be overexpressed in 10% of clear cell renal carcinomas [161] 
ESR1 …also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis [161] 
GATA3 …has a strong association to estrogen receptors in cancer [161] 
DDR1 …has been shown to be significantly overexpressed in several human tumors [161] 
NAT1 …has been associated with increased risk of colon and urinary bladder cancers [161] 
 
 
 
5.6.7 Trait-cluster relationships in the GTK set 
We have used the genes in the GTK set to search for relations between cluster eigengenes and 
clinical traits, finding strong correlations, even for the elusive relapse. The set was tested in the 
BC data, and considering the selection process, high correlation was expected and achieved. The 
gene set was also tested in the Sorlie dataset, achieving also high correlation and in the same 
pattern as in the BC dataset. This shows the accuracy of the methodology, which develops an 
effective predictor of relapse, by using selected bimodal genes. 
Using the WGCNA tool Figure 68 and Figure 69 were created, showing a summary of the 
relations on the BC and Sorlie datasets respectively. The figures show in each row a cluster and in 
each column a clinical trait. The colors (and the numbers in the cells) represent the correlation, 
positive or negative, and the associated Student asymptotic p-value for correlations is given, 
where the null hypothesis considers that the current result would have been found if the 
correlation coefficient were in fact zero.  Strong correlations between clusters and traits can be 
seen, and this correlations hold consistently in the two data sets tested. 
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Due to the interest of the investigation, we focused our analysis on Grade, ER status and 
Relapse.   
Grade. The first and fourth clusters show a high correlation to grade in both data sets. A 
correlation can be seen to the third cluster in the BC dataset, but this relation is not clear in the 
Sorlie dataset. Similarly, the second cluster in the Sorlie dataset shows an important correlation, 
but this finding is not seen in the BC dataset. Nevertheless, the trait analysis shows a correlation 
in both cases, although it cannot be taken as substantial, it can serve to support the validity of the 
results. 
ER status. Clusters 1,2 and 4 show a strong relation to ER status, and since this trait is known 
to have strong influence in the gene expression, the results positively recreate a valid prediction 
scenario. The third cluster shows a correlation, stronger for the Sorlie data set, but not as strong as 
with the other clusters. 
Relapse. Being this the primary focus of our prediction objectives, the results are particularly 
important, and even more considering how most of the other methods used, not only by us but 
also in literature, fail to do good job [116,118,85,87]. The trait relationship to the cluster show 
significant correlations, although not as strong as with other traits, relapse is clearly related to 1, 3 
and 4, and is correlated to cluster 2 with less clear results.  
Each gene cluster was tested to see the relation between gene significance for a trait, calculated as 
the correlation between gene expression and the trait values (y-axis) versus the gene membership 
to a cluster, calculated as the correlation between gene expression and the module eigengenes (x-
axis), giving additional information on the cluster standing for a specific trait. This calculation is 
done by using the correlation between gene expression and the module eigengenes.  
Figure 70 shows the results for cluster 4 and relapse, on the left for BC and on the right for Sorlie. 
The correlation for BC is 0.45 and the calculated Student p-value is 4.6e-0.9; for Sorlie, the 
correlation is 0.25 and the p-value is 0.1. The result is stronger for the BC dataset, where a clear 
relation is seen, then this cluster is strongly related to genes that influence the relapse value, and 
therefore the cluster is related to the trait. A similar relation can be seen in the Sorlie graphic, 
although it seems to have outliers. Since the cluster centers where calculated using the BC data 
set, this outliers can be caused by the over fitting of the clusters to this data set. 
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Figure 68. Cluster-Trait relation on BC data For each of the clusters of GTK genes in the BC data, 
eigengenes were calculated, and used to determine a correlation coefficient to each of the traits. A positive 
correlation is shown in red, while a negative is shown in green. The clusters are shown in the y axis, in the following 
order: 1(turquoise), 2(blue), 3(brown) and 4(yellow). On the x axis the clinical traits are shown, from left to right: 
NS, grade, tumor size, age, ER status and relapse. The clusters show significant correlations to grade, age ER status 
and relapse.  
 
 
Figure 69. Cluster-Trait relation on Sorlie data For each of the clusters of GTK genes in the Sorlie data, 
eigengenes were calculated, and used to determine a correlation coefficient to each of the traits. A positive 
correlation is shown in red, while a negative is shown in green. The clusters are shown in the y axis, in the 
following order: 1(turquoise), 2(blue), 3(brown) and 4(yellow).  On the x axis the clinical traits are shown, from 
left to right: NS, grade, tumor size, age, ER status and relapse. The clusters show significant correlations to 
grade, age ER status and relapse, in the same pattern (positive or negative correlation) as seen in the BC dataset.. 
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A clear relation is also seen in the first cluster, where both data sets show a pattern in the 
correlation.  In the case of cluster 3 the correlation looks very strong in the BC dataset and not so 
much in the Sorlie case. The second cluster shows no strong correlation, probably due to the fact 
that this cluster holds only 9 data points. 
 
 
Figure 70. Cluster 4 and Relapse relation (BC and Sorlie) The figure depicts the relation between 
cluster membership (x axis) and correlation to relapse (y axis) in the fourth cluster, on the left for the BC dataset, and 
on the right for Sorlie.  
 
 
In a sense, the workflow can be considered per se as a machine learning methodology, using the 
BC dataset for supervised learning and the Sorlie dataset for testing.  These results prove, not only 
that the suggested workflow can accurately find genes that highly correlate to clinical traits, but 
also that these same genes can be ‘exported’ and will produce the same accurate results in a 
dataset whose samples are independent of the ones used for selection.  
 
5.7 Neural network prediction 
The RBF neural network gave the best results in predicting the clinical traits.  
5.7.1 BC training and testing 
5.7.1.1  Relapse 
The network was trained using 80% of the samples (chosen randomly), and tested with the 
remaining 20%.  We trained one network per cluster (5 times, with different training data), and 
then combined the results using the mean value of the predictions. The mean training errors 
(RMSE) per cluster were (in order of cluster): [0.22, 0.29, 0.24, 0.28]. Figure 71 shows the results 
for false positives (fp), false negatives (fn), true positives (tp) and true negatives (tn), for each of 
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the clusters. In the graphic the number of false positives is the bigger problem in the prediction. 
The final accuracy of up to 78% (turquoise in the graphic) is obtained by combining the cluster 
results using the mean value per sample.  
The results, as a common disadvantage of neural networks, are highly dependent on the training 
data, which is why the final accuracy is calculated as a range and not as a specific value. The test 
was performed using different random sets, producing final accuracies from 65% to 80%. The 
results can be improved if the training set is chosen using expert knowledge, and by changing the 
networks parameters. 
 
Figure 71. Neural network results BC-relapse The results of the network prediction are shown, for 
false positives (fp), false negatives (fn), true positives (tp) and true negatives (tn), for each of the clusters. The 
last set of bars, colored in turquoise, shows the mean values for the combined results of all clusters.  
5.7.1.2 Grade 
We used the network to predict if a sample is grade 3 or not. As before, we used an 80-20 division 
for training and testing. The mean training errors (RMSE) per cluster were (in order of cluster): 
[0.19, 0.228, 0.197, 0.21]. These results, as with other methods, are more accurate than for 
relapse. 
Again, the results depend on the training data, giving a final accuracy between 70% and 82%. 
  
5.7.2 BC and Sorlie training and testing 
We used the BC dataset for training and the Sorlie dataset for testing. The results were not 
positive, producing less than 60% accuracy for relapse and less than 65% for grade.  Again, the 
training and the parameters in the network can be the responsible for this result, since the RBF 
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layer creates models based on the specific values of input and output, and of course they can be 
off by some decimals when compared in different studies.  
To confirm this idea, we tested the Sorlie dataset alone, using random training and testing, and 
we came up with results similar to the ones achieved in the BC data set, with accuracy up to 80% 
for relapse and 85% for grade. This confirms the idea of the difficulty of comparing different 
datasets using a general neural network. 
We consider that the network could be adjusted to ignore the small differences, and focus in the 
general correlations, but the proof is left as future work.  
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Chapter 6 
Conclusions 
 
 
The analysis of genomic and proteomic data has come to the point where large amounts of 
information need to be analyzed and accurately modeled into useful input for clinical treatments. 
Specifically in cancer research, this goal has been approached from several angles, and the results 
still give space for improvement. The analysis of genetic data and its relation to clinical traits have 
shown to be challenging [162], up to now there is no method known to us that accurately predicts 
this relation for a parameter such as relapse, and several studies are currently involved with this 
problem [167,169]. A relation to ER status has been established through biomarkers [54,100], and 
those are a reliable method for prediction [31], and therefore an important achievement in current 
research.  
We have pointed our research efforts into the matter of finding significant relations between gene 
expression and clinical parameters, by establishing a general workflow for cancer data scrutiny 
and a specific workflow for finding a set of bimodal genes that show high relation to clinical 
traits. 
In this work, we have successfully related breast cancer genomic data to clinical traits as ER 
status, tumor grade and relapse. Using a clustered group of bimodal genes, we are able to correlate 
with high accuracy (p value under 0.05) the known patient data to gene expression in different 
data sets, so that the predictive abilities of the methodology are not dependent on the data set.  
We have also defined a systematic algorithm that allows to find common patterns and to clean 
input data (remove outliers and allow different data set comparison), so that the specific 
subsequent analysis can be determined over the results of statistical analysis. This workflow 
allowed us to demonstrate different findings related to gene expression and clinical parameters, 
such as the possibility of clustering cell lines according to their origin (tumor type), the 
advantages of different types of regression analysis, and the advantages of NMF in a non-
supervised analysis. 
In this chapter we will summarize the most important results achieved, in the two main 
problems addressed, and the future work.  
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6.1 Gene expression data analysis 
 
There is a void in the majority of publications that address with gene expression investigation, 
which concerns the initial analysis needed to clean and understand the data set and the steps 
required to decide further procedures. Usually, research papers ignore this first steps in an attempt 
to focus on the specific processes that is the center of the document; the problem is that in order to 
reproduce the results, to apply them to a different data set or to understand the line of thinking of 
the researchers, it is necessary to recognize the available information and the possibilities it offers. 
We have run different tests on 4 data sets, described in Chapter 3; they contain samples of 
different cancers and have different clinical information available. We have used dimensionality 
reduction techniques, clustering analysis, regression analysis, gene ontologies, and a combination 
of them in order to show the possibilities that these methods offer in terms of extracting 
information.  The resulting workflow is explained in Chapter 4, as a new compilation of 
methodologies and tools; we claim that following it will lead to a deeper understanding of any 
dataset, and to important information that will determine the possible analysis that can be 
performed. Even more, this workflow can confirm relations between samples and clinical 
parameters, and therefore it can give a lead on what to search and how to search it. In the 
following lines, a summary of the main findings will be depicted. 
The use of PCA and NMF has shown to be very important in gene data analysis. When 
comparing them, we found that NMF allows a better decomposition of the gene expression data. 
In fact, the results accomplished with NMF have revealed similarity to PCA calculated using 
clinical information (malignancy axes), showing that for a non-supervised analysis, NMF is a 
better choice and can provide better extraction than PCA. 
In terms of clustering we achieved accurate separation of samples, according to clinical traits.  
In the breast cancer dataset it was possible to cluster samples (using knn and enriched PCA) such 
that their mean values for the clinical parameters could be easily separated. This first result shows 
how information can be cataloged using reduction and clustering techniques, but also shows a 
need of further research, since it only allows considering mean values and therefore singular 
samples are hard to classify, the method is highly dependent on the dataset, and the predictive 
abilities are very low. 
In the VTT and BSP datasets it was possible to correlate cell lines with same source organ, and 
the results showed additional correlations between different types of tumors known to literature, 
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demonstrating that the workflow explained in Subchapter 4.5 can be used to successfully cluster 
cancer samples using NMF. 
Diverse regression techniques were employed in the search for relations between gene 
expression and clinical parameters. We used regression over complete and reduced datasets, and 
all methods showed better results in the reduced matrix. From results of Subchapter 5.3, it is clear 
that simple linear regression is not enough, and the patterns shown in the analysis require more 
complex methods. In fact, logistic regression can accomplish good results, depending on the 
provided data. This analysis exposed that tumors treated with chemotherapy or hormonal 
treatments show a more intrinsic pattern than tumors with no systemic treatment, making more 
difficult to establish an effective regression formula. 
Neural networks, splines regression and radial basis functions showed better results, providing 
models with a p value under 0.05 for grade and ER status, but they were unable to deliver high 
accuracy on relapse. 
 
We have presented a workflow that allows explaining the information concealed in gene 
expression data, and understanding and planning research steps to further unveil the desired 
evidence. This workflow was tested in data sets with different origin and different cancer types, 
establishing an initial algorithm of data analysis independent of the data and the ulterior objective 
of the study, which can be used to clean and appreciate the data and to define the possibilities. 
We have shown the difficulties for prediction of relapse and grade with the use of common 
methodologies, and how the results resist improvement even when more complex methods are 
used.  
 
6.2 Clinical parameters and genetic data 
 
Dimensionality reduction, clustering and regression could only provide a limited amount of 
information. Yet, they give reasons to believe that the information can be extracted, and 
prediction can be possible. With this idea in mind, the investigation process turned to the search 
of different extraction processes, and to do so, it was necessary to contemplate where the 
information lies. 
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Using the Information Ratio methodology, we found that dimensionality reduction can be 
ineffective for some clinical parameters, due to a loss of information. Specifically, this result 
became clear for relapse, as shown in Subchapter 5.5.1; the information ratio showed that for this 
variable the data does not lie only in the principal components, and therefore other methods 
should be used. 
 
Following this idea, we studied genome graphics on the residuals, and developed mixture models 
for the expression data, which considered a fraction of the genes, aiming for those with the higher 
relation to clinical traits. The research on biomarkers, and biomarker sets, has used mixture 
models to test the accuracy of the biomarkers and to study the predictive capacity that can be 
obtained from them [101,58]; we showed how mixture models can be used to discover not only 
important gene sets, but also to unveil strong relations between genes. These relations indicate 
how gene clusters can be defined, and how some genes have stronger impact in the correlation 
between gene expression and clinical traits, and they seem to lead other genes towards a similar 
gene expression value. This important result illustrates the underlying information that is hidden 
by dimensionality reduction techniques. The analysis of these results directed the research 
towards genes that showed bimodal patterns, being those genes the ones pulling the gene 
expression patterns. 
By means of various methodologies, we searched for bimodal genes and we produced a final set, 
that we called GTK. This set of genes was analyzed with different methodologies; it was clustered 
in 4 groups that showed clear inner cohesion, and clear over expression of important ontologies, 
related to some of the genes that are known biomarkers. The whole process proved to be 
consistent with known literature, with the advantage of being data-based, requiring no additional 
user involvement for the gene selection. The clustering process showed robustness when tested 
through statistical methods, validating the idea of gene sets that pull expression patterns. 
 
The main result of the investigation comes to the correlation of these gene sets to clinical traits.  
 
We addressed cluster-trait correlation by means of calculating mean distances according to trait 
values and also by finding the cluster eigengenes and calculating their correlation to the clinical 
parameters (Subchapter 4.8).  This analysis showed high correlation of the cluster -as explained in 
the section 5.6.7- to ER status, grade, age and relapse, and with less accuracy to nodal status. 
These results showed the ability of the GTK gene set, selected without expert knowledge, for 
correlating with clinical parameters, including relapse.  
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In order to validate these results, the same set of genes was put to test with a different data set. In 
this way, the selected GTK genes where obtained from the second dataset and they were 
correlated to the clinical information available. The results were consistent for both data sets, 
showing that this set of genes can effectively correlate clinical parameters to gene expression. The 
importance of this result is in the fact that the selection process allows finding patterns in the gene 
expression data, without over fitting the results, offering a stable and significant gene set, which 
can be used as a predictor of correlation in any other breast cancer dataset, and whose predictive 
ability relates to several clinical parameters including relapse. 
 
We used also a neural network to predict clinical traits. The networked performed with a 60% to 
80% accuracy in the individual data sets, and showed much worse learning capabilities when the 
sets were combined. The network is highly dependent on the training and testing sets, and 
therefore is still not good enough for precise prediction. 
 
We have proposed an innovative workflow to choose gene sets, which have achieved accurate 
results for the correlation of gene expression and clinical traits.  Even a parameter as complex as 
relapse was successfully related to gene sets, which implies an advance for the research in 
systems biology.  These gene sets prove to be strongly related to clinical parameters, and can be 
used for prediction through different datasets.  
 
 
  
6.3 Future Work 
 
System biology is still a young field and there are many possibilities for improvement in all areas 
of research. The findings that this investigation has uncovered hold the key to further, more 
precise clinical developments, and despite the good quality of the results, we believe that there is 
room for progress. 
Some investigations [139,19] have shown that using a combination of carefully chosen studies 
to train predictive methodologies can reduce the bias of the experiment and can provide more 
accurate results. The decision on which studies to use must be considered by using expert 
knowledge and of course by analyzing the datasets and the additional information they can offer. 
Expert knowledge can also be used to detect important genes that are known biomarkers, which 
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may perhaps be left behind at some cutting point.  This will lead to improvement in the decision 
process for gene selection adding precision to the cutting points. 
Once a gene set is defined, by using this expert knowledge and by proving that those genes can 
be used through different studies with similar results, a deeper study of these gene set is 
necessary. This revision will lead to new biomarkers and to new biomarker sets. 
We strongly believe that the same methodology can be applied to other cancers, and that the 
result will be a different set of genes (or perhaps a similar one) that will give new information on 
the connection between cancer types. Then, we consider that this methodology should be applied 
to other datasets, and the results should be compared to find commonalities and differences in 
biomarker sets, specific for diverse tumors. 
The use of artificial intelligence methods have shown to be successful in several prediction 
attempts (as shown in section 2), but this science is still not exact and requires several trials to 
find optimal parameters. Therefore we believe that there is room for improvement by adjusting 
the parameters of the neural network and perhaps by using a combination of artificial intelligence 
methods to improve the quality of the results. 
Some of our results can only be tested through laboratory studies, such as the uncommon 
sample correlations between different types of cancer, or the ability of clusters to export IC50 
mean values to all of their members. Consequently we consider that there are many tests that 
would reinforce the obtained results, and could give a hand to new investigations for drug testing. 
As for the original goal of the MedSys project, we consider that we have given the bases to 
extract parameters for cancer models and by using this predictive methods, it is possible to 
construct a population dynamics model that will represent the evolution of cancer tumors.  
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Appendix A 
GTK List 
Gene  Cluster 
APC  1 
ARVCF  1 
BCAS1  1 
BMPR1B  1 
C14orf1  1 
CHAD  1 
CITED1  1 
EPHX2  1 
GAMT  1 
GFRA1  1 
GRIA2  1 
GRP  1 
PCDH12  1 
PGR  1 
PLXNB1  1 
PTK6  1 
PTPRT  1 
SEMA3B  1 
SERPINA5  1 
TNNT1  1 
CLCA2  2 
CPB1  2 
CYP27A1  2 
DKK1  2 
FABP7  2 
PEG3  2 
PRAME  2 
S100A8  2 
S100A9  2 
ABCB11  3 
ABCB8  3 
ABCC8  3 
ABCG5  3 
ACADL  3 
ACCN1  3 
ADAM7  3 
ADH6  3 
AHSG  3 
ALPI  3 
AMELY  3 
AMH  3 
ANXA13  3 
APC2  3 
APLP1  3 
APOA4  3 
AQP9  3 
AREG  3 
ARRB1  3 
ARSD  3 
ARSF  3 
ASCL1  3 
ATP11A  3 
AVPR1B  3 
AZU1  3 
B3GAT1  3 
BAGE  3 
BARX2  3 
BCL2L10  3 
BPNT1  3 
BST1  3 
BTF3L1  3 
CABP2  3 
CACNA1H  3 
CACNB4  3 
CACNG5  3 
CAMP  3 
CAPN11  3 
CASP5  3 
CAV3  3 
CBLC  3 
CCK  3 
CCNT1  3 
CD5  3 
CDA  3 
CDC45L  3 
CDH16  3 
CDR1  3 
CDSN  3 
CDX4  3 
CEACAM8  3 
CEL  3 
CHAT  3 
CHRM4  3 
CHRNA2  3 
CHRNE  3 
CHRNG  3 
CLCN1  3 
CLDN14  3 
CLDN17  3 
CLTCL1  3 
CNGA3  3 
CNGB1  3 
COLQ  3 
CRX  3 
CRYBA4  3 
CTAG2  3 
CYP21A2  3 
CYP4F11  3 
CYP4F8  3 
CYP7A1  3 
DKFZP434P21
1  3 
DLEC1  3 
DLX2  3 
DMP1  3 
DNASE1L2  3 
DRD3  3 
DRP2  3 
DUSP7  3 
DUX1  3 
EIF1AY  3 
ELL2  3 
EXTL1  3 
FABP6  3 
FBXO4  3 
FGF16  3 
FGF20  3 
FGF5  3 
FKBP5  3 
FKBP8  3 
FOLR3  3 
FOXE1  3 
GABRA5  3 
GABRG2  3 
GAGE1  3 
GBX2  3 
GDNF  3 
GFRA3  3 
GHRHR  3 
GIF  3 
GIT2  3 
GNMT  3 
GPR39  3 
GPT  3 
GRIA3  3 
GRID2  3 
GRIN2C  3 
GRM5  3 
GTF2A1  3 
GTF3C5  3 
HOXA2  3 
HOXB3  3 
HOXD13  3 
HSD3B2  3 
HSF4  3 
HTR7  3 
IBSP  3 
IL13  3 
IL17B  3 
IL19  3 
IL1R2  3 
IL1RL2  3 
IL2  3 
IL5  3 
IL9  3 
INE1  3 
  134 
ITIH1  3 
KCNA2  3 
KCNC3  3 
KCNE1L  3 
KCNK2  3 
KIAA0319  3 
KIAA0574  3 
KLF13  3 
KLF15  3 
KPNA5  3 
KRT4  3 
LAMC3  3 
LCAT  3 
LIPF  3 
MAFK  3 
MAG  3 
MAGEA11  3 
MAGEA3  3 
MAGEB1  3 
MAK  3 
MARCO  3 
MATK  3 
MEP1B  3 
MGAT3  3 
MKRN3  3 
MMP20  3 
MTM1  3 
MTMR7  3 
MUC8  3 
MVD  3 
MYBPC1  3 
MYF6  3 
N6AMT1  3 
NBR2  3 
NFE2  3 
NFKBIL1  3 
NPTXR  3 
NR1H4  3 
NRXN3  3 
OCA2  3 
ODF2  3 
OPRD1  3 
OR1A1  3 
OR2F1  3 
OSM  3 
PAX6  3 
PDE6B  3 
PDE9A  3 
PDHA2  3 
PKD2L1  3 
PLA2G2D  3 
PLXNB3  3 
PMCH  3 
PNLIP  3 
POU1F1  3 
POU3F2  3 
POU4F3  3 
PPFIA4  3 
PRB1  3 
PRG2  3 
PRKG1  3 
PSG5  3 
PTENP1  3 
PTPRS  3 
RAB9P1  3 
RDH5  3 
REG1A  3 
REN  3 
RFPL1S  3 
RGS11  3 
RHO  3 
RPE65  3 
RRAD  3 
RUNX1  3 
S100A3  3 
S100B  3 
SALL1  3 
SARDH  3 
SEMG1  3 
SFTPD  3 
SIGLEC5  3 
SLC1A6  3 
SLC22A1  3 
SLC2A4  3 
SLC34A1  3 
SLC4A1  3 
SLC6A11  3 
SLC6A6  3 
SLC6A9  3 
SLC7A2  3 
SLC9A2  3 
SNRPN  3 
SOX3  3 
SOX30  3 
SRC  3 
SSTR1  3 
TACR3  3 
TBR1  3 
TCF15  3 
TEP1  3 
TFPI2  3 
THPO  3 
TLX3  3 
TMPRSS4  3 
TNFRSF10D  3 
TNNI2  3 
TRDN  3 
TRPC4  3 
TSP50  3 
TUBA8  3 
UCP1  3 
UGT8  3 
UNC119  3 
UTF1  3 
VILL  3 
VNN2  3 
WNT7A  3 
ZIC1  3 
ZIC3  3 
ZNF155  3 
ZNF157  3 
ZNF208  3 
ZNF287  3 
ZNF80  3 
ADRBK1  4 
AGR2  4 
AGTR1  4 
AKR7A3  4 
BCAS2  4 
C5orf4  4 
CA12  4 
CD24  4 
CEACAM5  4 
COQ7  4 
CYP2A6  4 
DDR1  4 
DUSP4  4 
E2F4  4 
EEF1A2  4 
EPOR  4 
ERBB2  4 
ERBB4  4 
ESR1  4 
FBP1  4 
GATA3  4 
GGA1  4 
HMGCL  4 
IGHMBP2  4 
KIAA1033  4 
KIAA1324  4 
MVK  4 
MYB  4 
NAT1  4 
NUBP1  4 
PAX8  4 
PBX2  4 
PEX7  4 
PIP  4 
PRKCZ  4 
RPS15A  4 
RPS5  4 
SLC1A1  4 
SLC22A5  4 
TFAP2B  4 
TFF1  4 
TFF3  4 
VAV3  4 
XBP1  4 
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Appendix B 
GTK in Sorlie: distance metric 
 
 
Figure 72. GTK-Sorlie: cluster 1 distances analysis 
 
 
Figure 73. GTK-Sorlie: cluster 2 distances analysis 
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Figure 74. GTK-Sorlie: cluster 3 distances analysis 
 
Figure 75. GTK-Sorlie: cluster 4 distances analysis 
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Appendix C 
WGCNA gene ontology for GTK gene clusters 
MODULE  MOD SIZE 
TERM 
ID 
TERM 
ONTOLOGY 
TERM 
NAME 
TERM 
DEFINITION 
2  9  GO:0005576  CC  extracellular region 
The space external to the outermost structure of a cell. For cells 
without external protective or external encapsulating structures 
this refers to space outside of the plasma membrane. This term 
covers the host cell environment outside an intracellular parasite. 
2  9  GO:0001759  BP  organ induction  The interaction of two or more cells or tissues that causes them to change their fates and specify the development of an organ. 
2  9  GO:0002090  BP  regulation of receptor internalization  Any process that modulates the frequency, rate or extent of receptor internalization. 
2  9  GO:0002544  BP  chronic inflammatory response 
Inflammation of prolonged duration (weeks or months) in which 
active inflammation, tissue destruction, and attempts at repair 
are proceeding simultaneously. Although it may follow acute 
inflammation, chronic inflammation frequently begins insidiously, 
as a low‐grade, smoldering, often asymptomatic response. 
2  9  GO:0003136  BP 
negative regulation of heart induction 
by canonical Wnt receptor signaling 
pathway 
Any process that decreases the rate, frequency or extent of heart 
induction. 
2  9  GO:0003308  BP 
negative regulation of Wnt receptor 
signaling pathway involved in heart 
development 
Any process that decreases the rate, frequency, or extent of the 
series of molecular signals initiated by binding of Wnt protein to a 
frizzled family receptor on the surface of the target cell, resulting 
a change in cell state that contributes to the progression of the 
heart over time. 
2  9  GO:0010171  BP  body morphogenesis  The process in which the anatomical structures of the soma are generated and organized. 
2  9  GO:0010453  BP  regulation of cell fate commitment 
Any process that modulates the frequency, rate or extent of cell 
fate commitment. Cell fate commitment is the commitment of 
cells to specific cell fates and their capacity to differentiate into 
particular kinds of cells. Positional information is established 
through protein signals that emanate from a localized source 
within a cell (the initial one‐cell zygote) or within a 
developmental field. 
2  9  GO:0010454  BP  negative regulation of cell fate commitment 
Any process that stops, prevents or reduces the frequency or rate 
of cell fate commitment. Cell fate commitment is the 
commitment of cells to specific cell fates and their capacity to 
differentiate into particular kinds of cells. Positional information 
is established through protein signals that emanate from a 
localized source within a cell (the initial one‐cell zygote) or within 
a developmental field. 
2  9  GO:0030510  BP  regulation of BMP signaling pathway  Any process that modulates the frequency, rate or extent of the activity of any BMP receptor signaling pathway. 
3  250  GO:0055085  BP  transmembrane transport  The process in which a solute is transported from one side of a membrane to the other. 
3  250  GO:0009628  BP  response to abiotic stimulus 
A change in state or activity of a cell or an organism (in terms of 
movement, secretion, enzyme production, gene expression, etc.) 
as a result of an abiotic (non‐living) stimulus. 
3  250  GO:0005261  MF  cation channel activity  Catalysis of the energy‐independent passage of cations across a lipid bilayer down a concentration gradient. 
3  250  GO:0022857  MF  transmembrane transporter activity  Enables the transfer of a substance from one side of a membrane to the other. 
3  250  GO:0005215  MF  transporter activity 
Enables the directed movement of substances (such as 
macromolecules, small molecules, ions) into, out of or within a 
cell, or between cells. 
3  250  GO:0050877  BP  neurological system process  A organ system process carried out by any of the organs or tissues of neurological system. 
3  250  GO:0022891  MF  substrate‐specific transmembrane transporter activity 
Enables the transfer of a specific substance or group of related 
substances from one side of a membrane to the other. 
3  250  GO:0007610  BP  behavior 
The specific actions or reactions of an organism in response to 
external or internal stimuli. Patterned activity of a whole 
organism in a manner dependent upon some combination of that 
organism's internal state and external conditions. 
3  250  GO:0006811  BP  ion transport 
The directed movement of charged atoms or small charged 
molecules into, out of or within a cell, or between cells, by means 
of some agent such as a transporter or pore. 
3  250  GO:0006812  BP  cation transport 
The directed movement of cations, atoms or small molecules 
with a net positive charge, into, out of or within a cell, or 
between cells, by means of some agent such as a transporter or 
pore. 
1  20  GO:0045667  BP  regulation of osteoblast differentiation  Any process that modulates the frequency, rate or extent of osteoblast differentiation. 
1  20  GO:0030278  BP  regulation of ossification  Any process that modulates the frequency, rate or extent of bone formation. 
1  20  GO:0001649  BP  osteoblast differentiation 
The process in which a relatively unspecialized cell acquires the 
specialized features of an osteoblast, the mesodermal cell that 
gives rise to bone. 
1  20  GO:0030856  BP  regulation of epithelial cell differentiation 
Any process that modulates the frequency, rate or extent of 
epithelial cell differentiation. 
1  20  GO:0031346  BP  positive regulation of cell projection organization 
Any process that activates or increases the frequency, rate or 
extent of the process involved in the formation, arrangement of 
constituent parts, or disassembly of cell projections. 
  138 
1  20  GO:0005912  CC  adherens junction 
A cell junction at which anchoring proteins (cadherins or 
integrins) extend through the plasma membrane and are 
attached to actin filaments. 
1  20  GO:0045295  MF  gamma‐catenin binding  Interacting selectively and non‐covalently with the gamma subunit of the catenin complex. 
1  20  GO:0046332  MF  SMAD binding  Interacting selectively and non‐covalently with a SMAD signaling protein. 
1  20  GO:0048468  BP  cell development 
The process whose specific outcome is the progression of the cell 
over time, from its formation to the mature structure. Cell 
development does not include the steps involved in committing a 
cell to a specific fate. 
1  20  GO:0000904  BP  cell morphogenesis involved in differentiation 
The change in form (cell shape and size) that occurs when 
relatively unspecialized cells, e.g. embryonic or regenerative cells, 
acquire specialized structural and/or functional features that 
characterize the cells, tissues, or organs of the mature organism 
or some other relatively stable phase of the organism's life 
history. 
4  44  GO:0006412  BP  translation 
The cellular metabolic process in which a protein is formed, using 
the sequence of a mature mRNA molecule to specify the 
sequence of amino acids in a polypeptide chain. Translation is 
mediated by the ribosome, and begins with the formation of a 
ternary complex between aminoacylated initiator methionine 
tRNA, GTP, and initiation factor 2, which subsequently associates 
with the small subunit of the ribosome and an mRNA. Translation 
ends with the release of a polypeptide chain from the ribosome. 
4  44  GO:0035639  MF  purine ribonucleoside triphosphate binding 
Interacting selectively and non‐covalently with a purine 
ribonucleoside triphosphate, a compound consisting of a purine 
base linked to a ribose sugar esterified with triphosphate on the 
sugar. 
4  44  GO:0016773  MF  phosphotransferase activity, alcohol group as acceptor 
Catalysis of the transfer of a phosphorus‐containing group from 
one compound (donor) to an alcohol group (acceptor). 
4  44  GO:0005524  MF  ATP binding 
Interacting selectively and non‐covalently with ATP, adenosine 5'‐
triphosphate, a universally important coenzyme and enzyme 
regulator. 
4  44  GO:0000166  MF  nucleotide binding 
Interacting selectively and non‐covalently with a nucleotide, any 
compound consisting of a nucleoside that is esterified with 
(ortho)phosphate or an oligophosphate at any hydroxyl group on 
the ribose or deoxyribose. 
4  44  GO:0017076  MF  purine nucleotide binding 
Interacting selectively and non‐covalently with purine 
nucleotides, any compound consisting of a purine nucleoside 
esterified with (ortho)phosphate. 
4  44  GO:0044237  BP  cellular metabolic process  The chemical reactions and pathways by which individual cells transform chemical substances. 
4  44  GO:0016323  CC  basolateral plasma membrane 
The region of the plasma membrane that includes the basal end 
and sides of the cell. Often used in reference to animal polarized 
epithelial membranes, where the basal membrane is the part 
attached to the extracellular matrix, or in plant cells, where the 
basal membrane is defined with respect to the zygotic axis. 
4  44  GO:0016301  MF  kinase activity  Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule. 
4  44  GO:0004714  MF  transmembrane receptor protein tyrosine kinase activity 
Combining with a signal and transmitting the signal from one side 
of the membrane to the other to initiate a change in cell activity 
by catalysis of the reaction: ATP + a protein‐L‐tyrosine = ADP + a 
protein‐L‐tyrosine phosphate. 
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